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A bstract
The work in this thesis relates to the efficiency of cell-specific uptake of drugs 
mediated by peptide hormones. A model system was used to study hormonal 
targeting to B16 melanoma cells using melanocyte stimulating hormone. The 
rate of fluid-phase endocytosis was measured at 37°C, in B16 murine melanoma 
cells, by determining the fluid-associated accumulation of 125I-PVP. Fluid uptake 
was bi-phasic. A rapid phase of uptake in the first 10 minutes was thought to 
represent the filling of the cell endosomal compartment (the volume of which was 
estimated as 109 ±  40nl/106cells). After the establishment of steady-state fluid 
turnover by the endosomes, a slower linear accumulation of fluid (thought to be 
by the lysosomes) was observed for up to 100 minutes. The rate of this second 
phase was 0.038 ±  0.00l/d /hr/106cells. Different uptake profiles were observed 
for two other cell lines.
The interaction of methotrexate (MTX) with B16 cells was assessed using the 
tritiated drug. Binding at 4°C had a relatively low affinity, Ka 0.21/zM, with ap­
proximately 270,00 binding sites/cell. At 37°C the labelled drug was internalised 
presumably through the reduced folate carrier in the cell membrane, as uptake 
was inhibited by PCMPS and thiamine pyrophosphate. It was not possible to 
establish the growth of B16 cells in low folate medium.
The analogue of a-MSH, [Nle4,D-Phe7]-aMSH (NLDP-MSH), was successfully 
labelled with 125I, and the mono-iodinated product separated. Binding to B16 
cells at 4°C had high affinity, Ka c.0.6nM, but a low number of binding sites, 
c.4500 per cell. After 30 minutes at 37°C, 40% of the cell associated 125I activity 
was acid-wash resistant, and thus considered internalised. Cell surface binding 
reached a maximum after 30 minutes before declining. Uptake occurred through 
the binding site observed at 4°C, and displayed no signs of cooperativity.
MTX was successfully conjugated to NLDP-MSH, forming four equal products. 
This was due to racemization around the linkage to the a-carbon of the gluta-
mate moiety of MTX. The conjugate displayed no specific inhibition of 3H-MTX 
binding to B16 cells. However in a competition assay against 12?I-NLDP-MSH, 
the affinity of the conjugate compared to the labelled peptide was ten fold lower 
(Ka c.6.5nM).
NLDP-MSH-MTX was iodinated and the mono-labelled product purified. 125I- 
NLDP-MSH-MTX was internalised by B16 cells at 37°C and demonstrated sim­
ilar profiles of surface binding to the free peptide.
Using a spectrophotometric assay, the inhibition of dihydrofolatereductase (DHFR), 
the target enzyme for MTX, was examined. Free MTX and NLDP-MSH-MTX 
displayed IC50 values of 0.01 and 0.25/xM respectively, i.e. the conjugate had a 
forty fold lower affinity than MTX for DHFR. In vitro lysosomal degradation 
of the conjugate after a 16 hour incubation at 37°C, released products of an 
equipotent nature to free MTX.
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Chapter 1
Introduction
Most medications are associated to some degree with toxic side-effects, the clinical 
use of these therapeutic agents can only be justified if their therapeutic effects out­
weigh these undesirable actions. This is best illustrated in cancer chemotherapy 
where inhibition of tumour growth by various agents is invariably accompanied 
by toxicity to rapidly proliferating normal cells. The therapeutic effectiveness of 
these agents could be improved, and the toxic responses limited, by increasing 
their amount and duration at the site of action (tumour cells); whilst reducing 
the exposure of non-target cells. This principle is the very basis of site-specific 
drug delivery, or drug targeting. Although the reference of drug-complexes will 
mainly be related to cancer chemotherapy, site-specific drug delivery is pertinent 
to many other illnesses including diseases of the central nervous system, immune 
system, some cardiovascular related diseases and arthritis.
The lack of target specificity of conventional drugs is mainly attributable to 
the formidable barriers presented by the body, e.g. cell membranes, enzymes, 
passage through certain organs etc. A major approach to solving this problem 
has been the advent of prodrugs [1, 2] which appears the most promising means of 
improving drug delivery. Here the active chemical is transformed into an inactive 
derivative which reverts to the parent compound due to enzyme and/or chemical
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lability before or after reaching its site of action within the body. To this end the 
association or linkage of a drug to a carrier has been employed in an attempt to 
alter the tissue localisation [3]. The absorption and biodistribution of the drug 
is now largely dictated by the physico-chemical properties of the macromolecular 
carrier and so the choice of carrier. By definition these site-specific drug carrier 
delivery systems are of prodrug nature, unless the drug exerts its pharmacological 
action while attached to the carrier.
1.1 D esign o f M acrom olecular-Drug Conjugates
In order to achieve the successful site-specific delivery of drugs via a carrier, the 
resulting conjugate must conform to a multitude of guidelines which as yet have 
not been satisfied by any reported complex.
1. The carrier must protect the drug from inactivation and premature release 
during transit.
2. The carrier must localise the drug at the site of action via the vasculature 
possibly involving endothelial passage. This may require the interaction 
with specific membrane or intracellular sites with the target cells.
3. The release of active drug should be regulated by biological processes at 
controlled and predictable rates. This release should be restricted to the 
target site.
4. The drug and host must be protected from one another during drug transit.
5. The carrier should be biodegradable (or not display any serious accumula­
tion in the body), biochemically inert and non-immunogenic.
6. The carrier itself must not modulate the disease in question.
7. The complete entity should be convenient and cost-effective to prepare in 
a reproducible manner with homogenous yields.
8. The complete entity should be chemically and physically stable in its dosage 
form.
1.1.1 C hoice o f M acrom olecular Carrier
The choice of carrier will be dependent on many factors including any known 
pharmacokinetic distribution of the macromolecule. Other important properties 
a carrier should posess are:
1. Lack of intrinsic toxicity and antigenicity by the carrier and its metabolic 
degradation products.
2. The carrier must have adequate functional groups for chemical fixation.
3. The carrier-drug conjugate must retain the desirable specificity of the orig­
inal carrier compound.
There are two distinct classes of drug carriers, 1), particulate carriers such as 
liposomes [4], proteinaceous capsular particles [5] and cell carriers [6], and 2), 
soluble macromolecular carriers. Although particulate carriers offer many advan­
tages such as the well protected delivery of a relatively large amount of drug to 
a site of action, their use is limited due to their poor extravasation [2] and will 
not be considered in any further detail here.
Soluble macromolecular conjugates can be further subdivided into biological car­
riers e.g. proteinaceous, and synthetic polymers e.g. poly-l-lysine. Examples of 
some carriers so far investigated include antibodies [7, 8], albumin [9], glycopro­
teins [10], lipoproteins [11], lectins [12], hormones [13], dextran [14], deoxyribonu­
cleic acid [15] and N-(-2-hydroxypropyl)-methacrylamide (HMPA) [16], some of 
which will be mentioned in further detail.
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1.1.2 Choice o f Drug
There axe three main properties the cytotoxic component must posess:
1. It must have adequate groups in its molecular structure for chemical fixa­
tion.
2. It must be chemically stable in the conjugated form until released.
3. It must display sufficient toxicity at relatively low doses in order to decrease 
the load of the carrier molecule.
Although most cytotoxic agents used in cancer chemotherapy may prove good 
candidates especially in the experimental stage of development, the potential of 
site-specific drug delivery is more likely to be reached in the long term with new 
chemical entities [17]. Theoretically this mode of drug delivery permits the use 
of highly toxic components not used in standard therapy e.g. animal or plant 
toxins [18].
Linkage to the macromolecule is usually covalent employing functional groups 
such as amino, carboxyl and hydroxyl groups. The conditions for attachment 
must be mild enough to ensure no adverse effects on the biological activity of the 
drug, yet the nature of the linkage can alter the pharmacokinetics of the formed 
conjugate. For example when ricin-A chain was conjugated to a monoclonal 
antibody via a disulphide bridge, a protected -S-S- link or a sulphide link, the 
latter was found to be cleared more slowly from the circulation [19].
1.1.3 P assive/A ctive  Targeting
In general soluble and particulate macromolecular drug-conjugates are rapidly 
cleared from the blood by the cells of the reticuloendothelial system, mainly in
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the liver and spleen. Indeed when Hashida et al. [20] injected rats with R e ­
labelled mitomycin C-dextran conjugates of diverse molecular weights, radioac­
tivity rapidly disappeared from the blood. The extent of accumulation in the 
liver and spleen increased with the molecular weight of the carrier from 10,000 to 
500,000. The net charge also determined the distribution of the conjugate which 
was polycationic at physiological pH. Conjugates with a carrier weight of 10,000 
were rapidly distributed to the kidney where they were subsequently lost in the 
urine, whereas higher molecular weights were unaffected. It appears that the net 
charge and molecular weight of a macromolecular carrier can predetermine the 
biodistribution of the drug-conjugate, in particular to the liver and spleen. This 
localisation of drug away from the target site of action (in most situations) is 
the basis of ‘passive’ targeting which utilises the passive or natural distribution 
pattern of the carrier to deliver the drug to a specific site. However this does 
not generally lead to selective uptake at the appropiate target site. The normal 
distribution has to be selectively altered by specific means, i.e. active targeting. 
This is mainly achieved through specific membrane receptor recognising moieties 
such as sugar residues [12], hormones [13] and in particular antibodies [7, 8]. Note 
a limited degree of targeting can be achieved physically e.g. by intracompartment 
or intratumoural injection.
The addition of a targeting moiety to a conjugate will most probably alter the in­
teraction with individual cells, especially those which represent the target. These 
macromolecular complexes are unable to enter cells by diffusion across the plasma 
membrane; their general mechanism of entry is by endocytosis. Knowledge of this 
complex and intricate process has led to the improved design of drug-conjugates 
to increase cell-targeting, uptake and release of active drug at the target site.
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1.2 E ndocytosis
Due to their large size and hydrophilic nature, macromolecules are incapable of 
permeating cellular membranes without the assistance of specific cell-membrane 
transporters or carriers. Undoubtedly the most important transport process with 
respect to cell-function and macromolecular drug-delivery is endocytosis. Here 
plasma membrane invaginates and pinches off, internalising membrane proteins, 
lipids and extracellular solutes. These newly-formed vesicles and their contents 
are then processed through various intracellular organelles before ligands or recep­
tors generally reach the lysosomes, or are recycled back to the plasma membrane, 
figure 1.1. In polarised cells, e.g. epithelial cells, internalised macromolecules can 
be transported to the opposite side of the cell, a process known as transcytosis. 
Both endocytosis and transcytosis although well reviewed [21, 22, 23, 24] are 
very complex processes not yet fully understood. However a knowledge of their 
function is essential for the rational design of site-specific drug delivery systems 
as it is a process pertinent to almost all animal cells. Endocytosis is an essential 
part of many physiologic pathways including the transport of nutrients, regula­
tion of hormone actions, the control of metabolic reactions and the processing of 
antigens [21].
Interaction of macromolecules with cell membranes can result in basically one 
of two types of endocytic uptake, receptor-mediated or non-receptor mediated 
endocytosis.
1. Receptor-mediated endocytosis involves the precise binding of the macro­
molecular conjugate to a specific plasma membrane-associated protein, for 
example the ligand for such a high affinity protein may include an antibody, 
hormone or polysaccharide. Following binding, receptor-ligand complexes 
may concentrate in coated pits (clathrin-coated regions) which subsequently 
invaginate to form clathrin-coated vesicles. Many physiological ligands are 




Figure 1.1: A schematic representation of the vesicular pathways of endocytosis. 
(a) Formation of uncoated vesicles from uncoated pits which may fuse with each 
other before reaching the early endosomes (b). Vesicles from the endosomes, 
or directly from invagination of cell membrane, fuse with primary lysosomes to 
form secondary lysosomes (c). Some vesicles recycle back to the cell membrane 
(d). Coated regions of the membrane can give rise to vesicles with or without a 
clathrin coat (e). These either fuse with early endosomes, primary lysosomes, the 
Golgi complex, or the opposing cell membrane (transcytosis). (f) Vesicles from 
Golgi complex fuse with primary lysosomes. (g) Vesicles arising from lysosomes 
may fuse with the plasma membrane.
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ligand is not always a prerequisite for triggering this process. Transferrin 
receptors can concentrate in coated pits in the absence of ligand and become 
internalised unoccupied [26]. Other receptors (e.g. for EGF and insulin) can 
be randomly distributed on the plasma membrane in the absence of ligand 
and will only concentrate in coated-pits and be endocytosed upon binding 
[27]. Different ligands can be internalised within the same coated pit but 
divergence of the ligands and/or receptors may occur through intracellular 
sorting.
In some cases endocytosis may not be required for the physiologic func­
tion of ligands e.g. EGF or insulin [28], however internalisation of the 
ligand-receptor complex may serve to regulate and control the membrane 
associated signal. Conversely endocytosis of receptor-bound ligands such 
as transferrin [29] or LDL [30] is essential for their physiologic function.
2. Non-receptor mediated endocytosis can occur without the specific involve­
ment of a membrane receptor. Instead this type of endocytosis is derived 
from the constant internalisation of plasma membrane to form vesicles con­
taining the trapped extracellular fluid and a portion of cell membrane. Thus 
extracellular molecules are internalised either in the fluid phase or through 
non-specific adsorption to the membrane.
1.2.1 Fluid-Phase E ndocytosis (P inocytosis)
This is a constitutive cellular process involving internalisation of plasma mem­
brane and a portion of extracellular fluid. Since it does not require a membrane 
receptor the amount of uptake is only dependent upon the extracellular concentra­
tion of macromolecules and the rate of internalisation. Unlike receptor-mediated 
endocytosis, it is a non-saturable, non-concentrative and non-specific uptake pro­
cess.
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1.2.2 A dsorptive E ndocytosis
This involves the same cellular process as pinocytosis, except macromolecules 
gain entry by non-specific adsorption to the plasma membrane. The cell surface 
contains both cationic and anionic sites [31] so macromolecules which express a 
net electrostatic charge will adsorb readily onto the surface of the membrane. 
Positively charged macromolecules have a greater affinity towards the cell mem­
brane as the latter contains glycosylated proteins distributed on its outer surface 
which posess a net negative charge due to an abundance of carbohydrate residues. 
Also the hydrophobicity of the cell membrane lipid bilayer may accommodate 
strongly hydrophobic molecules. Unlike pinocytosis, this mode of internalisation 
is a saturable process due to the limited number of available membrane binding 
sites.
In order to appreciate the design and cellular processing of drug-conjugates a 
more detailed understanding of the intracellular organelles involved and their 
interplay with each other is required.
1.2.3 T he E ndocytic Vesicular Pathway  
Coated and Uncoated Vesicles
Coated regions of the plasma membrane are composed of clathrin and it has been 
recently demonstrated that the cytoplasmic tail of the LDL and the mannose-
6-phosphate receptors will bind to this protein [29]. The position of a tyrosine 
residue in the tail may be essential for this process [32]. This binding is probably 
linked to the clustering of receptors into coated pits before the formation of coated 
vesicles. Once internalised, these vesicles rapidly lose their coat (c. 15-60 seconds). 
The newly formed uncoated vesicles have a half-life of 1-2 minutes and transport 
the receptor-ligand complexes and solutes to the early endosomes. It should be 
noted that a controversial issue is still unresolved as to whether fluid-phase uptake
9
occurs through coated pits or a clathrin independent pathway.
Early Endosomes
Early endosomes are a heterogenous population of vesicles, tubules and vacuoles 
(0.4-0.7/xm in diameter) that receive ligands 2-5 minutes after uptake. They have 
an internal pH of 6.0-6.2 which is lower than that of the extracellular medium 
(pH 7.2) but higher than that of lysosomes (pH 5.3) [33]. This acidic milieu 
is created by vacuolar H+-ATPase, however the internal pH of early endosomes 
is not uniform and may be regulated by the presence of Na^/K4" ATPase in 
some endosomes and not others [33]. This pump is electrogenic and increases the 
vesicular membrane potential that then limits the activity of the H+-ATPase, 
although how endosomes acquire the latter is unknown.
Early endosomes have been referred to as CURL (compartment for uncoupling 
receptor and ligand [34]) as it is the site where membrane and dissociated ligands 
are sorted to various destinations. Certain receptors, for example those for LDL, 
asialoglycoprotein and mannose receptors axe transported back to the plasma 
membrane [35]. Fluid that is trapped in these vesicles is also returned to the 
cell surface (diacytosis). Indeed the majority of the fluid internalised through 
pinocytosis does undergo diacytosis (see chapter 3). Recycling is thought to 
occur mainly from the endosomes due to the rapid recycling times (< 5 minutes) 
inferred for several receptors [36]. Other receptors (e.g. EGF), ligands and solutes 
are directed to the prelysosomes whilst in polarised epithelial cells some molecules 
(e.g. polymeric immunoglobulin) are transported to the opposing membrane [23]. 
Some ligands do not dissociate from their receptors and so may also recycle, 
e.g. transferrin [37], or be transported to the lysosomes e.g. polyvalent immune 
complexes [38]. Small amounts of some receptors that escape recycling e.g. the 
transferrin receptor, are transported to the trans Golgi reticulum.
The mechanism of early endosome sorting is still unresolved but the low pH
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appears to account for a basic step in the process, allowing ligands and receptors 
to dissociate and follow separate pathways [23]. It is generally believed that 
solutes, ligands and membrane components then follow a non-selective pathway 
to the lysosomes with only selected membrane receptors being diverted away and 
recycled to the cell surface. However it was demonstrated recently that three 
different receptors were recycled to the plasma membrane at identical rates [39], 
the interpretation of selective sorting may now shift from recycling receptors to 
those that escape this process, as the former would predict different rates of 
recycling.
The biogenesis of endosomes is still under debate due to their heterogenous com­
position and transient nature. Two models for the process have been proposed 
[40]:
1. The Maturation Model assumes no permanent endosomal membrane com­
ponents and that uncoated vesicles fuse with one another to form early 
endosomes. Plasma membrane components axe then removed for recycling 
and lysosomal membrane supplied.
2. The Vesicle Shuttle model simply assumes the delivery of the contents from 
uncoated vesicles to pre-existing endosomes by fusion.
Although doubt remains over each model, the latter seems the most plausible as 
if the maturation model was appropiate then uncoated vesicles and endosomes 
would be expected to display similar properties, but this is not the case.
Prelysosomes
Following sorting in the early endosomes ligands are next observed in prelyso­
somes which probably mature from the former, but the transport of endocytosed 
molecules via vacuoles to prelysosomes in a microtuble dependent manner has
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been observed. Prelysosomes are thought to be the site where lysosomal enzymes 
are delivered from the trans Golgi reticulum to the endocytic pathway via the 
mannose-6-phosphate receptor. However the delivery of prelysosome contents to 
the lysosomes remains unclear. Another maturation model assumes the vesicle 
changes with time as the lysosomal enzymes are delivered, whilst a second model 
proposes the fusion of prelysosomes with lysosomes (which has recently been 
demonstrated in vitro [41]).
Lysosomes
Lysosomes are generally considered inactive organelles with respect to membrane 
traffic, being the end-point of the endocytic pathway. But a lysosomal membrane 
protein has recently been discovered to be slowly transported from the lysosomes 
to the plasma membrane [42].
Lysosomes are 0.2-0.4/im in size and are composed of a variety of acid-dependent 
hydrolases capable of degrading most biological macromolecules. Although they 
are considered the terminal degradative compartment of the endocytic pathway, 
earlier organelles, e.g. early endosomes, do contain some proteases [43]. However 
they are not termed lysosomes as they lack the full complement of enzymes. Once 
within lysosomes endocytosed ligands and tracers are either degraded or reside 
indefinitely within the organelle, they are not generally released intact into the 
cytosol.
From the brief description of the endocytic pathway it can be appreciated that 
many factors can determine the cellular uptake and fate of a macromolecular 
conjugate, which in turn can dictate subsequent alterations in its design.
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1.2.4 Enhancem ent o f E ndocytic U ptake O f M acrom olec- 
ular Conjugates
Interaction of conjugates with the plasma membrane can be altered to enhance 
uptake via non-specific pathways (i.e. adsorption to the membrane) or through 
specific interactions with distinct membrane sites.
Non-Specific Carriers
Poly-l-lysine is a good example of carrier-mediated uptake via adsorptive en- 
docytosis due to its net cationic charge. Indeed it can increase the uptake of 
the fluid-phase marker HRP (horseradish peroxidase) by 1000-fold in cultured 
mammalian cells [44]. The same principle of non-specific adsorption onto cell 
membranes is applied to cationised proteins, which after conjugation of di- or 
polyamine molecules through carboxylic acid residues, have a resultant net pos­
itive charge. For example when /9-endorphin, a non-transported peptide, was 
conjugated to cationised albumin, it experienced adsorptive endocytosis into the 
brain capillary endothelium [45].
The group of glycoproteins referred to as lectins have affinity towards certain 
carbohydrate and sugar residues on the cell surface. For example when the plant 
lectin wheat germ agglutin (WGA) binds to sialic acid and N-acetylglucosamine 
residues on the cell surface, it is internalised via adsorptive endocytosis [46]. 
Lectins can therefore be used as carriers to increase binding and uptake of other 
compounds, e.g. WGA linked to HRP increased the uptake of the latter [47].
Finally it should be noted that the uptake of proteins and peptides can be 
enhanced through increasing their lipophilicity by conjugation with lipophilic 
molecules. For example fatty acid binding to albumin has been shown to in­
crease transcytosis of the latter across lung capillary endothelium by 2-3 fold 
over unconjugated protein [48].
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Specific Carriers
Targeting to particular cells and tissues can be achieved by using ligand contain­
ing carriers which interact with specific receptors on the cell surface, e.g. EGF 
[49], transferrin [50] and in particular antibodies which have been studied ex­
tensively in drug delivery. However from the general overview of the endocytic 
pathway, many factors of targeting via a membrane bound receptor have to be 
considered:
1. The number of binding sites per cell.
2. The distribution of binding sites on other (non-target) cells.
3. Does ligand binding induce receptor-mediated internalisation?
4. If the receptor is recycled does the ligand dissociate wthin the cell and if 
so, is it transported further along the endocytic pathway or is it returned 
to the cell surface intact with the receptor?
5. How long before re-expression of the receptor on the plasma membrane 
after internalisation?
In particular the number of receptors per cell will determine the amount of drug 
required to be associated with each macromolecule. If there are a small number 
of available receptors then the conjugation ratio of drug to macromolecule will 
need to be high (unless the cytotoxic agent was very potent, e.g. ricin-A-chain).
1.2.5 O ptim isation o f Drug R elease and/ or Carrier Degra­
dation
The major site for enzymatic metabolism of an endocytosed conjugate will be in 
the lysosomes, although some proteases are present in earlier organelles e.g. early
14
endosomes [43]. Lysosomal sensitive peptide spacer linkages have been employed 
between drug and carrier in order to enhance the release of active drug from the 
conjugate (see chapter 7). Also drug complexes employing carbohydrate linkages, 
using either the side-chain of a glycoprotein [51] or dextran as a spacer [52], are 
most likely to be processed by glycosidases present in lysosomes.
Most drug conjugates which release their cytotoxic component once selectively 
delivered to the lysosomes can be termed as ‘lysosomotropic’ agents, as defined by 
De Duve et al. [53]. Some agents which are not lysosomotropic can be converted 
through the conjugation to a macromolecule, as in many cases for selective-drug 
delivery.
Organelles of the endocytic pathway are acidified soon after their formation near 
the cell surface (pH 6.2 for early endosomes) and the pH decreases to about 4.5-
5.0 in the lysosomes [33]. This change in enviroment has led to the development 
of several acid-sensitive linkages [54] for the release of drugs from macromolecular 
carriers.
Reductive cleavage of disulphide bonds is known to be important in the pro­
cessing of endocytosed proteins [55], however the molecular mechanisms and the 
site of action in the internalisation pathway is relatively unknown. Disulphide 
reduction is required for the activation of several protein toxins, e.g. ricin [56]. 
Knowledge of this has been utilised in the formation of immunotoxins (toxin- 
antibody conjugates) where a disulphide linkage between the two components is 
essential for an active conjugate [57].
It can be clearly observed that knowledge of the endocytic pathway has influenced 
the development of macromolecular-drug conjugates, in order to improve their 
efficiency and therapeutic effectiveness.
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1.3 Types o f M acrom olecular Carriers an d /or  
Targeting A gents
1.3.1 A ntibodies
The advent of high yield and purity of monoclonal antibodies by the application 
of hybridoma technology has offered new approaches in the targeting of cytotoxic 
drugs. Many of these antibodies react with cell surface associated glycoproteins 
and glycolipids of malignant cells, specificity relying on the sole, or increased 
expression of these antigens when compared to normal tissue.
Although still in the experimental stage, many antibody conjugates have been 
studied containing various cytotoxic elements [7, 8 ], e.g. antibiotics (daunomycin, 
adriamycin), alkylating agents (trenimon, p-phenylenediamine mustard), plant 
(saporin, gelonin, ricin, abrin) and bacterial (diphtheria) toxins. Here antibody 
conjugates containing methotrexate (MTX) will primarily be described in detail 
as a model example of the design and development of a macromolecular drug- 
conjugate.
Design and Mode of Action of Antibody Drug Conjugates
The mode of synthesis is very important in order to incorporate as many drug 
molecules per antibody, whilst maintaining its immunological reactivity. Kulkarni 
et al. [58] produced MTX conjugates by three different methods, the first via 
direct ECDI reaction produced unwanted cross-linking between antibodies and 
resulted in reduced binding activity of the final product. Activation by the initial 
production of a MTX mixed anhydride before linkage failed to incorporate 2-3 
molecules of MTX before a significant decrease in antibody activity. However 
when an active-ester method was employed 10 molecules of MTX were linked 
whilst the antibody retained 90% of its immunological activity.
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It is generally considered that incorporation of more than 10 drug residues often 
results in unacceptable loss of antibody reactivity, although in some cases this 
can be lower [59]. Estimations have suggested that conjugation ratios of this 
value have limited potential and will prove insufficient in achieving the desired 
level of toxicity [60]. This has resulted in the use of carriers such as HSA [61] 
and dextran [62], which can be loaded with drug molecules and then linked to 
the antibody. Using HSA, incorporation values of 32-96 molecules of MTX per 
antibody have been achieved [60].
In order to reduce non-specific toxicity in any form of macromolecular drug tar­
geting, linkage of drug to carrier must be stable. This is particulary important 
when employing carriers like serum albumin which in the case of MTX, will phys­
ically bind the drug to some extent [63]. Conjugation of MTX to this protein 
[64] or directly to antibodies [65] has resulted in unstable complexes which slowly 
release the drug in solution and so give false toxicity values. When MTX was 
directly linked to an antibody [65] the cytotoxicity of the conjugate was found 
to decrease in the presence of thiamine pyrophosphate (a MTX uptake inhibitor 
[6 6 ]), thus implying some of the toxic action was due to free MTX. Hydroxalamine 
treatment of the conjugate was found to remove the less stable bound MTX and 
so decrease the non-specific toxicity.
Although some of the MTX-antibody conjugates formed can inhibit the drug’s 
target enzyme, DHFR [58, 65, 67, 6 8 ], the proposed route of cellular entry will 
be via the lysosomal pathway. Evidence to support this includes a decrease in 
cytotoxicity when in the presence of ammonium chloride [69, 70]. This compound 
is thought to inhibit lysosomal enzymes by raising their pH optimum [71, 72]. Also 
the lysosomal protease inhibitor leupeptin has demonstrated partial protection 
against conjugates [69, 73] indicating that some lysosomal enzymes are involved in 
the degradation of the conjugates. In view of this Umemoto et al. [69] synthesised 
a MTX-antibody conjugate containig an oilgopeptide (-Leu-Ala-Leu-Ala-) spacer 
linkage, which was more cytotoxic than the parent conjugate. To confirm the 
linkage was being degraded by lysosomes, identical conjugates were synthesised
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with poly-d-lysine replacing the antibody. This polymer is totally resisitant to 
lysosomal attack [74] and non-toxic, however when linked to MTX via the peptide 
spacer linkage toxicity was observed. Although the cytotoxic action appears to 
be linked to the endocytic pathway, it has been suggested that internalisation 
does not occur for all antibody conjugates [75].
The in-vitro growth inhibition and cytotoxic assays for MTX-antibody conjugates 
display equal or greater potency than free MTX [67, 6 8 , 73], but they tend to be 
weaker inhibitors of DHFR [67]. This implies an efficient delivery of MTX to the 
cell cytoplasm via endocytosis or defective membrane transport of MTX. In vivo 
testing is difficult to interpret due to limitations in experimental design, although 
some conjugates have revealed promising results with increased effectiveness over 
free MTX [7, 58].
Antibody-conjugates display good selectivity to antigen expressing cells in vitro 
[60, 67], with toxicity being related to the degree of antibody binding [60]. Shen et 
al. [73] effectively blocked the antigen sites on mouse F-9 bearing teratocarcinoma 
cells with free antibody thereby preventing any internalsation (and toxicity) until 
after 4 hours. At this point the free antibody had either dissociated or the antigen 
had recycled.
Limitations of Use
The i.v. injection of radio-labelled antibody results in only a small proportion 
accumulating in solid tumour deposits [7]. This resides primarily in the periphery 
of the main tumour and its metastases. Once the antibody is part of a conjugate 
its biodistribution is likely to be highly altered due to its new size, charge etc. 
Pimm et al. [76] demonstrated a direct antibody-drug linked conjugate to deliver 
drug to subcutaneous human xenografts in mice, however the achievable tumour 
drug concentration was unlikely to be therapeutic. When Garnett et al. [60] 
employed a MTX-antibody conjugate with HSA as a carrier, it was rapidly cleared
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from the circulation of mice by the liver and spleen. It appeared that the overall 
net negative charge encouraged removal from the vasculature by phagocytes.
A major limitation for antibody and indeed most macromolecular conjugates, 
is their poor extravasation partly due to their large molecular size (e.g. up to
340,000 Da). This results in insufficient levels being attained in tumour tissue. 
Extravasation is a highly desirable characteristic for a site-specific drug conju­
gate in cancer chemotherapy as it would permit exposure of the metastatic tu­
mours mostly responsible for the high fatality associated with this disease. The 
widespread location and number of these secondary tumours renders conventional 
therapy with surgery and irradiation virtually useless, thereby leaving chemical 
therapy practically the only option.
Immunotoxins (antibody conjugates to animal or plant toxins) posess a great 
advantage due to their high potency (only one toxin molecule generally rquired 
to cause cell death). In vivo they are rapidly cleared from the blood by the 
liver (probably due to mannose and fucose residues present in the toxin) which 
causes further problems due to the release of free antibody [7, 77]. This may 
then saturate the antigen binding sites preventing any intact immunotoxin from 
binding. The highly toxic component of these conjugates may prove undesirable 
if there are low levels of cross-reactivity, i.e. antigen expression, albeit at a low 
level, on normal tissues.
Various methods have been employed to improve tumour localisation and toxicity, 
including intracavity administration, enhancement of target antigen expression 
by interferons and the use of vasoactive agents to increase tumour blood flow 
[7]. An interesting development has been the production of bi-specific antibodies 
with dual specificity i.e. one Fab site reacting with tumour antigen, the other 
with the drug and/or carrier [78]. This would allow the separate administration 
of both components which would not only allow better tissue penetration, but 
the antibody retains fully immunoreactive in the process. Using this in vivo 
conjugation approach Pimm et al. [78] discovered they could deliver up to 40
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molecules of MTX per antibody via a carrier.
Another approach for increased drug incorporation has been the use of IgM as 
opposed to the usual IgG antibodies, the former posessing ten antigen binding 
sites instead of two. Persiani et al. [79] incorporated 65 molecules of MTX directly 
to an IgM antibody without a significant decrease in its immunoreactivity. The 
resulting conjugate was more effective than free MTX during in vivo experiments, 
but this could be due to it functioning as a slow release form for MTX. The high 
molecular mass of such a conjugate would however restrict it to the vasculature.
The use of Fab-fragments has resulted in a more rapid passage through the vascu­
lature, but absolute levels achieved in tumours make them less effective targeting 
agents than whole antibodies [7]. Also lower incorporation values result from 
fewer lysine residues present and a more rapid decline in immunoreactivity per 
bound drug molecule [80].
Another potential problem is the heterogeneity in antigen expression among ma­
lignant cells, even within a single tumour and its metastases, which will limit the 
antibody directed localisation e.g. in lung cancers [81], breast carcinoma [82]. 
This could theoretically be overcome with a mixture or cocktail of antibodies 
to different antigens, however in order to saturate each individual antigen the 
amount of antibody would have to be increased resulting in further non-specific 
binding and immunogenicity problems.
A major drawback to the use of antibody conjugates, besides poor tumour lo­
calisation, is the problem of immnuogenicity. Antibodies of mouse or rat origin 
used for tumour imaging in clinical practice have evoked the production of an­
tibodies to these foreign proteins [83]. If this area of targeting is to succeed the 
use of human antibodies is advantageous but their production to a wide range of 
antigens and their immunogenicity will need to be evaluated.
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A M acromolecular Conjugate Model
Form this brief overview of antibody conjugate design the basic model for a 
macromolecular drug complex can be envisaged (figure 1.2). The drug carrier, 
in this case a polymer, can have three different functional groups attached. The 
therapeutic agent is usually joined via a covalent linkage either directly or by a 
spacer moiety (to enhance drug release if related to a steric function i.e. enzyme 
cleavage). A control device may also be present to maintain the desired overall 
physiochemical properties of the conjugate, e.g. molecular weight, solubility, 
hydrophilic/lipophilic balances and electric chaxge. Finally site specific moieties 







Figure 1.2: A basic model for a macromolecular-drug conjugate. This is composed 
of three components; a control device for maintaining the overall physicochemical 
properties of the conjugate (1 ), a cytotoxic agent covalently linked either directly 
or via a spacer (2), and a targeting moiety (3).
1.3.2 A lbum in  and G lycoproteins
Albumin has proved a popular choice of carrier in experimental studies, it offers 
many advantages including its ready availability in a pure form, good biological
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stability, large numbers of free carboxyl and amino-groups for chemical substi­
tution, low toxicity and antigenicity and lastly established properties for cellular 
interaction and pharmacokinetics. The protein itself lacks intrinsic site-selectivity 
but specificity has been provided when used as a carrier with antibodies (see pre­
vious section).
Conjugation to albumin is generally via covalent bonds, the drug being released 
by enzymatic cleavage inside the cell. When the two inhibitors of DNA synthesis, 
5-fluorodeoxyuridine and cytosine arabioside were linked to albumin [84], both 
were effective in inhibiting cellular growth. Cleavage of drug from the carrier 
was inferred to occur inside the cell since the covalent bond present involved 
the primary hydroxy groups of both drugs which must be phosphorylated before 
either can exert their pharmacological action.
However the stability of other conjugates has been in doubt, especialy when MTX 
is used (see previous section). The conjugate of MTX to bovine serum albumin 
(BSA) was found to be more effective than equivalent doses of free drug when 
delivered i.p. in reducing the growth of tumours, and the number of subsequent 
metastases, in female mice implanted subcutaneously with Lewis lung carcinoma 
[85]. However the same conjugate was found to be relatively ineffective against a 
MTX transport resistant strain of Reuber hepatoma 1135 cells in vitro [8 6 ]. This 
implied a proportion of the pharmacological action of MTX-BSA was due to the 
extra-cellular liberation of free MTX with its subsequent uptake across the cell 
membrane. This underlines the importance of chemical stability when the drug 
is linked to a carrier.
The use of glycoproteins as drug carriers has been investigated [87], although they 
display no site selectivity. However when the sialic acid moieties are removed from 
the terminal sugar branches, the resulting asialoglycoproteins are rapidly recog­
nised and cleared by certain cells of the liver (depending on the sugar group(s) 
exposed). Therefore glycoproteins can be modified to deliver drugs in a site 
specific manner e.g. hepatocytes posess receptors for galactosyl-terminated gly-
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coconjugates [8 8 ] which has resulted in asialofetuin (galactosyl-terminated fetuin) 
being developed as a hepatocyte-specific drug carrier [89].
Other plasma proteins in addition to albumin have been suggested as carriers of 
anticancer agents including fibrinogen and globulin [90].
1.3.3 D ext ran
The polysaccharide dextran has been used for many years as a plasma expander 
but has generated much interest as a drug carrier due to the following properties:
1 . A well characterised polymeric structure.
2. High water solubility.
3. High stability.
4. Availability of different molecular weight fractions.
5. Presence of numerous reactive hydroxy groups for chemical fixation.
6 . Low pharmacological activity and toxicity.
7. Protection of conjugated drugs from biodegradation.
Drugs can be coupled to the hydroxyl groups of dextran by a variety of techniques 
including periodate oxidation, cyanogen bromide activation and diazotization 
[14]. This demonstrates the versatility of dextran as a drug carrier.
The antitumour antibiotic mitomycin C was conjugated to dextran of vary­
ing molecular weights (10,000, 70,000 and 500,000) [91]. The resulting poly- 
cationic conjugates were almost as effective as free drug in growth inhibition of 
L1210 mouse leukemia cells after continuous exposure (short term acute exposure 
showed little cytotoxic activity). It was concluded that the conjugates acted as a
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prodrug of mitomycin C, exhibiting their activity after release of the drug proba­
bly by chemical liberation and not by the lysosomal enzymes. In vivo experiments 
employed murine models inoculated i.p. with various tumour cell types followed 
by i.p. drug treatment [92]. Although the conjugate was effective against some 
tumours in prolonging survival time the relevance of such an in vivo model has 
to be questioned when the tumour inoculation and subsequent treatment are via 
the same anatomical compartment. When the conjugate was administered by 
intravenous injection it displayed only modest activity.
Dextran has also been used as drug-carrier for linkage to antibodies [93] allowing 
a greater drug to antibody ratio.
1.3.4 Polypeptides
Synthetic polypeptides such as poly-l-lysine, polyaspartic acid and polyglutamic 
acid have been proposed as drug carriers, in particular the polycationic polypep­
tide poly-l-lysine. This compound itself has some affinity for specific tumour cells 
and is capable of arresting their growth [94], furthermore its cellular uptake by 
endocytosis and susceptibility to degradation by trypsin, enhances its potential 
use as a drug carrier.
Ryser and Shen [95] conjugated MTX to poly-l-lysine and tested it against a 
MTX-uptake resistant Chinese Hamster ovary cell line. They discovered en­
hanced uptake and increased cytotoxicity compared to the free drug or the car­
rier and drug administered separately. Cell death was caused by the intracellular 
hydrolysis and subsequent release of free drug. When poly-d-lysine was used as 
the carrier, the conjugate was internalised but inactive [74]. It was suggested that 
intracellular enzymes could degrade and release free MTX only from the natural 
1-isomeric derivative. Thus by conjugating MTX to the polypeptide enabled the 
drug to enter the cell via an alternative route, thereby overcoming one form of 
resistance that is characteristic of its treatment.
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An identical conjugate was found to express differential toxicities against various 
tumours in vitro [96], being predominantly more inhibitory to solid tumours. 
However these effects were not totally reflected in vivo,demonstrating in vitro 
situations can be misleading. The original antineoplastic activity of poly-l-lysine 
can complicate the evaluation of results and in fact the limiting factor in the use 
of MTX-poly-l-lysine conjugates was suggested to be the toxicity of the carrier 
[97]. In all reports of poly-l-lysine conjugates cytotoxicity only occurred when 
active free drug was liberated upon lysosomal degradation i.e. the conjugates can 
be considered lysosomotropic agents.
Polyanionic polypeptides have also been employed as drug-carriers, for example 
when daunomycin was coupled to poly-l-aspartic acid the conjugate was less 
effective than free drug in vitro. The situation was reversed in vivo and was 
attributed to a significant reduction in drug toxicity. The anion charge of these 
carriers (and the cationic charge of poly-l-lysine) may alter the bio-distribution 
of conjugated drugs due to the affinity of these charged polymers for any cationic 
or anionic charges in the body respectively.
1.3.5 D eoxyribonucleic A cid
Site specificity of deoxyribonucleic acid (DNA) is based on the concept of lyso­
somotropic chemotherapy [53], the drug-carrier complex enters the cell by en­
docytosis and is transported to the lysosomal compartment. The basis for the 
site-specificity of DNA is that certain tumour cells exhibit higher endocytic ac­
tivity than normal cells, plus DNA is a potent inducer of pinocytosis and easily 
degraded by lysosomal hydrolases [98].
Relatively stable drug-carrier conjugates have been formed between DNA and 
daunorubicin or adriamycin [99]. Both conjugates displayed equal or increased 
effectiveness over free drug in animal models. The conjugates were also associated 
with decreased toxicity as the bio-distribution of the drugs had been altered. In
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clinical trials the amount of cardiac toxicity was greatly reduced, this was credited 
to the fact that the myocardium has little endocytic activity and would therefore 
not be expected to accumulate the drug-conjugate [1 0 0 ].
The use of DNA drug complexes alone is fairly limited as generally they have to 
be administered by the same route as the tumour cells in order to be effective 
[53], otherwise the conjugates become located in non-specific areas, mainly the 
cells of the reticuloendothelial system.
1.3.6 Synthetic Polym ers
Although most macromolecular drug-conjugates employ biological molecules, some 
synthetic polymers have been studied, in particular poly [N-(2-hydroxypropyl)- 
methacrylamide] (HMPA). The biological and chemical properties of this hy­
drophilic polymer have been extensively studied and reviewed [16]. Uptake of 
HMPA in various tissues occurred slowly via pinocytosis. Modification of the 
polymer e.g. with targeting residues thus had the potential for delivery to spe­
cific cells. When tyrosinamide residues were incorporated an increase in endocytic 
uptake followed. The increased hydrophobicity of the modified polymer led to 
increased membrane binding and so adsorptive endocytosis. Cellular delivery 
was still occurring in a passive, non-specific manner, therefore high levels of drug 
loading had to be avoided as they were likely to precipitate unwanted carrier- 
membrane interactions.
Site-specific drug delivery was then attempted through the inclusion of carbo­
hydrate moieties such as glucose, mannose and galactose which are known to 
be involved in receptor-mediated endocytosis in macrophages and hepatocytes 
[101, 102]. Polymers containing galactose residues had altered bio-distribution 
and were cleared from the blood more rapidly than unmodified HMPA. Further 
studies demonstrated that the galactose-containing polymer was delivered pre­
dominantly to the hepatocytes of the liver, whereas with the inclusion of mannose
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it was mainly found in the Kupffer cells of the liver. Thus the use of carbohydrate 
moieties in low molecular weight (c.25,000) HMPA polymers can selectively alter 
body distribution. Other targeting residues studied included monoclonal anti­
bodies which posed problems in direct conjugation.
Uptake of HMPA polymers by endocytosis resulted in the carrier being exposed to 
the lysosomes of the cell. Extensive studies with various oligopeptidyl side chains 
terminating with a drug analogue were performed to optimise the amount and 
rate of drug release by lysosomal proteases (see chapter 7). Therefore through 
the inclusion of targeting residues and peptide spacer linkages, HMPA offers the 
advantage of being tailor-made or modified to suit the tumour line in question.
Other potential soluble synthetic drug carriers include Pyran (divinyl ether- 
maleic anhydride), polyphosphazenes, poly(ethylene-oxide) and derivatives of 
poly(methacrylic acid) [103]. A major drawback to their use is their interac­
tion with the body, e.g. heamolytic activity, pyrogenicity, osmotic properties, 
but in particular immunogenicity. When HMPA was used in five genetically dif­
ferent strains of mice it was not recognised as a foreign molecule, however when 
oilgopeptide side chains were present immunogenic activity occurred [104, 105]. 
Whether immunogenicity of synthetic polymers will pose a severe drawback re­
mains to be resolved.
1.3.7 Lectins
Lectins are proteins that agglutinate cells by binding to specific carbohydrate 
residues which has resulted in their study as drug carriers [12]. They contain the 
usual functional groups of proteins which has permitted the coupling of various 
drugs, e.g. daunomycin [106], MTX [107], chlorambucil [107] and toxins such 
as ricin A-chain [108]. Although the conjugates have proved effective against 
various tumour types their use is limited to local chemotherapy [109]. Due to 
the widespread distribution of sugar residues in the body, an injected lectin con­
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taining solution remains at the site of injection as there is immediate binding to 
carbohydrate residues. Also the adverse interactions of lectins [12] with tissues 
severely limits their use to local chemotherapy e.g. the lectin Concanavalin A 
has been shown to be cytotoxic to most tissues.
1.3.8 H orm ones
As hormones generally exert their effects after binding to specific receptors on 
their target cells, they have potential for selective drug-delivery. Hormones that 
have been investigated as drug or toxin carriers include human placental lactogen 
[1 1 0 ], human chronionic gonadotrophin (hCG) [1 1 1 ] and EGF [112]. They were 
studied primarily to investigate if the hormones were internalised after binding.
When diphtheria toxin fragment A was conjugated to human placental lactogen 
the conjugate bound but was non-toxic to cells expressing the hormone receptor. 
This demonstrates that if a hormone exerts its biological action merely by binding 
to the cell surface without any subsequent intemalistion it is unlikely to be an 
efficient cell-specific carrier.
Ricin A-chain when conjugated to hCG was toxic to rat Leydig cells expressing 
the receptors for the ^-subunit of hCG but did not affect mouse L-cells which 
are devoid of these receptors. This demonstrated the in vitro specificity of the 
hormone binding and subsequent internalisation. The same toxin linked to EGF 
displayed a toxic effect at a similar concentration range (10~9 -10“loM) at which 
the hormone exerts its biological action. The very high affinity demonstrated by 
some hormone receptors may permit the advantageous use of hormone conjugates 
at low concentrations. One such hormone that has received particular attention 
is MSH (a-melanocyte stimulating hormone), which will be briefly described as 
it has formed the basis of this study.
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a-M elanocyte Stimulating Hormone
This basic tridecapeptide [113] is synthesised by the pars intermedia of the pitu­
itary gland of most vertebrates. In man this region of the gland is only present 
during foetal growth when large amounts of MSH are found in the pituitary. The 
hormone shares the same pre-cursor, pro-opiomelanocortin (POMC) as other re­
lated peptides or melanotropins. The peptides only become biologically active 
when they are cleaved from POMC by glycosylation, amidation or acetylation. 
The predominant form of MSH in man is a-MSH which shares an identical central 
sequence with /?-MSH and ACTH (adrenocorticotrophic hormone), (figure 1.3). 
It is hardly suprising that these peptides also display some MSH-like activity.
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Figure 1.3: The amino acid sequences of aMSH, /?MSH and ACTH.
Secretion of the hormone by the pituitary is under the control of the hypotha­
lamus and is subject to circadian rhythm. Various peripheral tissues are MSH 
sensitive, primarily the skin where melanocytes are situated. Circulating hormone 
is mainly inactivated by the skin and skeletal muscles as well as the kidneys, liver, 
lung and intestines. This inactivation is due to enzymatic cleavage primarily by 
an endopeptidase at Phe7-Arg8  in the sequence, followed by exopeptidases caus­
ing degradation to free amino acids. The peptide is also synthesised and secreted 
within the brain, it is considered a neuropeptide with various CNS related ef­
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fects on development, adaptive behaviour, learning, neurotransmission and nerve 
regeneration.
Distribution of the native peptide is not well understood. However when a ra­
diolabelled MSH analogue was injected into B16 melanoma bearing mice, initial 
uptake occurred in the kidney, liver, spleen, tumour and adrenals. No preferance 
was displayed for the tumour and transport, across the blood-brain barrier was 
minimal.
The primary effect of MSH in the periphery is related to skin darkening, it stimu­
lates melanogenesis, proliferation and differentation of melanocytes. The complex 
process of skin pigmentation although well defined in other species, e.g. amphibia, 
is less well defined in man. Skin darkening is basically caused by cell melanisation 
by melanin involving the enzymatic (tyrosinase) oxidation of tyrosine to melanin.
The hormone elicits its biological effect by binding to an extracellular receptor 
since intracellular administration of MSH displayed no response [113]. MSH bind­
ing and subsequent signal transduction appears to require extracellular calcium. 
Binding stimulates adenylate cyclase causing intracellular levels of cAMP to rise, 
this in turn activates protein kinase(s) and causes protein phosphorylation. It is 
unknown how the signal caused by MSH binding is terminated, but one or more 
of three possibilities is thought to occur:
1 . Dissociation of MSH from the receptor.
2. Internalisation of the receptor/ligand complex.
3. Inactivation of MSH.
Although at least part of the receptor/ligand complex is known to be internalised
[114] its intracellular pathway and localisation is unknown.
MSH binding and subsequent signal transduction appears to require extracellu­
lar calcium. Binding stimulates adenylate cyclase causing intracellular levels of
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cAMP to rise, this in turn activates protein kinase(s) and causes protein phos­
phorylation.
The use of MSH as a drug carrier has several advantages in addition to its ‘target­
ing’ potential. It is relatively easy to obtain in a pure form, its small size avoids 
the problems associated with larger conjugates and permits the study of chemical 
manipulations in the peptide sequence (which has shown identical homology in 
all mammals so far investigated). Low immunogenicity would be expected due 
to its natural structural similarity but this may pose the potential problem of 
cross-recognition of the hormone by different receptors. The sequence homology 
with other hormones is very close, ACTH has an identical central sequence to 
a-MSH.
To envisage the use of MSH for selective drug delivery the pertinent characteristics 
for receptor-mediated endocytosis have to be elucidated (see section 1.2.4). This 
therefore involves the determination of receptor binding characteristics, kinetics 
and the subsequent fates of ligand and receptor.
1.4 Therapeutic Agents
Although the use of different cytotoxic agents has been mentioned already ranging 
from conventional drugs to toxins, it seems logical to employ a well characterised 
drug in the experimental stage of any conjugate system. If the pharmacological 
effects of this component are already established (in vitro and in vivo), it permits 
a more defined interpretation of experimental results with the conjugate form. 
For these reasons MTX has proved a popular choice for experimental studies.
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1.4.1 M ethotrexate
Methotrexate (MTX) is a widely used antimetabolite in cancer chemotherapy and 
its structure consists of three components. A multi-ring pteridine group linked 
to para-aminobenzoic acid, which in turn is connected to a terminal glutamic 
acid residue (this displays chirality in its 1-form). MTX (4-amino-4-deoxy-N10- 
methylpteroyl-L-glutamic acid) is a strutural analogue of the natural substrate 
folic acid (figure 1.4), with a 4-amino group instead of a hydroxyl group on the 
pteridine ring, and a methyl group at the N10 position. Since its synthesis in 1949
[115] MTX has proved an effective antitumour agent and has been well reviewed 
[116, 117, 118, 119], particulary with respect to its cellular entry, antimetabolic 
activity, formation of active metabolites and cellular resistance.
Membrane Transport
MTX is a weak bicarboxylic acid and is essentially ionised and lipid insoluble at 
physiological pH. The intracellular accumulation of MTX is via a carrier mediated 
system which has the plasma folate, 5-methyl tetrahydrofolate, as its preferred 
substrate (reviewed by Sirotnak [120]). Transport of MTX results from the dy­
namic interplay between two distinct membrane carrier systems, influx displays 
high affinity for reduced folates and MTX, but low affinity for folic acid. Although 
the carrier has a high saturability (Km 3-26/iM for MTX), entry of these com­
pounds is mediated by a low capacity process. Uptake is saturable, demonstrates 
competitive inhibition by structural analogues, is pH and temperature dependent 
and requires the interaction with specific membrane receptor sites containing sul- 
phydryl groups [121]. Although an energy linked process, the carrier can continue 
to operate in a ‘facilitated’ diffusion mode if uncoupled from its energy source 
[122].
Unlike the entry mechanism, efflux occurs as a first order process with low sat­






















H -  O H CO,H
I II I I
CH2— N---- £  ------C— N---- CH CH2 CH2 CQjH
H,N N
Folic acid
C— N----- CH CH2 CH2 COjH
7,8-Dihydrofolate
H r = \ 9 ? 9°2h
■» \  /
CH2—N (\ /)----c—N-----CH--- CH2--- CH2----COjH
5,6,7,8-T etrahydrofolate
Figure 1.4: The chemically related structures of MTX, folic acid, 7,8-
dihydrofolate and 5,6,7,8-tetrahydrofolate.
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metabolic energy [123] and if blocked results in net augmentation of MTX into 
the cell.
Recently the existence of a second folate membrane binding protein has been 
observed in cells grown in low folate medium ([124, 125, 126, 6 6 , 127, 128]). It 
has a very high affinity (Km < nM) for folic acid over reduced folates, followed by 
MTX [124, 125,126], and is capable of accumulating folate such that intracellular 
concentrations exceed those in the media [129]. The exact transport process is 
unclear, however it is regulated by the folate content of the cell [129, 130] possibly 
explaining its late discovery as cells in culture are usually folate replete (due to 
the high extracellular folate concentrations in the media). Some authors have 
suggested uptake by this membrane protein via receptor-mediated endocytosis 
with recycling of the receptor [126, 6 6 , 129, 130, 131, 132, 133].
Mechanism of Action
MTX exerts its cytotoxic action through the competitive inhibition [74, 134] of 
dihydrofolate reductase (DHFR) due to its structural similarity with the natural 
substrates (figure 1.5). This enzyme catalyses the NADPH-dependent reduc­
tion of folic acid and its 7,8-dihydro- derivative, dihydrofolate (FH2 ) to 5,6,7,8 - 
tetrahydrofolate (TH4 ).
TH4 is responsible for at least 17 single carbon transfer reactions which form the 
building blocks for purine and pyrimidine bases of the nucleic acids, and hence 
DNA synthesis. One of the most important of these reactions is the conversion 
of deoxyuridylate (dUMP) to thymidylate (dTMP) by thymidylate synthetase. 
Here the methylene group of 5,10-methylene-TH4 (formed enzymatically in the 
presence of TH4 and serine) is transferred to the 5-position of the pyrimidine ring 
of deoxyuridylate. In this process TH4 is oxidised to FH2 and DHFR is required 
to complete the cycle by forming TH4 again. However TH4 is not solely used 



























Figure1.5 The mechanism of action of MTX 
* - MTX Block; ** -MTX(Glu)n Block 
D.H.F.R.: Dihydrofolate Reductase, T.S.: Thymidylate Synthetase, FH4: Tetrahydrofolate
FH2: Dihydrofolate, S-Am: S-Adenosyl Methionine, Glu: Glutamyl, M.S.: Methionine Synthetase
Methionine
N5-Methyl-FH4
substrate rather than coenzyme amounts [135]. This exceeds the delivery from 
exogenous 5 -methyl-TH4 sources and relies upon DHFR to replenish the TH4 
pool. Inhibition of DHFR leads to decrease in the cellular pool of TH4 derivatives 
and so a deficiency in thymidylate (thus disrupting nucleic acid production). This 
method of DNA synthesis disruption is the biochemical mechanism by which 
antifolates such as MTX exert their cytotoxic action.
The binding of MTX to DHFR, although not irreversible [136] results in a build­
up of FH2 behind the block [137]. The FH2 then interacts with unoccupied 
enzyme to an extent proportional to its increased concentration. For this reason, 
95% of the intracellular DHFR activity has to be inhibited to achieve an appre­
ciable reduction in cell growth [138]. Inhibition of DHFR is thereby determined 
by the levels of free intracellular MTX which are dependant on the extracellular 
drug concentration and the membrane transport system.
In humans MTX appears to inhibit DNA synthesis to a greater extent than 
RNA synthesis, suggesting that inhibition of thymidylate synthesis is the most 
important mechanism of MTX cytotoxicity [139]. The drug is thus highly cell- 
cycle dependant, so those tissues undergoing rapid cellular turnover with a high 
fraction of cells in cycle are the most susceptible to the cytocidal effects.
M etabolism of MTX
Folates exist primarily in the cell with 5-7 extra glutamyl residues added via the 
7 -carboxyl of the terminal glutamate residue [140]. These derivatives, formed by 
folate polyglutamate synthetase in the cell cytosol, are actually the preferred sub­
strates of DHFR [141]. MTX is also a substrate for this enzyme [142, 143, 144], 
the polyglutamates being formed having equal or even greater affinity for DHFR 
than the unaltered drug [145, 146]. They also dissociate at a much reduced 
rate making themselves less reversible inhibitors than MTX, they are also di­
rect inhibitors of thymidylate synthetase [137] and aminomidazolecarboxamide
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ribonucleotide transformylase [147], the latter involved in de novo purine synthe­
sis.
Once formed intracellulary, polyglutamates exit the cell much more slowly than 
the parent compound, the extent of their retention being dependent on the cell 
type and the glutamyl chain length [148, 149]. This indicates that the MTX 
poly glutamates play an important role in the overall pharmacological effects of 
the native drug. MTX is also oxidised in the liver by aldehyde-oxidase to 7- 
hydroxy-MTX, although reviewed [147], it will not be considered in this report.
Resistance to MTX
From the studies of experimental resistance to MTX, cells may display one or 
more of the following changes:
1. Decreased Membrane Transport
This represents a frequent basis for resistance both in cultured human and 
murine cell lines [150,151,152]. This may arise for a number of reasons, e.g. 
a reduced affinity of the binding protein for MTX, a diminished number of 
the former, or even a decrease in the rate of its translocation.
2. Decreased Affinity of DHFR for MTX
This has been demonstrated in murine and human models [153, 154, 155, 
156] and the altered DHFR may have a 2.5-270 fold decreased affinity for 
MTX [155, 157].
3. Increased Levels of DHFR
This can occur through the process of gene amplification leading to the 
over production of the target enzyme (reviewed [158]). In the experimental 
situation, large increases in DHFR can be induced by long-term incubation 
with increasing amounts of MTX [159].
37
4. Decreased Polyglutamation
There is only preliminary evidence of this type of resistance to date, a 
mechanism has been described in human breast cancer cell line [160], and a 
similar situation with leukemic cells where resistance was thought to occur 
by an alteration in folypolyglutamate synthetase [161].
5. Thymidylate Synthetase A ctivity
Low rates of thymidylate synthesis make cells less susceptible to MTX [162] 
as their demand for reduced folates is decreased.
Clinical Use and Toxicity of MTX
The antineoplastic activity of this drug is used (often in combination therapy) 
against a variety of tumours including acute (non) lymphocyte leukemia, breast 
carcinoma, ovarian cancer, osteocarcinoma, head and neck carcinomas and small 
cell-lung carcinoma [117]. MTX is also used as an immunosuppressive in the 
complication of ‘graft versus host disease’ in allogeneic bone marrow transplant 
[163], and in the treatment of inflammatory diseases e.g. rheumatoid arthritis.
MTX exerts its toxicity primarily on growing, self-renewing tissues, mainly the 
bone marrow and the gastrointestinal system [119].
MTX Use in Site-Specific Drug Delivery
Throughout this brief review of site-specific drug delivery conjugates utilising 
MTX as the cytotoxic component has often been quoted to emphasise its wide­
spread use in this field. Its well characterised pharmacological action and phys- 
iochemical properties makes it an ideal choice in the experimental stage of con­
jugate development, although it does posess some disadvantages e.g. some weak, 
non-covalent bonds when conjugated to proteins and peptides (see section 1 .3 .1 ). 
However in the clinical situation it is envisaged that MTX will be superseeded
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by a more potent drug moiety. It has been estimated that at least one million 
molecules of MTX are required to achieve cell death which would demand high 
drug incorporation ratios into a conjugate or a very efficient mode of cell up­
take and drug release. A more potent compound would ease these demanding 
limitations.
1.5 Sum m ary
The development of macromolecular drug conjugates can be established depend­
ing upon the disease state in question. Most work has involved cancer chemother­
apy with limited success in vivo. The design of these conjugates has to be based 
on the characteristics of the tumour cells (e.g. cell type, localisation), the phys- 
iochemical properties of the drug employed and their interaction depending upon 
the (un)modified carrier. The success of these ‘tailor-made’ complexes will be 
linked to their pharmacological and physiochemical properties plus their degree 
of specificity. Therefore the field of site-specific drug delivery involves a multi­
disciplinary approach.
1.6 Overview
In order to assess the cellular interactions of a macromolecular conjugate the 
binding characteristics and fate of the individual components must be evaluated 
before using the entire complex. As already emphasised, the fate of a targeting 
moiety alone will partly predetermine its potential use, i.e. it should ideally 
be readily internalised and display minimal cross-reactive binding. Non-specific 
uptake processes also need to be assessed in order to estimate the degree of 
toxicity to non-targeted cells. This entails investigating any cellular binding due 
to the carrier and drug molecules of the conjugate, plus an evaluation of non- 
selective pinocytic uptake by cells.
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The conjugate system under investigation in this study employed an analogue of 
the hormone aMSH as a potential targeting group and MTX as the cytotoxic 
component, the two were then linked in a ratio of 1:1. The binding and uptake 
characteristics of the individual components on B16 murine melanoma cells was 
studied with the use of radio-isotopes before being compared to their conjugate 
forms. The non-specific process of pinocytosis was also assessed for this tumour 
cell line and two others in order to ascertain the importance of this non-selective 
entry route into the cell.
Finally toxicity was studied by investigating the release of active fragments from 
the lysosomal degradation of the conjugate in vitro through the inhibition of 
DHFR, the target enzyme for MTX. The assumption was that if the conjugate 




M aterials and M ethods
2.1 Cell Culture
Cell Lines
Three different transformed cell lines were employed, studies with B16 murine 
melanomas formed the majority of the cell-culture based work. The two other 
cell lines were of human origin, HMB-2 melanoma cells and SVK-14 keratinocytes. 
The B16 and SVK-14 cells were propagated in RPMI 1640 medium, whilst HMB- 
2 cells utilised DMEM.
2.1.1 Solutions 
Water
All water employed in the preparation of cell culture media and solutions was 
freshly double glass distilled by a bi-distillation Fistreem still (Fisons Ltd) fitted 
with a Fistreem predionizer (Fisons Ltd).
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Balanced Salt Solution
Phosphate buffered saline (PBS) (without calcium and magnesium) was obtained 
from Oxoid Ltd in a tablet form. Ten tablets were dissolved in 1 L of freshly double 
distilled water and divided into 125ml Flow bottles before being sterilized and 
stored at 4°C.
Base Solutions
Both sodium bicarbonate (7.5% w/ v) and sodium hydroxide (2M), from BDH 
Chemicals, were prepared with double distilled water, sterilized and stored at 
room temperature.
Ethylenediaminetetraacetic Acid (EDTA)
A 0 .0 2 % w/ v EDTA solution prepared with sterile PBS was passed through a 
0.2/zm diameter filter and 2 0 ml fractions aliquoted into sterile universals (Sterilin 
Ltd). These were stored at -20°C until required.
Trypan Blue
The stain, obtained from Sigma Ltd, was stored at room temperature as a 0.4% 
solution in PBS.
Growth Media and Components
RPMI 1640 (Flow Laboratories) and DMEM (Gibco Ltd) were both obtained 
as lOx liquid concentrates containing phenol red indicator but deficient in 1- 
glutamine and sodium bicarbonate. The following media supplements were all
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obtained sterile from Flow Laboratories, 1-glutamine (2 0 0 mM), an antibiotic so­
lution (pen/strep) of penicillin (5000 IU/ml) and streptomycin (5000/ig/ml), and 
non-essential amino acids (NEAA). Growth media and NEAA were stored at 4°C 
whilst 1-glutamine and pen/strep were kept frozen at -2 0 °C.
Foetal calf serum (FCS) from Flow Laboratories was batch-tested for the support 
of cell growth supplemented at 10% v/ v to normal growth medium. Maximum 
growth occurred with batch number 9130102 which was used throughout the 
work. Serum arrived in 500 ml bottles and was stored at -2 0 ° C.
Cell growth media was aseptically prepared from sterile components according to 
the following recipe, stored at 4°C and used within two weeks:
RPMI 1640 DMEM
lOx Media 50 ml 50 ml
Water 421.5 ml 410 ml
1-Glutamine 5 ml 5 ml
Pen/Strep 5 ml 5 ml
NEAA 5 ml 5 ml
NaHC03 13.5 ml 25 ml
FCS 55.6 ml 55.6 ml
Both media required a small addition (c.lml) of sterile 2M NaOH (BDH Chemi­
cals) to attain a final pH of 7.2-7.4.
Autoclave labile solutions were sterilized in small volumes by membrane filtration 
using sterile 0.2/mi filters from Gelman Sciences. All other solutions were steril­
ized in an autoclave (British Sterilizer Co. Ltd, Swingclave Type SFT-LAB) at 
121°C for 15 minutes.
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2.1.2 Equipm ent
All manipulations involving the mammalian cell lines were performed in a verti­
cal recirculating laminar flow cabinet (MDH Ltd). Experimental protocols not 
requiring sterile technique were performed at the bench.
A LEEC PF2 anhydric incubator (Laboratory and Engineering Company) with 
forced air circulation was used with thermostatic controls adjusted to give a 
temperature of 37°C for culture incubation. It was regularly checked with a 
digital thermometer with a thermocouple probe (Jenway Ltd).
All cells were stored in 2ml ampoules shelved in the vapour phase of a Union 
Carbide LR-40 liquid nitrogen refrigerator at approximately -148°C.
An inverted biological microscope WILD M40 (Wild Heerbrugg Ltd) was used 
for the examination of growing cell cultures and haemocytometer counting (a 
standard double grid haemocytometer (Fisons Ltd) was used throughout).
Sterile tissue culture flasks (25, 75 and 150cm2 in size) were regularly obtained 
from Flow Laboratories or Sterilin Ltd. Tissue culture tubes, 100x16mm with 
screw caps and 30ml screw capped universal containers were also obtained sterile 
from Sterilin Ltd. Polypropylene 2ml ampoules with screw-caps used for the 
storage of cells in the vapour phase of liquid nitrogen were obtained sterile from 
J. Bibby Sciences.
2.1.3 C ell C ulture M ethods
Preparation of Glassware and Non-Glassware Items
All recycled items were rinsed in tap water immediately after use and then pro­
cessed as follows. Glassware was soaked in a 2 % solution of RBS 25 (Fisons Ltd) 
at approximately 40°C for 30 minutes, then thoroughly cleaned using a nylon
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brush. Articles were subsequently rinsed in three changes of tap water, leaving 
for 30 minutes in the last rinse. The process was then repeated using single dis­
tilled water. Finally all glassware was left to stand in a large volume of freshly 
collected double distilled water for no longer than 1 hour. After drying in a hot 
air oven (Gallenkamp) all items were capped with aluminium foil and sterilized 
by dry heat at 160°C (Gallenkamp Sterilising Oven) for a minimum of 1 hour.
Non-glass items, mainly tips for replicating pipettes, bottle caps and syringes 
were rinsed immediately after use and then cleaned by boiling in three changes of 
fresh distilled water. Finally they were rinsed and left for 1 hour in a large volume 
of freshly double distilled water, dried, sealed in autoclave bags (DRG Hospital 
Supplies) and sterilized in an autoclave (Drayton Castle Laboratory Steriliser) at 
121°C for 15 minutes.
Cell Line Sub-Culture
Sub-culture was undertaken when the cells had reached confluency and the growth 
rate had almost ceased. In this state the cells completely covered the floor of the 
tissue culture flask and further growth was limited by contact-inhibition and 
the availability of nutrients in the media (the latter turned orange/yellow in 
appearance the longer cells remained confluent). At this point the culture was 
subject to a sub-culture routine which involved removing a fraction of the cells 
and seeding them into a new flask with fresh media.
Initially the existing culture was optically examined to ensure the cells were 
healthy in appearance with no free-floating cellular debris or any signs of contam­
ination. At the laminar flow cabinet the old media was then decanted off before 
the culture received two 5ml washes of pre-warmed PBS (37°C) and was gently 
agitated to ensure the cell monolayer was entirely rinsed during each wash. The 
flask was then incubated at 37°C containing 2ml of pre-warmed 0.025% EDTA 
for 1 0  minutes.
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Upon removal from incubation the flask was gently agitated to dislodge the cells 
from the surface of the plastic before the addition of 5ml of fresh media. Using 
a sterile plugged pasteur pippette, the cell suspension was gently aspirated and 
transferred to a sterile test-tube in order for the cell density to be determined. A 
new 150cm2 tissue culture flask containing 45ml of pre-warmed media was then 
innoculated with a known number of cells and purged with 5% CO2 in air (BOC 
Special Gases) for 20 seconds before the cap was tightly sealed. The culture was 
then gently dispersed by agitation and placed in a dark, 37°C enviroment until 
confluent.
B16 cells were sub-cultured three times a week in order to maintain the culture 
in an active state of growth i.e. confluency was never fully achieved. This was 
attained by seeding new cultures on a Monday and Wednesday with 4.5xl06 cells, 
and on a Friday with 3.0xl06 cells. Other cell lines employed were maintained in 
a similar state of growth.
Determ ination of Cell Density and Cell Viability
Cells prepared in a suspension form were thoroughly mixed and a small volume 
removed from just below the fluid surface with a pasteur pipette before being 
loaded into a haemocytometer chamber under a coverslip. Each chamber was 
divided into nine large squares by triple white lines, the four corner squares 
being further sub-divided into 16 squares per corner. A total count was made 
on eight large squares of the haemocytometer grid (using a double chambered 
haemocytometer) with an inverted microscope.
If cell clumping was observed the count was abandoned and the cell suspension 
further aspirated before a new sample was taken. If the cell density was greater 
than 150 per large square then counting became impeded by over-crowding and 
the original cell susupension was diluted accordingly before a new count. Con­
versely if a low count was observed (<25 cells per large square) the cell suspension
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was concentrated by centrifugation (lOOOg for 5 minutes).
Each large square had an area of 1mm2, when the coverslip was pressed down 
such that interferance patterns appeared, the depth of the chamber was 0 .1 mm. 
The total volume of each square was therefore:
1 x 1 x 0 . 1  =  0 .1 mm3 =  0 .0 0 0 1 cm3 =  1 0 "4ml
The total count per ml, i.e. cell density, was given by 104 n, where n is the average 
number of cells per large square.
Cell viability could also be determined during a haemocytometer count with the 
use of trypan blue. Viable cells exclude the dye whilst non-viable cells are stained 
a dark blue, a cell density count would include the former only.
This procedure involved mixing 0 .2 ml of cell suspension with 0.3ml PBS and
0.5ml of 0.4% trypan blue (Sigma Ltd) and allowed to stand for 10-15 minutes 
(any longer involved the loss of viable cells). A dilution factor of 1 in 5 had to 
be considered due to the mixture.
Cell Storage
All cells were routinely stored frozen in the vapour phase of liquid nitrogen, in 
the presence of a cryoprotectant (10% dimethyl sulphoxide, DMSO). Cells were 
required to be in an active state of growth for storage, hence cells ready for routine 
sub-culture were suitable. Cell suspensions were prepared from the monolayer 
state and centrifuged at lOOOg for 5 minutes (Jouan B3-11 bench centrifuge). 
The supernatant was removed and the cell pellet resuspended in a volume of 
filter-sterilised growth media containing 10% DMSO to attain a final cell density 
of 2xl06 cells/ml. Replicate volumes of 1 ml were placed in 2ml polypropylene 
ampoules (J.Bibby Sciences) and a maximum of eight were placed in a Union
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Carbide BF6  biological freezer unit plug in the top of a Union Carbide LR 33-10 
liquid nitrogen refrigerator. Here the cells cooled to below -70°C in the vapour of 
the liquid nitrogen at a rate of about l°C/minute before being rapidly transferred 
to a liquid nitrogen freezer (Union Carbide LR-40) for long term storage.
Recovery of Cells from Storage
Immediately upon removing an ampoule from storage it was placed in a 37°C 
waterbath until completely thawed and then swabbed in 70% ethanol (care was 
taken to ensure the ampoule was not completely immersed above the screw- 
cap lid). The contents were aseptically removed and diluted in 9ml of normal 
growth media before being centrifuged at lOOOg for 5 minutes. The supernatant 
was removed and the cells resuspended in 3ml of growth medium before being 
transferred to a culture flask containing 40ml of pre-warmed medium. After 2-3 
days the cells had formed a monolayer suitable for routine sub-culture.
Preparation of B16 Cells in Multi-Well Plates
Many experiments employed B16 cells grown in multi-well plates that had just 
attained confluency. The cell density was determined for a cell suspension from 
routine sub-culture before 12-well plates (2.4x1.7cm, Flow Laboratories) were 
innoculated with 0 .6 x l0 5 viable cells per well plus growth medium to reach a 
final volume of 1 ml in each well. A maximum of eight plates were then placed in 
a rigid clear polystyrene 3.25 litre box (Gallenkamp) containing a small beaker 
of sterile water, the box sealed with gas tight vinyl tape (Intech Tapes Ltd) 
and incubated at 37°C in the dark. After seven days the cells were ready for 
experimental use.
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2.2 Cellular U ptake o f Iodinated Polyvinyl-Pyrro- 
lidone (P V P )
It was decided from the outset to employ a cell-suspension technique rather than 
to use cell monolayers. The latter method can give rise to apparent non-cellular 
uptake due to entrapment in extracellular spaces. The first attempt was a shake- 
flask method. 5xl06cells were suspended in 5ml of serum free medium contained 
in a cotton-wool stoppered flat-bottom flask. The suspensions were agitated in a 
shaking water bath at 37°C. Cell clumps began to form after 15 minutes so the 
method was abandoned in favour of the current method described below.
The uptake of 1 2 5I-PVP (ICN Radiochemicals Ltd.) was measured in three cell 
lines, B16 mouse melanomas, HMB-2 human melanomas and SVK-14 human ker- 
atinocytes. A cell suspension from one of the lines was prepared using three pre­
confluent 150cm2 culture flasks (four flasks with SVK-14 cells) and centrifuged 
at lOOg for 5 minutes. The supernatant was discarded and the cell pellet re- 
suspended in 4.5ml of growth media before the cell density and viability were 
determined. A volume of 4.1ml of cell suspension was subsequently transferred 
to a glass test-tube and incubated in a 37°C waterbath. Cells were held in suspen­
sion by a glass paddle being rotated at approximately 70-90 rpm by a Gallenkamp 
motor.
After one hour 0.9ml of pre-warmed media containing c.1 . 8  million cpm/ml of 
1 2 5I-PVP was supplemented to the suspension, this point being time zero. At 
desired time points 0.5ml of the suspension was removed and diluted with 4.5ml 
of ice-cold media devoid of FCS but containing lmg/ml of unlabelled PVP (in 
order to minimise non-specific binding of the radio-label to the plastic [164]). 
The sample was then centrifuged at lOOg for 1 minute at 0°C before the su­
pernatant was removed and retained for assessment of radioactivity. The cells 
were resuspended in 5ml of identical fresh ice-cold media and recentrifuged. Each 
of the nine samples received five centrifugation washes, the cell pellet from the
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final wash being resuspended in 1 ml of media and the activity assayed (along 
with the supernatants of each wash) using a gamma-counter (LKB Wallac 1277 
Gammam aster).
A control experiment in the absence of radio-labelled PVP revealed no appreciable 
decrease in cell viability during the 37°C incubation or the centrifugation washes.
2.3 Interaction o f Tritiated M ethotrexate w ith  
B16 Cells
Tritiated Methotrexate (3 H-MTX) was obtained from Sigma Chemical Co. and 
stored in a diluted form with 160mM Hepes buffer (pH 7.4) at -20°C. Cyanamid 
UK Ltd supplied the unlabelled drug which was prepared fresh in solution with 
an identical buffer immediately before use. All binding and uptake experiments 
hereafter employing radioligands used a 160mM Hepes buffer (Calbiochem) ad­
justed to pH 7.4 with 1 M HC1.
2.3.1 B inding o f 3H -M T X  at 4°C
Media from 12-well plates containing cell monolayers (see section 2.1.3) was re­
moved by vacuum and each well received one 3ml PBS (4°C) wash. Ice-cold 
incubation buffer (1 ml/well) was supplemented to each plate and incubated at 
4°C for 30 minutes unless otherwise stated. Incubation buffer consisted of 160mM 
Hepes containing either 3 H-MTX and/or an excess of unlabelled MTX (100/zM). 
At high concentrations of MTX insufficient labelled compound was available, in­
stead 3 H-MTX was mixed with a known amount of ‘cold’ MTX and a dilution 
factor taken into consideration (this assumed equal binding affinities of the two 
compounds).
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When the 4°C incubation was terminated, binding buffer was removed by pipette 
and each well received 3x3ml ice-cold PBS washes. At this point if an acid-wash 
was employed desired wells received 0.5ml of citrate buffer (pH 2.5) for 5 min­
utes at 4°C after which the citrate buffer was removed and the well exposed to 
a 1 ml PBS wash. Cells were then digested with 1 ml of 1 M NaOH per well and 
transferred to scintillation vials containing 1ml of 1 M HC1. Vials were supple­
mented with 8 ml Optiphase (from LKB Scintillation Products) scintillation fluid. 
Vials were then thoroughly mixed and left overnight before being counted on a 
beta-counter (LKB Wallac 1215 Rackbeta liquid scintillation counter).
The PBS and acid-wash routine, plus the cell monolayer digestion with NaOH 
was standard for all experiments employing radiolabelled compounds. The acid- 
wash buffer consisited of 21.01g of citric ac id .l^ O , 5.43g of NaCl and 23.44ml 
of 1 M NaOH made up to 1L with distilled water.
The cell density per well for this type of experiment was determined from a single 
plate exposed to the experimental procedure but in the absence of radioligand. 
Cells were detached with a 0.025% EDTA solution.
2.3.2 B inding and Uptake o f 3H -M T X  at 37°C
The experimental protocol was essentially identical to that at 4°C, except the 
cells were initially washed with 3ml of pre-warmed (37°C) PBS before incubation 
with the radio-ligand (incubation buffer was also pre-warmed before use). Plates 
were incubated at 37°C until removed and subjected to the standard PBS and 
acid-wash protocol.
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2.3.3 Inhibition of 3H-MTX Binding (4°C) by NLDP-
MSH-MTX
These experiments was performed in order to investigate the binding inhibition by 
the conjugate against a fixed concentration of 3 H-MTX (25nM). Cells grown for 
7 days were washed with ice-cold PBS and incubated with 1 ml of Hepes binding 
buffer containing 200nM NLDP-MSH (to minimise binding of the conjugate due 
to the NLDP-MSH moiety) and 0.2% BSA for 1 hour at 4°C. A further volume of
0 .1 1 ml was then supplemented to each well containing labelled and/or unlabelled 
MTX plus increasing concentrations of the conjugate. This was incubated for 
a further 1 hour at 4°C before plates were washed and the activity assayed by 
the standard procedure. Two 12-well plates contained labelled and/or unlabelled 
MTX only (total and non-specific binding respectively).
Two ‘forms’ of NLDP-MSH-MTX were used corresponding to two peaks from the 
HPLC purification of the conjugation reaction, probably corresponding to linkage 
via the a  or 7  carboxyl groups of the MTX glutamyl moiety (see chapter 6 ).
2.4 Interaction o f 125I-N leu4-D P h e7-oM SH  w ith  
B 16 M urine M elanom a
2.4.1 Synthesis o f N leu 4-D P h e7-aM SH  (N L D P-M SH )
The synthesis of the peptide and its conjugate with MTX was performed by 
Dr G. W. Olivier, therefore the protocol for their manufacture will not be de­
scribed in full. Peptides were prepared by solid-phase synthesis using the Fmoc 
strategy as developed by Atherton and Sheppaxd [165]. The peptides were pre­
pared as their carboxyamide forms using the AM-linker on Pepsyn K resin. All 
the amino-acid reagents were used as their pentafluorophenyl esters with the
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exception of serine in which the 3,4-dihydro-4-oxobenzotriazin-3-yl ester was em­
ployed, and Fmoc-DPhe-OH which was treated with DIC and HOBT to form 
its HOBT active ester in situ. Side chains were protected as follows: Arginine, 
methoxytrimethylbenzene-sulphonyl(Mtr); Glutamic acid, t-butoxy (OBut); His­
tidine, t-butoxy-carbonyl (Boc); Lysine, (Boc); Serine, t-butyl (But); Tyrosine 
(But). A four-fold molar excess of reagents was used in all instances.
Deprotection and cleavage was performed using 2% EDT, 2% anisole and 1 % 
water in TFA for 8 hours at room temperature. Peptide was purified using 
semi-preparative HPLC employing a gradient elution of 0.1% TFA in water and
0.1% TFA in acetonitrile:water (70:30) at a flow rate of 3ml/minute. The elu­
ent was continuously monitored by UV spectrophotometry at 217nm. Fractions 
were collected in 1.5ml aliquots and each fraction was tested by analytical scale 
HPLC. Fractions were bulked according to their chromatographic profile and 
freeze-dried. Identity was confirmed by co-chromatography with authentic [Nleu4, 
DPhe7]aMSH (Sigma Chemical Co.) and by FAB-MS. Prior to experiments the 
peptide was prepared at a stock concentration of lmg/ml in sterile O.lmM HC1 
and stored at 4°C.
2.4.2 Synthesis o f N a-M T X - [Nleu4,D P h e7]-aM SH  (N L D P -
M SH -M T X )
The peptide conjugate was prepared by addition of NHS-MTX in DMF to 300mg 
of the resin after deprotection of the N-terminus. The target peptide was obtained 
after deprotection and cleavage of the petidyl resin and HPLC purification using 
the same conditions as for the NLDP-MSH analogue. Identity was confirmed by 
FAB-MS.
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2.4.3 Iodination of NLDP-MSH
The peptide was iodinated at the tyrosine residue (position 2) using a procedure 
based on the protocol described by Eberle [113]. The following stock solutions 
were routinely prepared and stored at 4°C:
1 . 0.25M Na2 H P0 4 in H2 0.
2 . 0.25M NaH2 P 0 4 in H2 0.
3. 1% TFA (trifluoroacetic acid) in H2 0 .
4. 50, 60 and 80% methanol with 1 % TFA.
The following solutions were prepared daily prior to each iodination:
1. 0.25M phosphate buffer (PB), pH 7.4 (from Na2H P 0 4 and NaH2P 0 4 stock
solutions).
2 . 0.25% BSA in 0.25M PB.
3. 1% Polypep in 0.25M PB.
4. 0.1% Chloramine T (BDH Chemicals Ltd) in H20  (dissolved immediately 
prior to use).
Initial iodinated peptide was purified with a C18 reverse-phase column with 
Spherisorb ODS ‘Bond Elut’ (Analytical International, MFG Code OH53). The 
column was prepared and conditioned by receiving the following wash routine 
(each wash being 1 ml):
1. 3x1% TFA.
2. 3x80% methanol/1 % TFA.
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3. 1 x 1 % Polypep.
4. 3x80% methanol/1 % TFA.
5. 3x1% TFA.
A 1.5ml eppindorf containing 20/zl of 0.25M PB and 1.5/d of peptide (from a 
lmg/ml stock) was transferred to a radioactive fume hood for the addition of 
1.5mCi of 1 2 5INa. This was followed by 1 0 /d of freshly prepared 0.1% Chlo- 
ramine T which marked the start of the reaction. After 30 seconds 0.6ml of
0.25% BSA was added to the eppindorf to halt the reaction. The entire con­
tents were then loaded onto the pre-conditioned C18 column which received the 
following 1 ml washes:
1 . 2x0.25M PB.
2. 4x50% methanol/1% TFA.
3. 2x60% methanol/1 % TFA.
The last two sets of washes were saved (6 ml in total) and the peptide was further 
purified by HPLC using a C18 reverse-phase wide pore (300A) column, 25cm 
in length and 4.6mm in diameter. The methanolic wash was loaded onto the 
column which was run with an exponential gradient starting at 95% A, 5% B 
and after 55 minutes reaching 40% A, 60% B before returning to the original 
values. The solvents were 0.1% TFA in water (A) and 70% acetonitrile/0.1% 
TFA (B). A UV detector was employed at 217nm. Ten 1 ml fractions were 
collected after 28 minutes (flow rate lml/minute) and their activity assayed on a 
gamma counter.
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2.4.4 Iodination  o f N L D P-M SH -M T X
The iodination procedure was identical to that for the unconjugated peptide 
except 5/xl of NLDP-MSH-MTX stock (lmg/ml) was used, the reaction time 
with Chloramine T was extended to 5 minutes and the washings of the C18 pre­
conditioned reverse-phase column once loaded with the reaction products were 
altered to:
1 . 2xlml 0.25M PB.
2. 2 xlml 40% methanol/1 % TFA.
3. 2xlml 50% methanol/1 % TFA.
4. 2xlml 60% methanol/1 % TFA.
The remaining 2ml from the 60% methanol/1% TFA wash was retained and 
further purified by analytical HPLC. The chromophore of MTX permitted in­
creased UV detection of the peptide conjugate with a change in the wavelength 
from 217nm to 300nm, whereas NLDP-MSH has a poor UV absorbance.
2.4.5 B inding Isotherm  o f 125I-N L D P-M SH  on B16 Cells
The 4°C binding experiments, and all subsequent work with 1 25I-NLDP-MSH and 
B16 cells involved the 7 day growth of the latter in 12-well tissue culture plates 
as previously described. The structure of the protocols were similar to those 
employed for tritiated MTX.
Media was removed from confluent plates and each well received a 3ml ice-cold 
PBS wash. Plates were then incubated at 4°C with 0.5ml/well of binding buffer 
(160mM Hepes, 0.2% BSA and 0.3mM 1,10-phenanthroline) supplemented with 
1 25I-NLDP-MSH with or without an excess (1/fM) of unlabelled NLDP-MSH.
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A standard incubation period of 8  hours was employed (unless otherwise stated) 
for each binding isotherm which was terminated by the standard PBS wash pro­
cedure. Cell-monolayers were digested as previously mentioned with 1 M NaOH 
and the 1 ml solution transferred to counting tubes and the activity assayed with 
a gamma counter.
2.4.6 U ptake o f 125I-N L D P-M SH  at 37°C
Medium was removed from the plates and each well washed with 3ml of PBS 
(37°C) before being supplemented with 0.5ml of pre-warmed binding buffer and 
incubated at 37°C. Uptake was terminated by the standard PBS wash routine 
after which some wells (exposed to 12 5I-NLDP-MSH only, i.e. no unlabelled 
peptide present) received an acid-wash. Monolayers were then digested and the 
activity assayed.
2.4.7 B inding and Uptake o f 125I-N L D P-M SH  at 37°C
Plates were washed with 3ml of ice-cold PBS and incubated at 4°C with 0.5ml/well 
binding buffer containing 0.5nM iodinated NLDP-MSH (with or without excess 
unlabelled peptide). After one hour plates were removed from the 4°C enviro- 
ment and received the standard PBS wash before being reincubated with binding 
buffer with or without 1 /zM cold peptide at 37°C for various lengths of time. The 
cells were finally washed again before being digested and the activity assayed. 
Some wells received an acid-wash after the final PBS rinse.
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2.4.8 B inding Inhibition  o f 125I-N L D P-M SH  by th e N L D P- 
M SH -M T X  Conjugate
These experiments studied the binding inhibition of 0.25nM labelled NLDP-MSH 
by increasing concentrations of the NLDP-MSH-MTX conjugate at 4°C. Wells 
were first washed with ice-cold PBS and then incubated for 30 minutes at 4°C 
with 0.45ml/well of Hepes binding buffer containing 0.3mM MTX (in order to 
minimise any binding of the conjugate due to the MTX moiety). A further volume 
of 0.05ml was supplemented containing 1 2 5I-NLDP-MSH and the conjugate. After 
an 8  hour incubation cells were washed, digested and the activity assayed.
2.4.9 Interaction o f 125I-N L D P-M SH -M T X  w ith  B16 M urine 
M elanom a
Two types of experiments were employed, incubation at 37°C only, and exposure 
to 125I-NLDP-MSH-MTX first at 4°C, the cells washed and then reincubated 
at 37°C in binding buffer only. The protocols used were identical to those for 
1 2 5I-NLDP-MSH, substituting the labelled conjugate for iodinated NLDP-MSH.
2.5 D ihydrofolate R eductase E nzym e A ssay
2.5.1 M aterials
The main buffer employed in the assay was 0.5M sodium acetate with 0.6M 
potassium chloride (BDH Chemicals), adjusted to pH 6.0 with glacial acetic acid.
A second buffer was also prepared consisting of 0.15M mercaptoethanol (Sigma 
Chemical Co.) in the former sodium acetate buffer.
The enzyme, bovine dihydrofolate reductase, was obtained from Sigma Chemical
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Co. and arrived in a stable form precipitated with ammonium sulphate to prevent 
hydrolysis of any hydrophobic groups on the protein surface. Five units of the 
enzyme were supplied and dissolved in 50ml of sodium acetate and KC1 buffer 
pH 6 . This was transferred to a cellulose acetate dialysis tube (pore diameter 
l-20nM) and suspended overnight in 3L of the aforementioned buffer in order 
to remove the ammonium salt. The buffer was continuously agitated with a 
magnetic stirrer. The contents of the tubing were then aliquoted in 1ml volumes 
into glass vials and stored at -20°C. Note:- 1 unit of enzyme will convert 1 .0 //mole 
of dihydrofolate and NADPH to tetrahydrofolate and NADP per minute at 25°C, 
pH 6 .
The compounds 7,8-dihydrofolic acid (dihydrofolate, FH2 ) and 5,6,7,8-tetrahydro- 
folic acid (tetrahydrofolate, FH4) were obtained in solid form (Sigma Chemical 
Co.). The entire contents of each vial were weighed and then dissolved in sodium 
acetate and KC1 buffer (containing mercaptoethanol as an antioxidant) to give a 
final concentration of 2.41mM. Aliquots of 1 ml were then stored in liquid nitrogen 
until used.
NADPH was obtained as a freeze-dried solid (Sigma Chemical Co.) in lmg vials 
and dissolved with 1 ml of sodium acetate and KC1 buffer immediately prior to 
use.
Methotrexate (Cyanamid) and NLDP-MSH-MTX were dissolved in sodium ac­
etate and KC1 buffer and stored at 4°C.
2.5.2 A ssay Procedure
The spectrophotometric assay was based on a method described by Peterson et 
al. [166]. A quartz cuvette, with an optical path length of 1 cm, contained 2.6ml 
of sodium acetate and KC1 buffer (pH 6 ), 0.15ml of NADPH (from a lmg/m l 
solution) and 0.1ml of DHFR enzyme stock. This was allowed to equilibrate
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for 5 minutes at 37°C in a Pye Unicam cell temperature recorder connected to 
a Pye Unicam PU8610 UV/V15 kinetic spectrophotometer with a PU8605 cell 
programmer.
The reaction was initiated upon the addition of 0.15ml of FH2 stock (120^M 
final concentration), each cuvette was thoroughly mixed by being inverted three 
times. The spectrophotometer was zeroed using a cuvette before the addition of 
FH2 . Absorbance readings were recorded for a maximum of six cuvettes every 
30 seconds at 343nm for 10 minutes.
The aforementioned cuvette mixture constituted a standard test reaction, nega­
tive controls were performed twice daily and consisted of 2.75ml of sodium acetate 
and KC1 buffer with 0.1ml of DHFR. After 5 minutes equilibration at 37°C, 0.15ml 
of NADPH (1 mg/ml) was added and the absorbance recorded for 10 minutes.
Assays in the presence of inhibitors substituted 0.3ml of the buffer for 0.3ml of 
inhibitor solution, cuvettes in all experiments had a total volume of 3ml. The 
inhibitor was allowed to equilibrate with the enzyme before the addition of FH2 .
2.5.3 Isolation o f Lysosom al E nzym es
Rat liver lysosomal enzymes were obtained by extraction based on the estab­
lished method of Trouet [167]. Five large male Wistar rats were injected intra- 
peri toneally with 20% w/ v Tyloxopol (formerly known as Triton WR1339) in 
water at a dose of 1 ml per lOOg body weight. Four days later the rats were 
sacrificed, their livers quickly removed and placed on ice in a 0.25M sucrose solu­
tion. The liver tissue was minced with scissors and homogenised in 0.25M sucrose 
solution using an Atomix homogeniser (MSE). The homogenate was then cen­
trifuged at 15,000 rpm for 10 minutes using a High Speed 18 centrifuge (MSE). 
The supernatant was removed, the pellet resuspended in 0.25M sucrose and the 
process repeated. The combined supernatants were subsequently centrifuged for
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60 minutes at 12,000 rpm. The supernatant was removed and the pellet resus­
pended in 45, 35.5 and 14.3% w/ v gradient sucrose solutions and centrifuged at 
25,000 rpm for two hours at 4°C in a Beckman L8 -M centrifuge. A distinct band 
of lysosomes collected at the interface of the 34.5 and 14.3% sucrose layers and 
was removed using a Pasteur pipette before being placed in 5ml vials and stored 
at -2 0 °C.
This method permitted the separation of lysosomes from other cellular compo­
nents of similar density as the surfactant specifically collects in the liver lysosomes 
producing a reduction in their equilibriation density. The Tyloxopol is unable to 
leave the vasculature except in the liver where the loose junctions of the sinusoidal 
capillaries allows the surfactant to penetrate the tissue.
2.5.4 Lysosom al D egradation o f N L D P-M SH -M T X
This was adapted from the method described by R. J. Marriott [168]. A degra­
dation mixture was prepared as follows and incubated at 37°C with samples 
removed after 0, 2, 4 and 16 hours and then serially diluted in sodium acetate 
and KC1 buffer (pH 6 ). The degradation mixture contained reduced glutathione 
for activation of the thiol proteases and the EDTA was used to chelate any metal 
ions present which may interfere with the enzyme activity. The sodium acetate 
and KC1 buffer was adjusted to pH 5 to optimise the lysosomal activity.
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Compound Volume (ml)
1 . NLDP-MSH-MTX (0.5mM) 0.50
2. Reduced glutathione (73.5mM) 0.08
3. EDTA (14.8mM) 0.08
4. 1 % Superonic OP 11 solution 0.03
5. Water 0 . 0 1
6 . Tritisome solution 0.30
8 . Sodium acetate and KC1 buffer (pH 5.0) 0.50
Chapter 3
Accumulation of Extracellular 
Fluid by Pinocytosis
3.1 Introduction
Iodinated polyvinyl pyrrolidone (12 5I-PVP) was used as a marker for fluid phase 
endocytosis as it has been shown not to adsorb to cell membranes, is not degraded 
and is easy to quantify [164, 169, 170]. The rate of fluid-associated uptake of this 
marker was measured at 37°C in B16, SVK-14 and HMB2 cells prepared from 
monolayer cultures.
3.2 M ethods
The suspension method employed for the three cell lines is described in section 2.2.
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3.3 R esults
These experiments were exquisitely sensitive and were required to be performed 
very carefully to avoid large error, as the amount of uptake being measured was 
so small. All extracellular 12 5I-PVP had to be thoroughly removed and this 
was achieved using five centrifugation washes. This protocol was established by 




cpm of 1 ml of supernatant




4 0 . 0 51.9
5 1.5 7.1
Table 3.1: The measured 125I activity in 1 ml of the centrifugation washes at 0°C 
of samples of B16 cells exposed to 1 25I-PVP for 10 and 150 minutes respectively 
at 37°C.
The volume of fluid uptake expressed per 106 cells was calculated from three 
determined values;
1. The known concentration of 1 2 5I-PVP in the medium (cpm per ml of medium) 
was determined from the supernatant washes. The activity of each super­
natant from the five centrifugation washes was assayed for the first and last 
0.5ml time samples. A mean value for the concentration of 1 2 5I-PVP per 
0.5ml sample expressed as cpm was obtained and converted to ‘cpm per ml 
of medium.’
2. The cell density per 0.5ml sample (x) was determined from the known cell 
density in the experimental medium. The latter was innoculated with the
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required number of cells from a cell suspension where the cell density and 
viability had been assayed by a haemocytometer count.
3. The 12 5I-activity associated with the cell pellet from each experimental 
sample (cpm per 0.5ml sample).
Using these values the cpm associated with 106 cells was initially calculated (equa­
tion 3.1) and then expressed as the volume of fluid uptake per 106  cells (equa­
tion 3.2). It was noted that any small error in the activity of a sample e.g. poor 
washing of the pellet, is magnified due to this method of calculation.
cpm per 1 0 * cells =  W f £ 0 | n l s ^  ( ( 3  ^
Volume of Fluid Uptake per 10® cells =  — cPm per lO6  cells
cpm per ml of medium
The results for each of the cell-lines are displayed graphically (figures 3.1, 3.2 
and 3.3), demonstrating the uptake of fluid associated with the marker over a 
150 minute period (105 minutes for B16 cells). Accumulation of extracellular 
fluid by the B16 cells was composed of two phases; an initial rapid uptake which 
was completed within the first 10 minutes of c.0.07-0.15/d per 106 cells followed 
by a reduced rate of continuous accumulation which was approximately linear 
for the remainder the experiment (figure 3.1). The four individual experiments 
showed variation in the volume taken up during the initial phase but accumulated 
12 5I-PVP at a similar rate during the linear phase. This could have been due 
to the use of different passages of B16 cells. Linear regression analyses of the 
data revealed the mean slope to be 6.28±0.23 xl0~4 /d/min/106 cells (mean and 
standard deviation) and the mean y-intercepts as 0.109±0.04//1/106 cells.
The fluid uptake profile of the remaining two cell lines (figures 3.2 and 3.3) was 
different to that seen in B16 cells. Both the SVK-14 and HMB-2 cells demon­
strated the rapid initial fluid uptake in the first 10 minutes (0.05-0.2/d) but there
was considerable variation thereafter. There was little apparent increase in fluid 
uptake with the SVK-14 cells over the remaining period, whereas the rate of 
uptake during the second phase diminished in HMB-2 cells after 20-30 minutes, 
reaching a plateau at approximately 100 minutes after a net increase of c.0.03-
0.05/d.
A greater insight into the fate of the internalised marker, and the possibility 
of exocytosis (the release of 12 5I-PVP back into the medium) occurring, would 
be gained by employing subcellular fractionation. This was attempted with the 
B16 cells using a technique described by England et al.[164]. A linear sucrose 
gradient (20-58% weight by weight sucrose) was prepared and the cells disrupted 
using a dounce homogeniser after being exposed to c.0.36xl06cpm/ml 1 25I-PVP 
for 100 minutes and then washed. After 4 hours centrifugation at 85,000g, 1 ml 
fractions were collected from the centrifuge tubes and their activity and density 
were measured (the latter by refractive index).
The vast proportion of the radioactivity occurred in the earliest fractions suggest­
ing endocytotic vesicles containing the marker were damaged (see figure 3.4). The 
vesicular bodies expected to contain the marker and hence display radioactivity 
are endosomes and lysosomes, of which the latter are reported to occur in the 
heavier fractions of a sucrose gradient(c.l.l8 gm/cm3 [171]). Due to a shortage 
of 125I-PVP it was not possible to refine this technique to remedy the probable 
breakage of the vesicles.
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Figure 3.1: Fluid associated 125I-PVP uptake with time by B16 cells in suspension
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Figure 3.2: Fluid associated 125I-PVP uptake with time by HMB-2 cells in sus­
pension at 37°C. Data with linear regression represent individual experiments.
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Figure 3.3: Fluid associated 125I-PVP uptake with time by SVK-14 cells in sus­
pension at 37°C. Data with linear regression represent individual experiments.
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Figure 3.4: The activity per density fraction of a B16 cell homogenate after 
incubation for 10 and 150 minutes with 12 5I-PVP (c.0.36xl06cpm/ml) at 37°C. 
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Figure 3.5: A graphical representation of the uptake (in arbitary units) of a fluid- 




The use of 1 2 5I-PVP as a marker for fluid phase endocytosis is well documented 
with many examples in the literature of its use in varying cell types e.g. rat liver 
parenchymal cells [164,170], macrophages [172], visceral yolk sacs [173,174, 175], 
and human fibroblasts [176]. 125I-PVP has been demonstrated to conform to the 
characteristics required for such a marker, i.e. does not adsorb or interact with 
cell membranes; it is internalised immediately upon addition to a cell-containing 
media at 37°C; its rate of uptake is proportional to its extracellular concentration; 
it is not degraded and resides in a vesicular body after uptake.
Fluid uptake in the B16 cells appears bi-phasic with an initial rapid phase followed 
by a reduced but linear uptake for the remainder of the experiment. Similar 
profiles of this nature have been reported in the literature [164, 173, 174, 175,177] 
using various markers but there are also examples of uptake proceeding with 
linearity from time zero [170, 172, 176, 178, 179].
The cellular uptake rate of a fluid-phase marker would be expected to be propor­
tional to its extracellular concentration and so appear linear as the cell internalises 
a constant volume of fluid and solutes per unit time (providing the extracellular 
concentration of the marker and the rate of pinocytosis by the cell both remain 
constant). This would not explain the apparent bi-phasic uptake which occurred 
with the B16 cells which could be due to:
1 . The rate of pinocytosis decreasing during the experiment.
2. Exocytosis of the 1 2 5I-PVP after a time lag.
3. A proportion of cells exhibiting a ‘leaky’ membrane due to recent harvesting 
from a monolayer state.
The last point can be immediately discounted as all of the cell lines were checked 
for viability (>99%) before and after the experiment by trypan blue exclusion.
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Commencing the experiment after varying lengths of cell suspension at 37°C in 
the presence or absence of unlabelled PVP would examine any changes in the 
rate of endocytosis with time under these conditions, but there are no reports of 
this occuring in the current literature.
To examine the process of exocytosis, cells could be loaded with 125I-PVP for 
various lengths of time, washed, and reincubated at 37°C in the absence of marker. 
If 125I-PVP was released into the medium relatively quickly it could explain the 
apparent decrease in the rate of pinocytosis observed. Various authors have 
indeed demonstrated this phenomenom with a variety of markers and cell types 
[164, 169, 172, 174, 176, 177, 178, 180, 181].
Fluid-phase uptake is thought to involve two intracellular compartments, early 
endosomes or pinosomes, and lysosomes; this has been established by using mor­
phological and subcellular fractionation studies. England et al. [164] demon­
strated that the appearance of 125I-PVP in the cell was related to two distinct 
density fractions (1.13 and 1.20g/ml) in rat liver parenchymal cells, the latter 
associated with the lysosomal marker B-acetylglucosaminidase. Other authors 
have made similar observations [170, 178]. Upon incubation with a fluid-phase 
marker the less dense fraction appears to contain the marker during the early 
stages [178]. Steinman et al. [182] noted that in mouse fibroblasts exposed for 
5-10 minutes to the marker HRP (horse-radish peroxidase), the enzyme first ap­
peared to be localised in small vesicles near the cell surface. After 60 minutes 
the enzyme was found throughout the vacuolar apparatus. Further studies by 
Steinman et al. [179] demonstrated that this less dense, early endosome fraction 
equilibrated in about 5 minutes with HRP associated fluid and thereafter its vol­
ume remained constant whereas enzyme in the lysosomal compartment did not 
appear until after 5 minutes and gradually increased until reaching a plateau at 
around 45 minutes. It appears that marker is first taken into the cell by early 
endosomes and then slowly transferred to the secondary lysosomes.
Pulse-chase experiments have also revealed the kinetic interplay between these
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two compartments. Release or exocytosis of previously intracellulary located 
marker has also displayed bi-phasic kinetics [172,174,177,178,180,181] involving 
an initial rapid phase with a half-time in the order of 5 minutes, followed by a more 
gradual release of marker with a half-time in the range of 180-800 minutes. When 
internalisation of fluid was studied intracellulary marker was found to disappear 
from the endosomes whilst showing an increase in the lysosomes [178, 182].
The bi-phasic uptake profiles are due initially to the filling of the early endosome 
compartment which is complete and at steady state after 5-10 minutes. After 
which, marker is either returned to the extracellular enviroment (exocytosis or 
diacytosis) or transferred to the lysosomes (as represented in figure 3.5). Thus 
the second phase of uptake is an actual measure of fluid transfer to the lysosomal 
compartment of the cell. The initial rapid phase of uptake and of release would 
therefore be expected to be similar as they represent the filling and emptying of 
the endosomes respectively, with a proportion being transferred to the lysosomes. 
The half-life for the initial release of marker is in the order of 5-10 minutes 
[172, 180, 181]. The results with the three cell lines used in this study correspond 
favourably as after the first sample at 10 minutes there is no increase in the 
rate of uptake, i.e. the endosome compartment is already at a steady state of 
turnover. The volume of the endosomal compartment would then be reflected 
by the intercept of the ordinate axis at time zero on a graph of fluid uptake 
versus time. The value obtained using the regression plot for the B16 cells was 
109±40 nl/106cells (meanistandard deviation), greater than the value reported 
for rat liver parenchymal cells [164] of c.30nl, or values using other methods; 
human fibroblasts [176] 2-4nl, guinea pig macrophages [180] 4nl and fibroblasts 
42nl, and bovine brain endothelia [177] 34nl. The reasons for this apparent high 
value are unclear, if not related to the experimental technique it may reflect a 
characteristic of tumour or melanoma cells.
The slopes of the plots for the B16 cells, 0.038/d/106cells/hr, which reflects the 
rate of lysosomal accummulation were of a similar order of magnitude to those 
reported by other authors:
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Human fibroblasts [164] 0.12-0.02//1/106cells/hr.
Rat liver hepatocytes [170] 0.08//1/106cells/hr.
Rat liver non-parenchymal cells [170] 0.07 /d/106 cells/hr.
Rat peritoneal macrophages [172] 0.034/xl/106cells/hr.
Mouse peritoneal macrophages [179] 0.1/d/106 cells/hr.
The rate of fluid uptake by the human melanoma HMB-2 appeared to decrease 
with time after the initial uptake of 0.06-0.12/d in the first 10 minutes. As 
the incubation time approached 100 minutes uptake had almost ceased. Non­
linear uptake has been cited elsewhere [180, 181] but accummulation of fluid still 
proceeded albeit at a decreased rate. Both authors ascribed this deviation to the 
exocytosis from a slow release compartment with a half-time of release in the order 
of 500 minutes. The decrease in uptake observed with the HMB-2 cells could also 
result from the commencement of exocytosis from a slower release compartment, 
or a decrease in the amount fluid transfer from endosomes to lysosomes with 
time.
The rate of pinocytosis could have been diminishing due to cell death or length 
of incubation at 37°C, but this was unlikely. Pre-loading the cells for various 
lengths of time, removing medium and replacing with ‘marker’ deficient medium 
to study the kinetics of release may give an insight to how the rate/amount of 
exocytosis compares to exposure time.
Uptake in the SVK-14 human keratinocytes has almost ceased after 10 minutes. 
This is unlikely to be explained by rapid entry into cells with damaged membranes 
(i.e. with no apparent 125I-PVP accumulation amongst the healthy population) 
as cell viability was always >99%. Interaction of 125I-PVP with the plasma 
membrane via non-specific adsorption binding sites which then become saturated 
after 10 minutes at 37°C is unlikely as 125I-PVP has not been reported to adsorb 
to cell membranes. However a balance of uptake versus release or a complete halt
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in uptake would be possible. Similar results have been obtained in other cell lines 
in the literature, reaching an apparent plateau in uptake after similar periods of 
time; 10 minutes in human lymphoblasts [183], 20-30 minutes in rat hepatocytes 
[184] and 15-20 minutes in bovine brain endothelia [177]. It seems likely that 
there is little or no transfer of fluid and marker from the early endosomes to 
the lysosomes, resulting in a steady-state of turnover in fluid between the early 
endosomes and the extracellular enviroment. Sasaki et al. [184] did demonstrate 
uptake into a ‘non-releaseable’ compartment of hepatocytes, but the rate was 
very slow with a non-linear relation to loading time. It may have represented a 
gradual transfer of fluid to the lysosomes.
Data points that appeared to represent a sharp increase or decrease in the rate 
of fluid uptake probably reflect the sensitive nature of the experimental system 
and are likely to be caused by technical problems, for example:
1. Poor sampling of cells, e.g. cells not kept constantly in suspension.
2. Loss of cell viability during an experiment due to shearing forces of the 
paddle if the motor was not properly adjusted.
3. Poor centrifugation washing i.e. loss of cells during washing or incomplete 
removal of marker.
It is clear from these experiments that the profiles and kinetics of fluid phase 
uptake vary with differing cell types and origin. It is possible that the described 
uptake is pertinent only to 125I-PVP or the experimental technique employed. 
The use of a second marker would help resolve the matter alongside subcellular 
fractionation studies. There was though, a similarity in the initial amount of 
uptake by all three cell lines but the values were much greater than those reported 
elsewhere in the literature. Further experiments to have helped validate that 
endocytosis was occurring by demonstrating the characteristics established for 
this particular mode of uptake [185, 22] are:
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1. Examining the rate of uptake with varying concentrations of marker and 
cell density, pinocytosis being independant of these two parameters.
2. Demonstrate uptake at low temperatures.
3. Uptake should be metabolically dependant.
4. The use of other fluid-phase markers for comparision e.g. 
horse-radish peroxidase (HRP).
Although fluid phase endocytosis is well reviewed [185, 22, 23] the precise inter­
play between the various vesicular compartments is uncleax. For example Casey 
et al. [186] have described uptake of HRP in Chinese hamster ovary cells to be 
initially associated with two distinct populations of endosomes, separate from 
the lysosomes. However the value reported for the linear uptake of fluid into B16 




Binding and Uptake of 
M ethotrexate
4.1 Introduction
The binding and uptake of methotrexate by B16 melanoma cells has been studied 
to allow the rate of accumulation of the free drug to be compared with that of the 
free hormone, (see chapter 5) and the drug conjugate. Cytotoxicity experiments 
would have provided a more useful direct measure of cellular uptake. Clonogenic 
cytotoxicity tests were attempted, however this line of approach proved difficult 
with the B16 system. In the absence of a cytotoxicity assay the kinetics of cellular 
binding and uptake have been used to give an indication of the differences between 
the free drug and its hormone derivative.
4.2 M ethods
The protocols described in detail in section 2.3, concern the bulk of work when 
B16 cell monolayers were employed. Various attempts at 3H-MTX binding (4°C)
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were made using centrifugation techniques to remove unbound ligand in order 
to avoid problems of desorption during washing steps. However none of these 
methods proved satisfactory as the non-specific binding remained high (see in 
figure 4.1). Briefly the centrifugation method used involved seeding 107cells per 
tube (10ml Cell-Cult centrifuge tubes) and incubation at 4°C with radioactive 
tracer in a final volume of 1ml. After incubation the tubes were spun at lOOOg 
for 15 minutes at 0°C and the supernatant removed by pipette. An attempt to 
remove the final amount of fluid associated with the cells was made using small 
strips of filter paper in contact with the cell pellet for 10 seconds as described 
in the literature [187]. Further efforts to improve the technique with varying 
incubation vessels and wash protocols led to very erractic results. This method 
was investigated in anticipation of the relatively low binding affinity of MTX, as 
extensive washing of cells could potentially remove bound ligand by desorption. 
However the methods proved impractical and attentions were turned to use of 
monolayers.
4.3 R esults
4.3.1 W ashing R egim e
Determination of the 3H activity in washes of monolayers in wells, after expo­
sure to 3H-MTX, indicated that three rinses with ice-cold PBS were sufficient 
to remove the majority of unbound ligand (see table 4.1), but a small amount 
of bound 3H-MTX appeared to be dislodged even after four washes when wash 
counts were compared to controls. (Background counts of the order of 50-60 dpm 
were obtained using 2ml of PBS and 8ml of Optiphase). Although washings were 
rapid care had to be taken not to dislodge cells from the wells.
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Table 4.1: 3H activity in washes for two wells exposed to 1ml of lOnM 3H-MTX, 
initial activity in the order of 300,000 dpm. Each wash consisted of 3ml of ice-cold 
PBS, the resulting activity of which is shown above.
4.3.2 B inding o f 3H -M T X  at 4°C.
The B16 cells were initially incubated with 25nM 3H-MTX to establish the 
binding profile with respect to time (figure 4.2). Maximum specific binding of 
c.60fmoles/106cells occurred between 30 minutes and 2 hours, the value appar­
ently declining thereafter (low values at 4 hours may be explained by some cell 
detachment). A final incubation period of 30 minutes was chosen, there being no 
significant difference between specific binding after 30 minutes and 2 hours. It 
was noted that non-specific binding was a relatively high proportion of the total 
bound ligand. In retrospect this was probably due to the large surface area of 
plastic in relation to cell monolayer in the well. A smaller size well may have 
improved the assay by resulting in a lower proportion of non-specific binding.
Three binding isotherms are represented in figures 4.3, 4.4 and 4.5, ranging from 
l-150nM extracellular 3H-MTX. All three display specific binding of the tracer to 
the cells with a small degree of variation but apparently did not reach a state of 
saturation. At 150nM (see figure 4.3) binding reached c.200fmoles/106cells and 
was still increasing. Two further experiments carried out at higher concentrations 
(150-1000nM) figures 4.6 and 4.7, suggested that binding reached saturation at 
around 375fmoles/106cells although non-specific binding had greatly increased 
and represented a greater proportion of the total binding. It should be noted
80
at this stage that at higher concentrations 3H-MTX had to be diluted with non­
labelled MTX for economical reasons, the assumption being made that there 
was no difference in the binding affinity of tritiated and unlabelled ligand. This 
was found to be the case when 30nM pure 3H-MTX and a 50% dilution with 
non-labelled MTX resulted in identical estimates of specific binding at 4°C of 
54.92±2.99 and 54.58±1.29fmoles/106cells respectively.
The data was considered to fit a Langmuir isotherm model and the appropiate 
parameters were obtained by least squares non-linear regression using a computer 
programme called MINSQ. The following equation (4.1) was used:
D N.K»[3H — MTX]
B°Und =  1 +  K,[3H — MTX] (4'1}
Bound represented the specific binding per 106cells, N the number of binding 
sites per 106 cells and Ka the binding affinity. A model for a single population 
of binding sites was used for reasons explained later. It is observed however 
that in figure 4.4, the isotherm displays an inflection at c.l5nM 3H-MTX, and 
also in figure 4.5 at c.8nM 3H-MTX. The exact nature of this is not apparent, 
such an inflection could represent the binding to a high affinity/low capacity 
site. However it is more likely to be an experimental artifact especially since the 
inflection is absent in figure 4.3.
A suitable isotherm model for figure 4.5 could not be found because binding 
saturation was not being reached as the curve did not start to plateau. The same 
problem might be anticipated with the two remaining isotherms, though a fit was 
obtained. To circumvent this problem the data from figure 4.7 expressing binding 
at high 3H-MTX concentrations was added to data for each of the isotherms 
(now denoted as isotherm 1A, 2A and 3A). The resulting values for Ka (affinity 
constant) and N (maximum binding of 3H-MTX) from the models are expressed 
in table 4.2.
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Isotherm Ka(xl0“7 M"1) N (fmoles/106cells) Binding sites/cell
1 0.55 ±  0.61 420 ±  367 252966
2 0.39 ±  0.05 554 ±  50 333674
3 - - -
1A 0.46 ±  0.05 455 ±  23 274046
2A 0.48 ±  0.04 451 ±  18 271637
3A 0.47 ±  0.07 452 ±  27 272240
Mean 0.47 453 272842
Table 4.2: Values for binding affinity (Ka) and binding sites per cell (N) for 
binding of 3H-MTX at 4°C to B16 cells, obtained from a Langmuir model using 
a least squares minimisation regression programme.
The mean binding affinity of 0.47 x 10“7M_1 corresponds to a Ka, dissociation 
constant (K d=l/K a) of 0.21/iM which correlates well with work by Henderson et 
al. [187] using L1210 cells who reported a value of 0.35^M. However the number 
of binding sites per cell was lower in the latter study (80,000) than the present 
study (270,000).
4.3.3 B inding and Uptake at 37°C.
In preliminary experiments B16 cells were incubated at 37°C with 50 and lOOnM 
3H-MTX and the cell association of the tracer measured with time, figures 4.8 
and 4.9. However in these experiments the use of a Hepes-based acid buffer (pH 
2.0) was unsuccessful in the removal of extracellular bound tracer. The buffer 
resulted in visual damage of the cells (vacuole-like bodies became apparent on the 
cell surface upon inspection with an inverted microscope) and caused inadequate 
removal of cellular material from the wells with 1M NaOH (insufficient washing 
of the well to remove residual acid-buffer could have been to blame). Therefore 
only a measure of cell-associated 3H-MTX is recorded. At 50nM 3H-MTX the 
amount associated with the cells after 15-30 minutes was c.45 fmoles/106cells
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which was lower than that bound at 4°C after 30 minutes c.80fmoles/106cells. 
Thereafter the amount bound increased to a maximum of c.70fmoles/106cells at 
45 minutes before gradually declining over 100 minutes to a value lower than the 
first measurement at 15 minutes. This decrease could have been due to:
1. Loss of cells by detachment as the incubation period increased. It was 
observed that after a period at 37°C occasionally cells detached rather easily 
when being washed with ice-cold PBS. Care had to be taken to avoid this 
problem.
2. Efflux rate of 3H-MTX increasing as the experiment progressed. This was 
considered to be unlikely and would not give a lower value at the end of 
the experiment unless binding decreased (see below).
3. Decrease in the binding affinity at 37°C coupled to an inactivation process. 
If this was the case initial amounts of cell associated 3H-MTX would indeed 
be lower than values at 4°C. If the folate carrier was ‘inactivated’ after 
transporting 3H-MTX or took a long recovery time before it was capable 
of binding and transporting another molecule then the values in the latter 
part of the experiment would reflect internalised tracer only. The use of a 
reliable acid wash technique would enable the simultaneous study of surface 
bound and internalised ligand with respect to time.
The cell-association profile at lOOnM extracellular concentration was slightly dif­
ferent, an initial value at 15 minutes of c.70fmoles/106cells increasing to c.125 
fmoles/106cells at 30 minutes (c.l60fmoles/106cells at 4°C), and then remaining 
relatively constant for the next 75 minutes. The peak of cell associated 3H-MTX 
occurred earlier at an extracellular concentration of lOOnM but the non-specific 
value at 45 minutes seemed abnormally high (probably due to poor/insufficient 
washing in one or two wells) possibly masking a peak of specific cell association. 
A decrease in cell associated activity was not observed after 30 minutes indicat­
ing that the most likely reason for that seen with 50nM 3H-MTX was due to cell
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detachment.
Using an improved acid-wash treatment with a citrate buffer (pH 2.5), cells were 
incubated with lOOnM 3H-MTX at 4°C and 37°C (figure 4.10). Binding at 4°C 
remained relatively constant between 1 and 2 hours with the acid-wash treat­
ment totally removing all the 3H-MTX specifically associated with the cells, thus 
demonstrating no uptake at 4°C and confirming the suitability of the acid buffer.
At 37°C total cell associated activity was lower than previously observed. Upon 
acid-washing the majority of the tracer was discovered to be internalised, increas­
ing from c.60 to 80% from 1 to 2 hours respectively. However the total amount 
associated with the cells decreased over the second hour suggesting instability of 
the cells for this length of time under these conditions.
Specificity of uptake was investigated using various known inhibitors of folate 
previously cited in the literature. Using lOOnM 3H-MTX, cells were incubated at 
37°C for 1 hour in the presence of folinic acid, tetrahydrofolate (FH4), dihydro­
folate (FH2), 5-methyltetrahydrofolate (5-MFH4), aminopterin (all at lOOnM), 
thiamine pyrophosphate (TP) at 50/iM and p-chloromercuribenzylsulphonic acid 
(PCMPS) at 100/iM. The results, displayed in table 4.3, demonstrate very little 
uptake of 3H-MTX into the cells as determined by the acid-wash treatment, al­
though total cell-associated 3H-MTX is comparable to earlier experiments. Due 
to limited resources it was not feasable to purchase further stocks of 3H-MTX to 
repeat the experiment so the present results from a single test must be treated 
with a degree of caution and so will not be discussed in detail.
Uptake was totally blocked by the two non-folates PCMPS and thiamine py­
rophosphate, the former functions as a sulphydryl inhibitor and has been re­
ported to inhibit MTX uptake [188], whilst the latter acts by competitive anion 
inhibition of uptake but does not affect binding [66]. The folate and antifo­
late (aminopterin) analogues display a degree of binding inhibition except for 






Control 75.72 ±  22.37 18.50 ±11.61
Folinic acid 121.33 ±21.82 10.37 ±  14.48
f h 4 43.27 ±  13.79 -9.93 ±  12.54
f h 2 47.67 ±  11.68 4.22 ±1.27
5-MFH4 268.04 ±  89,93 22.15 ±  14.50
Aminopterin 70.99 ±  26.73 0.39 ±12.11
PCMPS 169.32 ±  42.65 -14.49 ±  18.50
TP 75.14 ±  35.65 -7.27 ±22.16
Table 4.3: The specific and acid-washed specific values for B16 cells incubated 
at 37°C for 30 minutes with 25nM 3H-MTX in the presence of various inhibitors. 
Non-specific values were 51.25 ±  11.03fmoles/106cells.
apparent increases caused by PCMPS, 5-methyltetrahydrofolate and folinic acid. 
A repitition of the experiment would provide a clearer explanation of the results.
4.3.4 C ell Growth in Low Folate M edium
An attempt was made to grow B16 cells at normal physiological folate levels 5-50 
nM [189] rather than those found in the RPMI medium (2.2/zM folic acid). The 
purpose being to enable the detection of a high affinity folate binding membrane 
protein that has been identified in cell lines predominantly grown only in low 
folate medium [66, 124, 125, 126, 127, 128]. However this adaptation to growth 
in a decreased amount of folate can take time; seven months in one example [125].
Folate free medium was obtained specially prepared from Gibco Ltd and medium 
was prepared in the absence of any form of folate except for that present in the 
serum. The growth passages of B16 cells with normal and low folate media were 
measured in parallel in 150cm2 and then 75cm2 (at passage 3) tissue culture flasks.
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Both cultures received identical seeding values limited from passage 5-9 due to 
the slow growth of the cells in low folate media. Growth in low folate medium 
was expressed as a percentage of the total number of cells grown in normal media 
(with identical seeding and incubation values); and also as a direct measure of 
their own growth rate, by comparing the final number of cells to the seeded value 
(summarised in table 4.4).
Cell growth dropped dramatically upon incubation in low folate medium to only 
2% of normal cells by passage 5. This was presumably due to depletion of the 
intracellular folate concentration. Growth actually ceased between passages 4-7 as 
the final number of cells was less than the seeded value. Growth was not improved 
upon the addition of lOnM 5 -MFH4 plus daily re-feedings to the medium but 
growth did proceed to a small extent at lOOnM 5 -MFH4 . From passage 7-9 
normal B16 cells failed to reach previous values at confluency for a given time 
period, this is probably due to a very low seeding value. This would provide a 
sparse covering of cells initially in the flask causing an increase in the lag period 
before exponential growth. Consequently this would have hindered cell growth 
in low folate media as well. To circumvent this problem cells could have been 
transferred to a smaller flask. Returning the cells to standard media resulted in 
normal growth characteristics after three passages without daily re-feedings. It 
can be assumed that the cells were in a quiescent state in the low folate medium 
and were unable to divide until folate levels were increased to >0.1/xM.
The growth of B16 cells in low folate medium was abandoned due to the length 
of time it was likely to take to achieve a similar growth rate to cells in ordinary 
media.
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% of Control Low Folate 
Growth Rate
1 30 260.4 224.0 86.0 7.47
2 45 392.0 91.0 23.0 2.02
3 15 195.3 19.3 9.89 1.29
4 15 207.3 11.81 5.7 0.79
5 10 207.0 4.2 2.0 0.42
6(10nM) 4.2 192.5 1.53 0.8 0.36
7(20nM) 1.5 111.2 0.92 0.8 0.61
8(0.1/xM) 0.92 112.5 1.41 1.25 1.53
9 1.0 130 21.7 16.0 21.7
10 10 220 180 81.8 18.0
11 10 224 220 98.0 22.0
Table 4.4: Growth of B16 cells in standard RPMI media (control) and folate free 
RPMI both with 10% FCS. Seeding number varied according to total cell count 
from previous passage, cells were transferred from 150 to 75cm2 culture flasks 
at passage 3. Values in brackets are 5 -MFH4 concentrations in the media with 
daily re-feedings, from passage 9 all cells were grown in standard media without 
re-feedings. Low folate growth rate corresponds to the total cell number obtained 
divided by the initial seeding value at each passage.
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4.3.5 B inding Inhibition by N L D P -M SH -M T X  Conju­
gates
Two conjugates of NLDP-MSH-MTX were purified corresponding to two peaks 
obtained by HPLC, these were thought to be due to linkage via the a  or 7  car­
boxyl groups on the glutamic acid moiety on MTX. Both conjugates, denoted as 
G0133/1 and G0133/3, were incubated at increasing concentrations for 1 hour at 
4°C in the presence of 25nM 3 H-MTX. Cells were pre-exposed to 200nM NLDP- 
MSH to prevent binding of the conjugate to MSH receptors. The results of three 
separate experiments are displayed in figures 4.11, 4.12 and 4.13 showing the 
dpm/well versus conjugate concentration. The total and non-specific binding 
show good consistancy between the experiments resulting in a difference of about 
400-500 dpm. There was little difference between the two conjugates which ap­
peared to show a weak general trend towards more inhibition as the concentration 
increased (figure 4.14). Over a wide-range of concentration of the conjugates there 
was only a small change in the degree of inhibition, indeed in figure 4.11 only the 
highest concentration of G0133/1 appeared to have caused a significant amount 
of inhibition, whereas in figure 4.12 there was no significant difference in the final 
three concentrations. Likewise in figure 4.13 conjugate G0133/3 displayed only a 
small increase in inhibition and G0133/3 acted in a similar manner. However the 
specific binding in the presence of conjugates was erratic and did not compare 
well with the controls (figures 4.12 and 4.13). When the mean and standard 
deviation of individual wells were plotted as % of control binding (control equals 
specific binding of 3 H-MTX in the absence of conjugate) versus conjugate con­
centration, a shallow decrease in binding with increasing conjugate concentration 
was observed, figure 4.14. However the size of the error bars illustrate that there 
was little if any difference over the complete range of concentrations used. Higher 
concentrations could not be used due to limited amounts of the conjugates.
The difficulty of the experiment was hampered by the low affinity of the system 
studied but it appeared that NLDP-MSH-MTX had no specific inhibitory effect
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Figure 4.1: Incubation of B16 cells with 3H-MTX at 4°C in suspension for 30 
minutes. Each point represents the m ean isd  from three tubes each containing 
106 cells. Total (•) and non-specific (O) binding.
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Figure 4.2: Binding of 25nM 3H-MTX with B16 cells at 4°C with time in a Hepes 
based buffer, pH7.4. Each point represents the m ean isd  for 6 wells. Total (•), 
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Figure 4.3: 1. Adsorption isotherm of increasing concentrations of 3H-MTX in­
cubated with B16 cells at 4°C for 30 minutes at pH 7.4. Each point represents 
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Figure 4.4: II. Adsorption isotherm of increasing concentrations of 3H-MTX in­
cubated with B16 cells at 4°C for 30 minutes at pH 7.4. Each point represents 
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Figure 4.5: III. Adsorption isotherm of increasing concentrations of 3H-MTX 
incubated with B16 cells at 4UC for 30 minutes at pH 7.4. Each point represents 
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Figure 4.6: I. Adsorption isotherm of high concentrations of 3H-MTX incubated 
with B16 cells at 4°C for 30 minutes at pH 7.4. Each point represents the 
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Figure 4.7: II. Adsorption isotherm of high concentrations of 3H-MTX incu­
bated with 1316 cells at. 4°C for 30 minutes at pH 7.4. Each point represents 
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Figure 4.8: Incubation of 50nM 3H-MTX with B16 cells at 37°C with time. Each 
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Figure 4.9: Incubation of lOOnM 3H-MTX with B16 cells at 37°C with time. Each 
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Figure 4.10: Incubation of lOOnM 3H-MTX with B16 cells at 4°C and 37°C 
respectively for 1 and 2 hours. Each incubation was terminated with ice-cold 
PBS after which a set of wells at each time point (exposed to labelled tracer 
only) received a 5 minute (4°C) acid-wash. All wells were then treated in the 
usual manner. Each bar represents the m ean isd  for six wells. Total binding (A), 
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Figure 4.11: I. 3II activity after incubation of 25nM 3H-MTX with B16 cells 
at 4°C for 30 minutes in the presence of increasing concentrations of the two 
conjugate forms of NLDP-MSH-MTX, G0133/1 (O) and G0133/3 (•). Each point 
represents the m ean isd  for 6 wells, total (v) and non-specific (j) binding from 12 
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Figure 4.12: II. 3H activity after incubation of 25nM 3H-MTX with B16 cells 
at 4°C for 30 minutes in the presence of increasing concentrations of the two 
conjugate forms of NLDP-MSH-MTX, G0133/1 (O) and G0133/3 (•). Each point 
represents the m ean isd  for 6 wells, total (v) and non-specific (r) binding from 12 
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Figure 4.13: III. 3H activity after incubation of 25nM 3H-MTX with B16 cells 
at 4°C for 30 minutes in the presence of increasing concentrations of the two 
conjugate forms of NLDP-MSH-MTX, G0133/1 (O) and G0133/3 (•). Each point 
represents the m ean isd  for 6 wells, total (v) and non-specific (?) binding from 12 
wells was measured in the absence of NLDP-MSH-MTX.
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Figure 4.14: Inhibition of 25nM 3H-MTX binding with B16 cells at 4°C by two 
conjugates of NLDP-MSH-MTX for 30 minutes. Values are expressed as a % 
of the control binding (control equals specific binding of 3H-MTX in the ab­
sence of conjugate) from single wells in individual experiments and represents 




The cellular uptake of MTX briefly mentioned in the introduction to this thesis 
has been well reviewed by Sirotnak [120], when the difference in membrane trans­
port of this folate analogue was compared between normal and tumour growing 
mammalian cells. Normal cells of varying types and sources display large variabil­
ity in Vmax and Km at 37°C, 0.003-220nmol/min/g dry weight and 0.6-2300/xM 
respectively. Whereas tumour cells show greater similarity, l.l-12.2nmol/min/g 
for Vmax and 2.3-26.2/zM for Km. This has been described as the classical ‘high 
affinity, low capacity’ folate system in tumour cells which displays high saturabil- 
ity for reduced folates (5-methyltetrahydrofolate and 5-formyltetrahydrofolate) 
but very poor affinity for folic acid. Sirotnak suggested, in review of other work, 
that this effective transport of serum folates may be essential for tumour growth 
as these cells may rely more strongly on de novo synthesis of nucleic acid precur­
sors, a process highly folate dependent.
Much work has focused on the presence of a second membrane folate binding 
protein which has been observed specifically in cell lines grown under physiologi­
cal levels of folates [124, 125, 126, 127, 128, 190], or in the continued presence of 
MTX [188]. Normal tissue culture media contains folic acid in the order of 2/xM, 
whereas serum concentration of folates (5 -methyltetrahydrofolate being the pre­
dominant folate) are 5-50nM [189]. Jansen et al. [124] grew L1210 mouse leukemic 
cells in progressively decreasing concentrations of folate and discovered the cells 
expressed high levels of a membrane-associated folate binding protein in addition 
to the ‘classical’ high affinity/low capacity carrier as described by Sirotnak [120]. 
Similar findings were also found by Henderson et al. [128] with the same cell line. 
In support of this, multiple membrane associated folate binding proteins have 
been observed in human leukemic and epidermoid carcinoma cells [191, 192].
The significance of this second folate binding protein in MTX binding and uptake 
is unclear. Attempts to grow B16 cells in low folate medium proved unsuccessful
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in the time scale tested. Cell growth became almost static presumably due to 
the lack of intracellular folate. Growth was slightly increased upon the addition 
of 5-methyltetrahydrofolate indicating some uptake had occurred and when the 
cells were re-incubated in standard media cell growth returned to normal (as 
compared to control cells) in only three passages. This demonstrated the cells 
retained the ability to transport folates into the cell.
Although growth became static at one point, binding experiments may have 
revealed the presence of a high affinity binding protein which has shown even 
greater affinity for folates upon cell incubation in completely folate free media
[125].
The likelihood of this second binding protein being expressed in cells cultured in 
standard medium is unlikely, its presence/activity could have been measured in 
two ways. Firstly measuring the binding activity of 3 H-folic acid at low concen­
trations. The membrane binding protein has a far greater affinity for folic acid 
compared to the reduced folate carrier [126]. Secondly measuring the uptake of 
3 H-MTX in the presence of thiamine pyrophosphate which inhibits transport via 
the reduced folate carrier but not by the membrane binding protein [6 6 ]. The 
binding data for 3 H-MTX at 4°C was therefore treated with a least squares min­
imisation programme for one binding site (although a fit could be obtained for 
two sites the errors were much greater). The values obtained for the binding 
dissociation constant Ka, and the maximum amount bound were in the order of 
0.21/xM and 453fmoles/106cells respectively. Few values for the binding affinity 
for MTX at 4°C are available in the literature for cells grown in normal tissue 
culture media. Henderson using mouse leukemic L1210 cells [187] obtained a Ka 
value of 0.35/zM. Human epidermoid carcinoma cells grown in low folate media 
had a Ka for surface binding of MTX of c.0.2/zM, other cell lines under similar 
conditions have displayed greater affinity than B16 cells, L1210 cells 30-35nM
[126], and monkey kidney cells 20nM [193].
Uptake of 3 H-MTX by B16 cells was initially difficult to establish with only a
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measure of cell-association being obtainable. Once a suitable acid-wash technique 
was available uptake was demonstrated after a 1 and 2  hour incubation with 
lOOnM extracellular 3 H-MTX at 3T°C. An identical incubation at 4°C using an 
acid-wash effectively removed all surface-bound ligand from the cells, showing 
no uptake had occurred. Although uptake has occurred at 37°C, this does not 
confirm its occurrence directly via the binding site (at 4°C), but transport was 
inhibited by PCMPS and thiamine pyrophosphate, both known inhibitors of the 
reduced folate carrier. One method to resolve this problem would be to allow 
binding at 4°C, wash the cells and reincubate in ligand free medium at 37°C 
for various time periods followed by an acid-wash treatment. There are many 
examples of MTX transport via the reduced folate carrier [187, 188, 194], in the 
review by Sirotnak [1 2 0 ] the Vmax at 37°C varies from l- 1 2 nmol/min/g in various 
tumour cell types.
Uptake of MTX has also been demonstrated via the folate binding protein present 
in cells grown at physiological levels of folate [66,124,126,195,129,196,130,131]. 
Westerhof et al. [132] even demonstrated the uptake of MTX in a previously MTX 
transport resistant human leukemic cell line, transferred to growth in low folate 
medium. The folate binding protein unlike the reduced folate carrier has high 
affinity for folic acid Ka 0.9nM [126], 0.07nM [6 6 ], 0.7nM [132], which is greater 
than for the reduced folates, whilst MTX has a low affinity. It appears that 
transport via this protein is regulated by the intracellular folate content of the 
cell [193, 130], whilst binding is relatively unaffected. The exact nature of influx 
is unclear however some authors have pointed towards receptor-mediated endo- 
cytosis and recycling of the protein [6 6 , 126, 193, 130, 131, 132, 133], partly due 
to the relatively slow rate of uptake (2.1 molecules of 3 H-MTX/binding site/hour 
for L1210-JT3 human leukemic cells in low folate medium [132]).
The question arises as to what degree do either of these transport pathways play 
in the uptake of folates and in particular the antifolate MTX. This problem has 
recently been addressed by Westerhof et al. [126] using L1210 cells and a subline 
L1210-B73 grown in low folate media which expressed both the reduced folate
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carrier and the folate membrane binding protein. Exploiting the difference in 
affinities for various compounds by the two binding/transport sites, they were 
able to evaluate uptake of folates and antifolates. They discovered the membrane 
folate binding protein mainly mediated the influx of folic acid (c.98%) and 5- 
formyltetrahydrofolate (c.81%), as opposed to MTX which was less than 30%. 
They concluded the membrane transport (and therefore the cytotoxicity) of MTX 
in the L1210-B73 cells was predominantly via the reduced folate carrier, this is 
not suprising since the folate binding protein has poor affinity for MTX. Similar 
findings were reported by Jansen and Schnoragel in a human leukemic cell line 
[195]. It must be noted at this point that these experiments have all occurred in 
tumour cell lines in culture, the role of these transport routes in vivo is not yet 
established.
From this brief overview of folate and MTX transport in tumour cell lines it is 
apparent that the influx of any NLDP-MSH-MTX conjugate in B16 melanoma 
cells due to the MTX moiety is likely to occur via the reduced folate carrier, 
the binding to which will give an indication to the amount of uptake expected. 
The maximum amount of binding of 3 H-MTX at 4°C corresponded to c.270,000 
binding sites/cell with a Ka value of 0.21^M. Uptake, under the culture con­
ditions used, did not proceed continuously. The total cell-associated 3 H-MTX 
was similar at 37°C and 4°C, the only difference being that at 37°C MTX had 
been internalised. The binding experiments with NLDP-MSH-MTX displayed no 
specific inhibition of 25nM 3 H-MTX by the conjugate up to a ten-fold greater 
concentration. It can only be concluded from this that the NLDP-MSH-MTX 
has at least ten-fold less affinity than MTX for the reduced folate carrier.
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Chapter 5
Binding and Uptake of 
125I-Nle4-D -Phe7-<*MSH
5.1 Introduction
In the design of a site-specific drug conjugate the targeting moiety is one of the 
most important factors. Without direction to the desired cell type the whole basis 
of drug targeting is undermined. The targeting component chosen in this study 
was alpha MSH (melanocyte stimulating hormone) or rather its analogue Nle4- 
D-Phe7-MSH (NLDP-MSH). This structure has been reported to have increased 
biological activity (measured by the activation of cell cAMP levels and tyrosinase 
activity) in mouse melanomas [197, 198, 199, 114, 200] and is less susceptible to 
enzymatic breakdown [114, 200, 201]. The binding of this analogue as with MSH, 
displays great specificity for sites on melanoma cells with a high binding affinity 
[198, 199, 114, 202, 203].
The radio-iodinated derivative of NLDP-MSH was used first for binding experi­
ments as the procedure for its preparation has been well reported [113] and the 
high activity of the purified radio-isotope allows the detection of low receptor
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populations. Cultures derived from the B16 mouse melanoma cell line have been 
used previously in binding and biological activity [197, 199, 114] studies of MSH.
The purpose of this study was to investigate the binding characteristics of 1 25I- 
NLDP-MSH and its fate after interaction with B16 cells at 37°C.
5.2 M ethods
All methods are described in full in section 2.4. The use of 0.3mM 1,10-phen- 
anthroline, an endopeptidase inhibitor [204], was based on its reported stabilising 
effect on MSH binding assays. The mechanism of stabilisation is thought to be 
prevention of degradation of the peptide [198, 199, 201, 203], which has been 
reported to occur in cell culture.
5.3 R esults
5.3.1 Iodination o f N L D P-M SH
The identity of the peptide was confirmed by FAB-MS, figure 5.1, (molecular 
weight 1647, calculated weight 1646). The protocol for the iodination procedure 
was based mainly on work by Eberle and colleagues [113] who used chloramine 
T as an oxidant. The purification of the reaction products was a two stage 
chromatographic procedure using a SepPak column and then HPLC. A typical 
trace from the latter (figure 5.2) displayed three peaks eluting at 30.5, 33.75 and 
38 minutes respectively. Sixteen 1 ml fractions were collected from 27 minutes on­
wards and their activity (figure 5.3) contained two main peaks which correspond 
well with the second two peaks on the trace. There was no significant activity 
associated with the first peak.
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5.3.2 W ashing Procedure
With the 12-well plates used in all the experiments, three washes of 3ml ice-cold 
PBS were sufficient to result in the removal of non-bound radio-ligand from the 
wells, as shown in table 5.1.








15.0 1 0 . 6
41.3 32.0
Table 5.1: The recorded washing activities (cpm) in 1 ml taken from a total of 3ml 
PBS used per well. Each well was incubated with 1 ml of O.lnM 1 2 5I-NLDP-MSH 
(c.300,000cpm). Incubation was for 8  hours at 4°C in the absence (Experiment 
A) and presence (Experiment B) of excess unlabelled NLDP-MSH (1/zM).
5.3.3 B inding o f 125I-N L D P-M SH  at 4°C
Incubation of B16 cells at 4°C with 0.1 and 0.4nM 12 5I-NLDP-MSH from 2-22 
hours is displayed in figures 5.4 and 5.5. These concentrations were chosen to 
reflect the range used for binding isotherm experiments with the expectation that 
the low concentration would be more sensitive to the experimental conditions 
governing binding. Non-specific binding was recorded in the presence of 0.1/zM 
unlabelled NLDP-MSH. The specific binding was obtained by subtracting the 
non-specific binding from the total binding.
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At 0.4nM 1 25I-NLDP-MSH binding effectively reached an equilibrium after 8  
hours at 6fmoles/106cells, there being no significant increase over the next 14 hours. 
Non-specific binding represented approximately 40% of the total bound after 
22 hours. At the lower concentration of O.lnM almost identical binding kinetics 
were observed with out any discernable increase in binding after 8  hours. Non­
specific binding again increased with time and represented about 40% of the total 
bound after 22 hours. All data points represent the mean and standard deviation 
from six wells and showed a small degree in variation. On the basis of this exper­
iment an incubation period of 8  hours at 4°C was chosen for the construction of 
a binding isotherm. Overnight incubation was avoided as prolonged time periods 
caused cells to be predominantly in a rounded state and liable to detachment.
The time taken to reach equilibrium at 4°C appeared particulary long although 
it was in agreement with published work [199]. It was decided to investigate if 
the presence of the BSA (0.2%) in the binding medium delayed the time course 
of 1 2 5I-NLDP-MSH binding to the cells. Albumin is well known to bind weakly 
with many compounds, indeed its presence in the medium is to ‘coat’ the plastic 
of the well and hence decrease the amount of non-specific binding. However it 
could also bind some of the tracer so prevent and/or delay the establishment of 
equilibrium binding to the cells. For this reason the bovine milk protein casein 
was chosen as a readily available substitute to examine any difference in binding 
kinetics.
An identical experiment to that represented in figure 5.4 was undertaken us­
ing an extracellular concentration of O.lnM 12 5I-NLDP-MSH (figure 5.6). The 
use of 0 .2 % casein resulted in a slow increase in binding over 2 2  hours with 
no sign of equilibrium occuring. Although the amount bound after 22 hours, 
1.5fmoles/106 cells, was identical to that determined with 0.2% BSA in the medium, 
binding in the presence of casein was still increasing after 22 hours. Initial values 
of specific binding were lower in the presence of casein and after 8  hours had 
not yet reached lfmole/106 cells. One advantage however was the apparent lower 
amount of non-specific binding which displayed only a small increase over the
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time period, reaching c.0.3fmoles/106cells. BSA was chosen as the most suitable 
protein to use in the assay since binding equilibrium was attained after 8  hours.
Two separate binding isotherms are represented in figures 5.7 and 5.8 using ex­
tracellular concentrations of 125I-NLDP-MSH ranging from 0.01 to l.OnM. In the 
first experiment (figure 5.7) specific binding increased to reach 5fmoles/106cells 
at 0.8nM before decreasing to 3fmoles/106cells at l.OnM. A similar degree of 
maximal binding was seen in figure 5.8 of 4fmoles/106cells at l.OnM, whilst non­
specific binding remained low reaching a maximum of lfmole/106 cells. However 
the second experiment displayed a greater increase in non-specific binding at 0 . 8  
and l.OnM to reach values of almost 3fmoles/106 cells. This increase observed in 
the final two points could have been due to inadequate washing of the wells.
The mathematical procedure for determining binding parameters from the data 
was used, as described for 3 H-MTX (see chapter 4). Values for the association or 
affinity constant and the number of binding sites/cell are displayed in table 5.2. 
One class of binding site for MSH derivatives was assumed.
Experiment Ka Bmax N
Number xlO- 9 M~l fmoles/1 0 6cells sites/cell
1 1.15 ±0.53 8.90 ±  2.69 5361 ±  1620
2 2.67 ±1.13 5.62 ±  1.29 3384 ±  777
Table 5.2: The affinity constant (Ka), maximum bound (Bmax) and the number 
of binding sites per cell (N) for the two binding isotherms, were obtained using a 
least squares minimisation fit to the data with the computer programme MINSQ.
The values for the affinity constant of 8.9 and 5.6 x 10- 9 M- 1  can be expressed 
as dissociation constants of 0.87 and 0.37nM respectively. The two experiments 
gave similar estimates of the number of binding sites/cell, considering binding 
was undertaken on cells of different passage number. A weighting value of one 
was used for the least squares fit as the majoritory of data points were located 
at the beginning of the isotherm, and also due to the relatively larger standard 
deviations at higher extracellular 1 25I-NLDP-MSH concentrations.
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5.3.4 U ptake o f 125I-N L D P-M SH  by B16 cells at 37°C
The cell association of the radio-ligand with B16 cells was measured at 37°C (fig­
ure 5.9) using an extracellular concentration of O.lnM. The cells were incubated 
for varying periods of time before being washed with ice-cold PBS, after which 
some wells received an acid-wash treatment identical to that used in chapter 4 
with 3 H-MTX.
Specific binding of the tracer reached a maximum of 0.8fmoles/106cells after 
30 minutes before steadily decreasing over the remainder of the experiment. It 
was discovered that with all 37°C work a degree of cell detachment occurred after 
1 2 0  minutes, therefore subsequent incubations at this temperature were limited to 
80 minutes. Non-specific binding remained relatively low except for an apparent 
small increase at 30 and 40 minutes, the reason for which is unknown. The data 
from the acid-washed cells showed a gradual increase to reach c.3fmoles/106cells 
after 60 minutes. Some of the decrease in binding beyond 60 minutes may have 
been due to some cell detachment. Acid-washed treatment removed all extracellu­
lar bound ligand (as will be demonstrated subsequently) and thereby represented 
internalised 1 2 5I-label. At 37°C 1 2 5I-NLDP-MSH was internalised (either com­
plete or in a fragmented form) by B16 cells, the amount increasing with time. 
After 1 hour approximately 40% of the cell-associated radioactivity was within 
the cell.
Cell surface binding was more rapid at 37°C, reaching a value of 0.8fmoles/106cells 
in 30 minutes, whereas at 4°C it took 2  hours to reach lfmole/1 0 6 cells.
The internalisation observed at 37°C could have been explained by mechanisms 
other than the MSH binding site. To investigate further, cells were first incubated 
at 4°C for 1 hour with 0.5nM 1 2 5I-NLDP-MSH to allow binding to occur. Cells 
were then washed (to remove unbound radioligand) and reincubated at 37°C in 
the absence (figures 5.10 and 5.11) or presence (figures 5.12 and 5.13) of excess 
unlabelled NLDP-MSH.
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Attempts were primarily made using a lower concentration of ligand for a longer 
time period at 4°C but cells were observed to detach upon re-incubation at 37°C. 
This problem was circumvented by using a shorter period at 4°C which neces­
sitated increasing the concentration of tracer to achieve a reasonable amount of 
binding.
Experiments in figures 5.10 and 5.11 show very similar trends, initial specific 
binding in the range of 4-6fmoles/106cells after the 4°C incubation. Acid-washing 
in all these experiments after incubation at 4°C displayed complete removal of 
1 2 5I-NLDP-MSH, i.e. all the ligand was surface bound at zero time, prior to re- 
incubation. For the experiment shown in figure 5.11 acid-wash treatment on cells 
incubated with excess unlabelled NLDP-MSH at 4°C (non-specific binding), gave 
almost identical results to the same treatment in the absence of cold NLDP-MSH 
(0.86fmoles/106 cells). However this value is a little lower than that for non­
specific binding (1.41fmoles/106cells) indicating the possible removal of a small 
amount of non-specific bound radioligand.
On re-incubation at 37°C the total specific binding decreased rapidly over the 
80 minute period. Internalisation of the tracer in both figures 5.10 and 5.11 
reached a maximum of c.l.75fmoles/106cells after 10-20 minutes before declining 
over the remaining 60 minutes. Non-specific binding decreased at 37°C and (as 
in figure 5.10) there was little difference between it and the acid-wash values.
To investigate whether cooperativity could have occurred identical experiments 
were performed as described previously except the incubation buffer at 37°C 
contained excess unlabelled NLDP-MSH (0.5/jM). The results as shown in fig­
ures 5.12 and 5.13 show no discernable difference in the internalisation, decrease 
in specific binding or the degree of non-specific binding. Both experiments as in 
figures 5.10 and 5.11, exhibited similar values for specific binding (4-6fmoles/106  
cells) after the 4°C exposure, which then decreased with incubation at 37°C. The 
profiles of the four graphs were very similar with the amount of surface-bound 
1 25I-NLDP-MSH decreasing rapidly at 37°C with a corresponding small amount
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of internalisation.
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Figure 5.1: The FAB mass spectrometry of NLDP-MSH.
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Figure 5.2: HPLC purification of the reaction products from the iodination of 
NLDP-MSH as measured by UV adsorption at 217nm. Peaks 1, 2 and 3 are 
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Figure 5.3: Activity per 1ml fraction from the HPLC purification of radio- 
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Figure 5.4: Binding of O.lnM 12’I-NLDP-MSH with B16 cells at 4°C with time 
in a Hepes based buffer containing 0.2% BSA, pH 7.4. Each point represents 
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Figin Figure 5.5: Binding of 0.4nM 125I-NLDP-MSH with B16 cells at 4°C with time
in a in a Ilepes based buffer containing 0.2% BSA, pH 7.4. Each point represents
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Figure 5.6: Binding of O.lnM 125I-NLDP-MSH with B16 cells at 4°C with time 
in a Hepes based buffer containing 0.2% casein, pH 7.4. Each point represents 















Figure 5.7: Adsorption isotherm of increasing concentrations of 125I-NLDP-MSH 
incubated with B16 cells at 4UC for 8 hours at pH 7.4. Each point represents 
the m ean isd  from 6 wells. Total (•), specific (t) and non-specific binding (v) 
respectively.
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Figure 5.8: Second adsorption isotherm of increasing concentrations of 125I- 
NLDP-MSII incubated with B16 cells at 4°C for 8 hours at pH 7.4. Each point 













Figure 5.9: 125I activity after incubation of O.lnM 125i-NLDP-MSH with B16 
cells at 37°C with time. Each incubation was terminated with ice-cold PBS after 
which a set of wells at each time point (exposed to labelled tracer only) received 
a. 5 minute 4UC acid-wash. All wells were then treated in the usual manner. Each 
point represents the m eanisd  from 4 wells. Total (•), specific (Jj) and non-specific 
binding (▼) respectively, and acid-washed cells (v).
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Figure 5.10: Incubation of 1316 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4. Cells were previously exposed to 0.5nM 125I-NLDP-MSH for 1 hour 
at 4°C before being washed with ice-cold PBS (time zero) and then reincubated 
at 37°C. Each point represents the m ean isd  from 4 wells. Total (•), specific (□) 
and non-specific binding (▼) respectively, and acid-washed cells (v).
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Figure 5.11: Second incubation of B16 cells at 37°C with time in normal Hepes 
binding buffer, pH 7.-1. Cells were previously exposed to 0.5nM 125I-NLDP-MSH 
for 1 hour at 4°C before being washed with ice-cold PBS (time zero) and then 
reincubated at 37°C. Each point represents the m ean isd  from 4 wells. Total (•), 
specific (□) and non-specific binding (▼) respectively, and acid-washed cells (v). 
Also an acid-wash of cells exposed to the radio-ligand in the presence of an excess 
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Figure 5.12: Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer supplemented with 0.5/tM NLDP-MSH, pH 7.4. Cells were previously 
exposed to 0.5nM 125I-NLDP-MSH for 1 hour at 4°C before being washed with 
ice-cold PBS (time zero) and then reincubated at 37°C. Each point represents 
the m ean isd  from 4 wells. Total (•), specific (□) and non-specific binding (▼) 
respectively, and acid-washed cells (V).
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Figure 5.13: Second incubation of B16 cells at 37UC with time in normal Hepes 
binding buffer supplemented with 0.5//M NLDP-MSH, pH 7.4. Cells were previ­
ously exposed to 0.5nM 1251-NLDP-MSH for 1 hour at 4°C before being washed 
with ice-cold PBS (time zero) and then reincubated at 37°C. Each point repre­
sents the m ean isd  from 4 wells. Total (•), specific (□) and non-specific binding 
(▼) respectively, and acid-washed cells (V).
5.4 D iscussion
The elution of the iodination products by HPLC revealed three peaks, two of 
which were associated with increased radioactivity. The first peak corresponded 
to non-labelled peptide (as no radioactivity above background was associated with 
it), the second and third corresponded to mono and di-iodinated NLDP-MSH 
respectively. These findings are almost identical to those of Eberle [113], elution 
times being slightly different. The iodination reactions proved very reproducible 
with a workable yield of mono-iodinated peptide being produced.
The binding of 1 2 5I-NLDP-MSH at 4°C reached equilibrium after 8  hours which 
was a relatively long time for a small peptide with a high binding affinity. Siegrist 
et al [199] observed similar kinetics with the analogue NLeu4-aMSH. After 8  hours 
at 4°C binding had still not yet reached a plateau.. In contrast Panasci et al. [114] 
used NLDP-MSH but with a different radio-label (3 H-norleucine being incorpo­
rated into the peptide); they achieved constant binding between 30 minutes and 
24 hours. Both authors used similar binding buffers and cells derived from the 
same line as in the present study. Panasci et al. used the FI varient of B16 cells 
but did not state how the cells varied from those of the parent cell line. The 
presence of the 125I atom may have altered the binding kinetics of the peptide as 
opposed to the use of a tritium label. Certainly Siegrist et al. [203] failed to find 
any significant difference in the binding affinity between iodinated and unlabelled 
peptide (similar results to the latter have been observed in our own laboratories).
The reason for this long equilibriation period is unclear, the fact that Siegrist 
et al. [199] obtained similar results with a related peptide on the same cell line 
indicates that it was not peculiar to the experimental protocol. They undertook 
binding studies in suspension, removing unbound tracer via centrifugation. The 
same group later failed to find any difference in binding of 125I-aMSH to a human 
cell line in suspension or as a monolayer.
Specific binding of 125I-NLDP-MSH at 4°C increased up to c.lnM extracellular
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concentration of the ligand, whilst it was felt the non-specific binding could have 
been limited for the same reasons in the use of 3 H-MTX, i.e. the use of a smaller 
size well. An isotherm fit was processed for one binding site as reports in the 
literature and in our own laboratories have reported the presence of only a single 
binding site [197, 198, 114, 203, 205]. This was further supported by the pho­
toaffinity labelling of a single membrane protein in the order of 45kDa [206, 207] 
which has subsequently been found to be a glycoprotein. Gerst et al. [208] have 
reported two membrane proteins of 43 and 46kDa respectively but this may be 
an artifact of the cell system or methodology used.
The values of Ka obtained from the isotherm model fit, 0.87 and 0.37nM, com­
pare favourably with other results from the same laboratory (with a slightly 
modified binding protocol) 0.395-0.588nM (unpublished data). However the ap­
parent number of binding sites per cell is variable and has been estimated as 
5900-35,700. The figures determined here 5361 and 3384 are representative un­
der normal culture conditions. Both the values for Ka and the number of binding 
sites per cell are in the same range as reported in the literature for identical or 
closely related peptides with B16 cells. Siegrist et al. [198] 15°C, 0.32±0.13nM 
(Kd) and 9570 ±  1750 sites/cell, Tatro et al. [205] 23°C, 0.056 ±  0.019nM and 
2805 ±  589 sites/cell, Panasci et al. [114] 4°C, 0.059nM and 4570 sites/cell (all 
experiments used B16 cells, the temperature of the binding assay is indicated).
The binding and biological response of MSH has been demonstrated to be de­
pendant on extracellular calcium ions [209, 210, 211], which were absent in the 
binding buffer used. This appears not to have affected the assay to a great extent 
as similar results were obtained in the same laboratory with a calcium replete 
buffer. The variation in the number of binding sites/cell could be due to pheno­
typic drift as the cells are being continuously passaged. Kameyama et al. [212] 
discovered that over six months cells retained the same affinity (22.0nM) for 1 2 5I- 
qMSH but were less sensitive to the hormone with a decrease in the receptor 
density. Siegrist et al. [203] also found that progressive subculturing of one cell 
line lead to the loss of receptor expression. Conversely Ghanem et al. [213] found
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binding characteristics for 12 5I-aMSH with a human melanoma cell line to remain 
fairly constant over two months.
It appears from published work that the value for Bmu is not a true reflection of 
receptor number of all cells within a population. Many authors have reported non- 
uniform binding/labelling of cell populations [214, 215, 216, 217] which may be 
due to their non-synchronised state. Varga et al. [217] and McLane and Pawelek
[218] reported binding of the MSH hormone to occur predominantly in the G2 
(and possibly late S) phase of the cell cycle and was associated with the Golgi 
complex [215], although Fuller and Brookes [219] dispute this point. However 
these authors failed to follow binding through more than one cell cycle as they 
reported loss in synchronisation. Shimizu et al. [220] have reported insulin recep­
tor regulation through the cell cycle in mouse melanoma cells with the highest 
activity in the S-phase. Others have found some melanoma cell lines failing to 
express any MSH peptide binding [198, 213]. Both these instances have occurred 
with various human melanoma cell lines, others seem to express a greater affinity 
for MSH but tend to have a lower receptor density when compared to murine 
melanoma cell lines [203]. The advent of more potent analogues such as NLDP- 
MSH has in one case revealed the presence of previously undetected binding sites 
(Libert et al. [221]), of course good radiolabel purification is required to measure 
small receptor populations.
Although the results reported here demonstrate binding to B16 cell membranes, 
which can be displaced by excess unlabelled NLDP-MSH, it does not provide 
evidence for interaction with the aMSH receptor. Binding of a fixed amount 
of 1 2 5I-NLDP-MSH in the presence of increasing concentrations of extracellular 
aMSH would confirm this specificity. This has been demonstrated for unlabelled 
NLDP-MSH in mouse and human melanomas by Siegrist et al. [199, 203] against 
125I-Nleu-aMSH and aMSH.
Apparent cellular binding of 1 25I-NLDP-MSH was more rapid at 37°C, reaching 
a maximum at 30 minutes before apparently declining. Of course at this tem­
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perature metabolic processes are operative. The rate of association was similar 
to other reports [198, 199, 114]. The subsequent decrease in specific binding was 
paralled by an increase in the acid-resisitant cell associated radioactivity. Acid- 
wash treatment removed surface bound ligand which revealed all tracer to be on 
the cell surface at 4°C. The remaining portion at 37° C must therefore have been 
internalised whole or fragmented peptide within the cell.
The decrease in bound ligand at 37°C has been observed by other workers using 
similar conditions. Siegrist et al. [199] used 12 5I-Nleu-aMSH with B16 cells, where 
association of the ligand also reached a maximum value after 30 minutes. The 
rate of dissociation however was very rapid which they accounted for due to 
degradation by tissue proteases. Panasci et al. [114] used 3 H-NLDP-MSH with a 
B16 variant and also achieved maximum cell-association of ligand at 30 minutes 
with a decline thereafter at 37°C. They demonstrated that the tracer was not 
degraded in the medium or within the cells for up to 2  hours which was not 
suprising as unlike the native peptide and some of its analogues, NLDP-MSH is 
more resisitant to enzymatic lysis [200, 201]. This is partly the reason for its 
greater biological activity compared to aMSH.
The measure of internalised (acid-resisitant) 125I-NLDP-MSH was in good agree­
ment with Panasci et al. [114] who also employed an acid-wash. A maximum 
amount was reached at 60 minutes with a following decline. The question that 
arises is can the internalisation of the ligand be related to the decrease of cell 
surface binding ? The latter is unlikely to be caused by NLDP-MSH degradation 
and although Siegrist et al. [199] demonstrated rapid dissociation of ligand at 
37°C, that was using 1 2 5I-Nleu-aMSH, which they found to have far less affinity 
for the binding site than NLDP-MSH. Two further results by Panasci et al. [205] 
concerned the appearance of partial degradation products within the cell after 4 
hours at 37° C, and an increase in the amount of internalised ligand in the pres­
ence of ammonium chloride. This acidotrophic agent is known to increase the 
pH enviroment of endosomes and lysosomes, which restricts lysosomal enzyme 
degradation and prevents vesicle fusion events in the endocytic pathway [71, 72].
132
The increase in the amount of internalised tracer could be due to non-degradation 
and subsequent accumulation of ligand, or the non-dissociation from internalised 
receptors which are now trapped inside the cell.
A possible explanation for the decline of surface binding at 37°C could be at­
tributed to internalisation of ligand-receptor complex with a temporay loss of 
membrane binding sites. Covalent labelling of the receptor and monitoring its 
movement after binding would help resolve the reasoning behind this decrease 
observed.
Of course the internalisation observed at 37°C of 12 5I-NLDP-MSH need not have 
necessarily occurred via the binding previously observed at 4°C (even though 
membrane binding was seen at the former temperature). For this reason in the 
last series of experiments the radio-tracer was allowed to bind at 4°C, excess 
unbound ligand removed, and the incubation temperature increased to 37°C. This 
resulted in a steady decline in membrane or surface bound 12 5I-NLDP-MSH with 
a concomitant appearance of internalised tracer. The latter was very small and 
displayed a maximum at 10-20 minutes. It therefore seems 12 5I-NLDP-MSH was 
internalised into B16 cells at 37°C possibly associated with the receptor/binding 
site. The decrease in internalised ligand after one hour at 37°C could either be 
due to recycling of receptor and ligand back to the cell surface with dissociation of 
the ligand (but an increase in membrane binding would occur unless the receptor 
was in an inactive form), or release of ligand either degraded or whole back into 
the medium. Receptor labelling and subcellular fractionation studies would give 
a greater insight into the internalisation process, of which there are very few 
examples in the literature. Siegrist et al. [198] observed the removal of 70-75% 
of surface bound 125I-Nleu-aMSH from B16 cells at 37°C compared to 90-95% of 
12 5I-aMSH in human melanoma cells. Other authors have also failed to observe 
internalisation [214, 216, 222] in human and mouse melanomas of MSH peptides 
in order to exert their biological action. It is interesting to note that Shimizu 
et al. [2 0 2 ] recorded the binding and subsequent uptake of iodinated insulin in 
Cloudman S-91 mouse melanoma cells which then underwent degradation.
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It appeared that internalisation of 12 5I-NLDP-MSH occurred via its binding site 
at 4°C although this was not definitive evidence for such a process. Also the ex­
periments failed to demonstrate if the 12 5I-NLDP-MSH was internalised complete 
or in a fragmented form, whether the 125I was still attached to its binding site 
or dissociated and entered via a different route. If internalisation did occur by a 
receptor-mediated process it may be influenced by the subsequent binding of more 
ligand, i.e. display cooperativity. McLane and Pawlek [218] proposed positive 
cooperativity to have occurred in synchronised cultures of Cloudman S91 mouse 
melanoma cells in response to /2-MSH binding. However when excess NLDP- 




NLDP-M SH -M TX Conjugate: 
Iodination and Cellular 
Interaction
6.1 Introduction
The targeting agent NLDP-MSH and the antimetabolite MTX can be combined 
to form a potentially site-specific drug conjugate. However the attachment must 
be performed to cause minimal loss of targeting or binding by the NLDP-MSH. 
Therefore the ‘binding sequence’ of this tridecapeptide must be established before 
conjugation can occur.
Eberle et al. [223] reported in 1977 that aMSH contained two message sequences 
capable of triggering melanophore receptors, a central portion and the C-terminal 
Try-Glys-Lys-Prol-Val.NH2 . The N-terminal sequence Ac-Ser-Tyr-Ser-Met- did 
not exhibit any biological activity alone but potentiated the activity of the C- 
terminal portion when combined. Further work [224] with the C-terminal struc­
ture demonstrated the importance of lysine and proline at positions 1 1  and 1 2
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respectively, whilst valine was not essential at 13 but a residue must be present 
for no loss in activity. This pointed towards a central to C-terminal binding 
sequence in the peptide. When aMSH was coupled to human serum albumin, 
thyroglobulin or tobacco mosaic virus via the N-terminal the complexes still re­
tained good activity. But when linked via lysine (position 11) the complexes were 
more than a 100-fold lower in activity than linked via the N-terminal.
From the quoted work a freely accessible C-terminus is essential for the biological 
(and therefore binding) activity of the native hormone. The shorter fragments 
(4-10 and 4-11) of NLDP-MSH have also demonstrated good biological potentcy
[219]. For these reasons MTX was linked to NLDP-MSH via the N-terminal in 
the hope of retaining similar activity to the free analogue. The conjugate wa-s 
iodinated and its interaction with B16 cells studied for a comparision of binding 
and most importantly uptake, to the free peptide.
6.2 M ethods
All methods are described in detail in section 2.4.
6.3 R esults
6.3.1 N L D P-M SH -M T X  Synthesis
The conjugate was prepared by attachment through the glutamyl residue of MTX 
to the N-terminal of the peptide and purified by HPLC employing an identical 
procedure as for the free peptide, except U V detection was now at 300nm, utilising 
the chromophore of MTX. On analysis by HPLC four peaks were observed to elute 
very close together after 30 minutes (figure 6.1). The identity of this product was 
confirmed as the MTX conjugate by FAB-MS, figure 6.2 (molecular weight 2041,
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calculated weight 2040). It appears that in the reaction the peptide couples 
through the a  or 7  carboxylic group of the glutamyl residue and forms a racemic 
mixture. Racemization is thought to occur at the a-carbon of the glutamine 
residue on MTX. Thus the four peaks observed are due to a di-isomeric racemic 
mixture.
6.3.2 Iodination o f N L D P-M SH -M T X  Conjugate
It was decided to use a similar iodination protocol as for the free peptide, how­
ever a difference in elution from the C18 SepPak was envisaged. Initially a pre­
conditioned column was loaded with 5/d of stock conjugate (lmg/ml) in 0.5ml of 
PB buffer. A 2xlml PB buffer wash of the column was first applied and discarded, 
followed by successive 2 xlml washes of 40, 50 and 60% methanol/1 % TFA. Each 
2 ml fraction was collected and purified by HPLC using an identical procedure as 
for the free peptide.
Each methanolic wash revealed a peak at an identical elution time to an ordinary 
injection of the conjugate (i.e. c.29.5 minutes), figures 6.3, 6.4 and 6.5. The 
greatest yield and cleaner trace occurred with the 60% methanolic wash. It was 
decided to wash the SepPak column with 40 and 50% methanol and retain the 
60% methanolic wash for further purification.
In all iodinations of the conjugate a stock volume of 5/d was used as opposed to 
1 /d of the free peptide as a poor yield would be expected due to the presence of 
the MTX. The first iodination used the standard 30 seconds reaction time with 
chloramine T. The resulting HPLC trace from the reaction (figure 6 .6 ) displayed 
one large peak at the expected elution time for free or non-labelled conjugate. 
Fractions of 0.5ml were collected from 28-43 minutes at a flow rate of lml/minute, 
their activity was assayed by a gamma counter (figure 6.7). One main peak of 
radioactivity was observed reaching a maximum value at 35 minutes. When the 
profile of activity was superimposed on the HPLC trace with the correct time
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scale (figure 6 .8 ), the peak of 125I activity did not coincide with the peak on 
the HPLC trace. With the knowledge of the order of iodination reaction prod­
ucts with the free peptide, it appeared that the peak observed on the trace was 
unlabelled conjugate. The mono-iodinated product, although displaying a peak 
via its activity was too small to measure by HPLC. Therefore using a 30 second 
iodination reaction gave a yield of mostly unlabelled conjugate. In theory if the 
reaction time is extended more mono-iodinated will be formed and a time will 
eventually be reached when di-iodinated conjugate would be predominant.
The reaction time was arbitarily extended to 5 minutes and again the products 
were purified with HPLC (figure 6.9) with 0.5ml fractions collected and the ac­
tivity quantified (figure 6.10). Two peaks on the trace (labelled 1 and 2) had 
similar profiles to the pure conjugate, the first eluting at 31.5 minutes, the sec­
ond at 34 minutes. The activity in the fractions displayed two distinct peaks, the 
first of which when superimposed on the trace (figure 6 .1 1 ), coincided with peak 
2. This was most probably the mono-iodinated, peak 1 the unlabelled and the 
second activity peak may represent the minor peak following number 2  on the 
trace (likely to be the di-iodinated). The yield of mono-iodinated product was 
greater using the extended reaction, as reflected by the level of activity recorded. 
A maximum of c.60 million cpm as opposed to just under 250,000. The mono- 
iodinated conjugate appeared in the four 0.5ml fractions from 34-35.5 minutes 
inclusive.
Figures 6 . 6  and 6.9 represent 0.5ml of a total of 2ml from the iodination. When 
the remaining 1.5ml were run through the HPLC very similar results occurred 
with the mono-iodinated peak of activity eluting in the same fractions.
From the above experiments an iodination reaction time of 5 minutes chlo- 
ramine T exposure was chosen. However it was noted that complete separation 
between the various products had not occurred and fraction collection of mono- 
iodinated conjugate may involve the risk of contamination with non-labelled or 
di-iodinated, and/or the complete omission of one of the four conjugate isomers.
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An experiment was performed to increase the chloramine T reaction time to 
30 minutes to observe if mainly di-iodinated product was formed. This resulted 
in one large broad peak obviously composed of mono and di-iodinated products 
together, figure 6.12 (HPLC trace) and figure 6.13 (125I activity). Although the 
activity associated with the fractions did display some resolution between the 
two labelled forms (figure 6.13).
6.3.3 B inding C om petition  w ith  125I-N L D P-M SH
The binding affinity of the conjugate at 4°C was assessed by a competition as­
say on B16 cells against a fixed concentration (0.25nM) of 1 2 5I-NLDP-MSH for 
8  hours. The conjugate concentration ranged from 0.05 to 0.5/zM, the presence of 
the MTX being likely to decrease the binding affinity of the NLDP-MSH moiety 
compared to the free peptide.
The results of two experiments, figure 6.14, displayed good similarity. Values for 
total and non-specific binding of the free peptide showed little variation and were 
consistant with earlier findings. As the concentration of the conjugate increased 
there was a greater degree of binding inhibition. At 0.2-5.0/jM binding of 125I- 
NLDP-MSH reached non-specific values.
The experiments can be described by equation 6.1, assuming that both ligands 
bind to the same receptor, the level of non-specific binding is identical and there 
is no significant depletion of the ligand in the binding medium.
P _______ [RLF]_______
([RLF] +  Krl.[CF]/Kc) 1 ' 1
where F is the relative fractional binding of the radioligand, [RLF] is its free 
molar concentration, [CF] is the free molar concentration of the competitor, Kri 
and Kc are the dissociation constants for binding of radioligand and competi­
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tor respectively. Estimates for Kc were obtained by fitting the data (cpm) to 
equation 6 . 2  using non-linear regression.
c p n w  =  ( c p n w  -  <?”*-)• ([RLF] +  Kr,.[CF]/Kcj +  Cpm“  (6‘2)
The subscripts test, max and ns refer to the cpm obtained in the presence of 
a binding inhibitor, the absence of inhibitor and the non-specific binding. The 
dissociation constants of NLDP-MSH-MTX for the two experiments were 5.56 ±  
1.82 and 7.49 ±  1.81nM respectively.
6.3.4 Incubation o f 125I-N L D P-M SH -M T X  at 37°C w ith  
B16 cells
The cell association of the iodinated conjugate at 37°C was very similar to the 
free peptide, figure 6.15. Binding increased to reach a maximum at 30 minutes 
of c.9fmoles/106cells, followed by a fairly rapid decrease in the amount bound. 
Although similar to NLDP-MSH, the levels of internalisation throughout the ex­
periment, as determined by acid-washing, were low. This was probably due to the 
degradation and subsequent exocytosis of internalised ligand and a corresponding 
loss of receptor expression on the cell surface.
Further experiments allowed the conjugate to first bind at 4°C for 2 hours; excess 
tracer was then removed by washing, and the cells reincubated at 37° C for varying 
time periods (figures 6.16, 6.17 and 6.18). After 2  hours at 4°C the amount bound 
ranged from 3.5- 10fmoles/106 cells. This was all surface bound as determined by 
acid-washing which decreased all activity to around non-specific values except in 
figure 6.16. Here non-specific binding appeared relatively high at time zero, but 
fell to expected values at the next time point.
As incubation at 37°C proceeded surface bound 125I-NLDP-MSH-MTX decreased.
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After 60 minutes in figure 6.17 no specific binding remained, whilst in the remain­
ing two experiments there was a 50% reduction after 30 minutes. After 1 0  minutes 
an acid-wash resistant fraction began to appear, representing internalised radioli­
gand. Its value, c.0.5-lfmoles/106cells remained almost constant throughout the 
experiment. Non-specific binding remained low for the three experiments all of 
which displayed similar profiles, i.e. a decrease in surface bound ligand with the 
appearance of internalised radiolabel (also similar to identical experiments with 
12 5I-NLDP-MSH).
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Figure 6.1: The HPLC purification of NLDP-MSH-MTX measured by UV ab­
sorbance at 300nm (vertical large squares represent 5xl0-3 absorbance units).
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Figure 6.2: The FAB mass spectrometry of NLDP-MSH-MTX
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Figure 6.3: The HPLC trace of a 2xlml 40% methanolic wash of a C18 SepPak
column pre-loaded with 5/d of NLDP-MSH-MTX (lm g/m l stock). Peak 1 repre­




Figure 6.4: The HPLC trace of a 2xlm l 50% methanolic wash of a C18 SepPak
column pre-loaded with 5^1 of NLDP-MSH-MTX (lm g/m l stock). Peak 1 repre­
sents the conjugate (vertical large squares represent 5xl0-3 absorbance units).
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Figure 6.5: The HPLC trace of a 2xlm l 60% methanolic wash of a C18 SepPak
column pre-loaded with 5/d of NLDP-MSH-MTX (lm g/m l stock). Peak 1 repre­
sents the conjugate (vertical large squares represent 5xl0-3 absorbance units).
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Figure 6.6: The HPLC trace of products from a 30 second chloramine T iodination
reaction of NLDP-MSH-MTX. Peak 1 represents the conjugate (vertical large
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Figure 6.7: 125I activity (cpm) per 0.5ml fraction of the HPLC purification (28-
43 minutes after injection) of iodinated NLDP-MSH-MTX (after a 30 second





Figure 6.8: The HPLC trace of products from a 30 second chloramine T iodi­
nation reaction of NLDP-MSH-MTX, with the associated 125I activity superim­
posed. Peak 1 represents the conjugate (vertical large squares represent lxlO-3 
absorbance units).
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Figure 6.9: The HPLC trace of products from a 5 minute chloramine T iodina­
tion reaction of NLDP-MSH-MTX. Peak 1 and 2 are thought to represent the 
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Figure 6.10: 125I activity (cpm) per 0.5ml fraction of the HPLC purification
(28-43 minutes after injection) of iodinated NLDP-MSH-MTX (after a 5 minute




Figure 6.11: The HPLC trace of products from a 5 minute chloramine T iodi­
nation reaction of NLDP-MSH-MTX, with the associated 125I activity superim­
posed. Peak 1 is thought to represent the unlabelled conjugate, and peak 2 the 
mono-iodinated (vertical large squares represent lxlO-3 absorbance units).
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Figure 6.12: The HPLC trace of products from a 30 minute chloramine T iod­
ination reaction of NLDP-MSH-MTX. Peak 1 is thought to represent the mono 
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Figure 6.13: 125I activity (cpm) per 0.5ml fraction of the HPLC purification (28-
43 minutes after injection) of iodinated NLDP-MSH-MTX (after a 30 minute
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Figure 6.14: Binding competition assay (representing two individual experiments) 
of 0.25nM 125I-NLDP-MSH incubated with increasing concentrations of NLDP- 
MSH-MTX at 4°C for 8 hours. The total (1) and non-specific (2) binding are 
displayed for the two sets of data, each point represents the m e an isd  from 6 wells.
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Figure 6.15: Cell associated 125I activity after incubation of InM 125I-NLDP- 
MSH-MTX with B16 cells at. 37°C with time. Each point represents the m ean isd  
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Figure 6.16: 1. Incubation of BIG cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4. Cells were previously exposed to InM 125I-NLDP-MSH-MTX 
for 2 hour a t 4°C before being washed with ice-cold PBS (tim e zero) and then 
reincubated at 37°C. Each point represents the m ean isd  from 4 wells. Total (•), 
specific (□) and non-specific (▼) binding respectively, and'acid-washed cells (v).
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Figure 6.17: II. Incubation of B16 cells at 37°C with time in normal Hepes 
binding buffer, pH 7.4. Cells were previously exposed to InM 125I-NLDP-MSH- 
MTX for 2 hour at 4°G before being washed with ice-cold PBS (time zero) and 
then reincubated at 37°C. Each point represents the m ean isd  from 4 wells. Total 
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Figure 6.IS: III. Incubation of BIG cells at 37°C with time in normal Hepes 
binding buffer, pH 7.4. Cells were previously exposed to InM 125I-NLDP-MSH- 
MTX for 2 hour at 4UC before being washed with ice-cold PBS (time zero) and 
then reincubated at 37UC. Each point represents the m ean isd  from 4 wells. Total 
(•), specific tjl and non-specific (▼) binding respectively, and acid-washed cells ^).
6.4 D iscussion
The elution time of the unlabelled conjugate on the HPLC system was almost 
identical to that of the free peptide. Detection with UV was easier due to the 
MTX moiety, allowing the wavelength to be increased from 217 to 300nm. Upon 
iodination, products eluted in the same order as those for NLDP-MSH, i.e. non­
labelled first, then mono and lastly di-iodinated peptides. However the reaction 
time was increased from 30 seconds to 5 minutes in order to improve the yield 
of mono-iodinated. Presumably the presence of MTX on the peptide decreased 
the efficiency of the reaction. It is also likely that 30 seconds is not the optimal 
reaction time for the iodination of NLDP-MSH. Resolution between the products 
was fairly good but by no means complete, as shown by both the HPLC trace and 
the activity of the fractions. Mono-iodinated conjugate was contained in fractions 
collected between 34-35.5 minutes inclusive, in two subsequent injections.
In retrospect the purity of the mono-iodinated conjugate could have been partially 
confirmed by re-injection of the chosen fractions. If totally mono-iodinated then 
one peak would have appeared, but it would be difficult to assess if all four forms 
of the conjugate were present.
The affinity of the unlabelled conjugate with B16 cells was assessed by a compe­
tition assay with 125I-NLDP-MSH at 4°C, the main assumption being that the 
two ligands were interacting with the same single class of receptors. The bind­
ing inhibition observed was sigmoidal in appearance, but a few more samples at 
lower concentrations would have been an improvement. The results from the two 
experiments were very close indicating a good consistency in the assay. Values 
for the dissociation constant of 5.56±1.82 and 7.49±1.81nM were obtained. If the 
average of these two values are compared to those of 1 2 5I-NLDP-MSH they axe 
approximately ten-fold greater, thereby indicating the conjugate has a ten-fold 
lower affinity for the MSH receptor.
To achieve a similar level of receptor occupancy to 1 25I-NLDP-MSH, InM of
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labelled conjugate was incubated at 37°C with B16 cells. The profile of specific 
binding for the conjugate was similar to the free peptide with maximal values 
at 30 minutes after which a decline was observed. However the maximal value 
attained by the conjugate was in the order of ten-fold greater (9fmoles/106cells 
compared to 0.8fmoles). This may reflect a significant change in binding affinity 
of the conjugate at 37°C compared to 4°C, which was not observed with NLDP- 
MSH; or a change in affinity due to the radiolabel (this did not occur with NLDP- 
MSH). Another possibility was greater receptor expression by the cells at that 
particular instance, but this was unlikely as similar passage numbers were used.
There was no clear evidence of internalisation during the 37°C incubation, though 
the internalised 125I may have been masked by a higher level of non-specific 
binding. It has been previously stated that a smaller size well may improve the 
assay by reducing non-specific binding, although levels were expected to increase 
as a greater amount of radioactivity was used (InM 125I-NLDP-MSH-MTX).
Uptake clearly occurred in experiments when the conjugate was allowed to bind 
to the cells at 4°C, with excess ligand removed prior to reincubation at 37°C in 
ligand free buffer. A lower level of non-specific binding in this technique may have 
been responsible for revealing the small amount of internalised label. These ex­
periments displayed similar profiles to the free peptide with a decrease in specific 
binding with time at 37°C. Both sets of experiments displayed an internalisation 
of ligand in the order of 0.5fmoles/106cells but this did not demonstrate if the 
ligands entered the cells complete or in a fragmented form.
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Chapter 7
Enzyme Inhibition by 
NLDP-M SH -M TX and its 
Lysosomal Degradation products
7.1 Introduction
As mentioned previously (chapter 1), MTX exerts its cytotoxic action primarily 
through inhibition of dihydrofolate reductase (DHFR). MTX binding to DHFR is 
extremely tight and rapid [225] and inhibition is stoichiometric at pH 6.0 [226]. At 
physiological pH the binding affinity is lower and becomes similar to the substrate 
dihydrofolate (FH2 ) [225]. The Km for the natural substrate is generally in the 
micromolar range (pH 7.4) while the Ki for MTX is below 10“loM [227].
In this part of the study it was decided to compare the inhibitory activities of 
MTX and the NLDP-MSH-MTX conjugate. The latter was expected to have 
lower activity because racemisation of the glutamate moiety was suspected. It 
was also of interest to determine how much activity was lost by conjugation of the 
peptide to MTX. However the cytotoxic action of the conjugate is not expected to
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be due to the complete molecule. Targeting of this complex to cells is expected 
to result in receptor-mediated uptake and subsequent delivery of the complex 
to the lysosomes. Here degradation is likely to occur followed by the possible 
release of metabolites into the cell cytosol which may or may not lead to a cyto­
toxic effect. To study this hypothesis, NLDP-MSH-MTX was incubated with a 
lysosomal enzyme extract for various time periods and the degradation products 
assayed for DHFR inhibitory activity as a mixture. This hypothesis is compa­
rable with reports of the in vivo effectiveness of a daunorubicin conjugate [228] 
which was found to be related to its susceptibility to lysosomal degradation (with 
release of free drug) and was more effective than daunorubicin alone. The latter 
study confirmed the cytotoxic action was due to endocytosis of the daunorubicin 
conjugate. In other studies the change in pH experienced by compounds entering 
lysosomes has been used as a means of drug release [229].
In the present study a spectrophotometric assay was employed using bovine liver 
DHFR, an easily obtainable and well documented enzyme. The human enzyme 
is not freely available due to difficulties in preparation as human tissue contains 
little DHFR [119]. Bovine DHFR was preferred to bacterial DHFR due to its 
closer homology with human DHFR. Although amino-acid sequence homology 
[230] is less than 30% between bacterial and vertebrate sources (75-90% homology 
in different vertebrates), X-ray crystallographic studies [231, 232, 233, 234] have 
shown that the overall tertiary structures are very similar. This is reflected in 
the very close binding requirements of DHFR from various sources for substrates 
and inhibitors alike. Differences are observed however in the varying affinities of 
inhibitors for the enzymes, e.g. trimethoprim is a potent inhibitor of bacterial 
DHFR but is several thousand fold less effective against mammalian DHFR [230]. 
Thus the bovine DHFR used in this study should be a good reflection of the results 
expected with the human enzyme.
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7.2 R esults
7.2.1 A ssay Conditions
The enzyme assay was based on the method of Peterson et al. [166] who estab­
lished a high yield purification of bovine liver DHFR. The reaction was measured 
by the rate of change in absorbance as dihydrofolate was converted to tetrahy- 
drofolate in the presence of NADPH as a co-factor. FH2 and FH4 at identical 
concentrations display a variation in absorbance (figure 7.1), the reaction being 
performed at a wavelength that maximises this difference. A scan of absorbance 
against wavelength demonstrated this wavelength to be 343nm on the spectropho­
tometer used (table 7.1).
All experiments were performed with a saturating concentration of the substrate 
in order to ensure that the reaction proceeded at its maximum rate. This was 
established by increasing the FH2 concentration in the cuvette until there was no 
further difference in the rate of absorbance change during the reaction (table 7.2). 
A value of 120/iM FH2 was found to saturate the enzyme and was employed 
throughout the study.
The assay was quantified by the rate of change in absorbance which proceeded 
with a close to linear relationship until the FH2 became depleted. The absorbance 
was recorded every 30 seconds for 10 minutes during which a linear rate of ab­
sorbance change was recorded (figure 7.2). The use of rate of change in absorbance 
ensured that any differences in absorbance due to ‘unmatched’ quartz cuvettes 
would be nullified in quantification of the experiment.
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Wavelength f h 2 f h 4 Difference
330 0.631 0.442 0.189
331 0.619 0.418 0 . 2 0 1
332 0.602 0.385 0.217
333 0.587 0.356 0.231
334 0.572 0.330 0.242
335 0.560 0.311 0.249
336 0.552 0.295 0.257
337 0.540 0.276 0.264
338 0.529 0.261 0.268
339 0.520 0.248 0.272
340 0.510 0.236 0.274
341 0.505 0.231 0.274
342 0.497 0 . 2 2 2 0.275
343 0.491 0.216 0.275
344 0.484 0 . 2 1 0 0.274
345 0.480 0.207 0.273
346 0.475 0 . 2 0 2 0.273
347 0.470 0.199 0.271
Table 7.1: Absorbance values and difference between equimolar (O.lmM) con­
centrations of dihydrofolate (FH2 ) and tetrahydrofolate (FH4 ) at different wave­
lengths.




1 0 0 0 . 0 2 1 1
1 2 0 0.0217
Table 7.2: The gradients of the rate of absorbance change with increasing con­
centrations of the enzyme substrate FH2 .
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7.2.2 Inhibition by MTX and NLDP-MSH-MTX
The rate of absorbance change for each experiment was calculated by performing 
linear regression on the data obtained. The control gradient, essentially ab­
sorbance change due to NADPH oxidation alone, was subtracted from all other 
gradients which were then expressed as a percentage of the maximum (120/iM 
FH2 with no inhibitor present).
Increasing concentrations of free MTX were added and a decline in the reaction 
rate was observed. An example of a typical experiment, figure 7.3, shows the 
test and control reactions plus three different concentrations of MTX. As the 
amount of MTX increased there was a corresponding decrease in the reaction 
rate. Complete inhibition occurred when the reaction had an identical rate to 
that of the control. The linear regression of the data also demonstrated the close 
linear relationship of the reaction and the validity of using linear regression.
Dose-inhibition curves for MTX and NLDP-MSH-MTX exhibited similar profiles 
as would be expected for genuine competitive inhibition (figure 7.4). The inhibi­
tion from 100% approximately to 20% of the test activity occurring over 2 to 3 
log cycles for both compounds. Inhibition was thought to take place through the 
same mechanism, both being competitive with FH2 for the enzyme. The data 
was fitted to equation 7.1, where A represents the % of DHFR activity, C the 
concentration of inhibitor, and B the IC 5 0  for the respective inhibitor. A value of
0.7 was assigned to m, using a parameter estimate from an initial fit of the data 
for MTX.
1 — Cm
A = 1 0 0  x -  —  (7.1)Cm + Bm v '
The IC5 0  values for MTX and NLDP-MSH-MTX were 8.98 ±  1.32 and 364.25 ±  
121.15nM respectively.
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7.2.3 Inhibition by th e lysosom al degradation products 
of N L D P-M SH -M T X
A concentration of the conjugate was chosen which exhibited an inhibitory effect 
whilst overlying part of the free MTX inhibition curve in order to compare the 
inhibitory effects of degradation products with both conjugate and free drug. A 
concentration of 20nM NLDP-MSH-MTX was chosen which allowed the reaction 
to proceed at 85% of the maximum rate of the test reaction. The corresponding 
reaction in the presence of 20nM MTX proceeded at 30% of the maximum rate. 
The concentration of conjugate exposed to the lysosomal enzymes was 0.25mM. 
The lysosomal reaction mixture was then serially diluted in the sodium acetate 
and KC1 buffer (pH 6.0), in order to minimise effects of the low pH buffer and 
the proteins themselves.
Two degradation reactions were performed at 37°C (reactions A and B) on dif­
ferent days with samples removed at 0, 2, 4 and 16 hours. The inhibitory activity 
was then assessed in the DHFR enzyme assay (table 7.3). Generally products 
of the lysosomal reaction mixtures displayed an increase in inhibitory activity 
as the length of lysosome degradation increased. Control samples at 0 hours re­
tained almost identical activity to the undegraded conjugate thus demonstrating 
no effect on the assay by buffer or lysosomal enzymes being carried over to the 
DHFR assay. No explanation is available why the 2 hour sample from reaction B 
exhibited a greater inhibitory action than at 4 hours. In reaction A the 16 hour 
sample was more inhibitory than the corresponding concentration of free MTX 
(18.65±2.54% activity compared to 30.25±2.94%) whilst the same time sample 




Percentage of DHFR Activity
Reaction A Reaction B
0 84.63 ±  6.38 88.77 ±  34.04
2 68.53 ±  12.29 26.15 ±4.02
4 34.66 ±  1.07 41.20 ±8.01
16 18.65 ±  2.54 28.15 ±0.58
Table 7.3: The percentage of DHFR activity (mean±sd) in the presence of the 
degradation products of NLDP-MSH-MTX after various lengths tritosomal incu­





Figure 7.1: Absorbance scan against wavelength of 1/zM FH2 and FH4 at room 
temperature.
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Figure 7.2: The rate of change of absorbance at 343 nm of 120/iM FH2 incubated 
with DHFR at 37°C in the presence of 50/zM NADPH
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Figure 7.3: Rate of change of absorbance at 37°C, 343 nm, of 120/* M FH2 with 
DHFR., 50/zM NADPH in the absence and presence of varying MTX concentra­
tions. The control represents DIIFR and NADPH alone. 120/*M FH2 (▼), 1 nM 
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Figure 7 A :In liib ition  ol' DHFR at 37°C by MTX (•{ and NLDP-MTX (■) ex- 
pressed as a percentage of maximum activity (120/tM FH2 represents 100%).
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7.3 D iscussion
The spectrophotometric assay employed enabled the measurement of initial rate 
of reduction of FH2 by the DHFR system. This permitted the compaxision be­
tween three different MTX derivatives, namely free MTX, the conjugate form 
NLDP-MSH-MTX and the degradation products of the latter after lysosomal 
attack. The validity of using the first ten minutes of the reaction to calculate 
reaction rate was established as the rate of absorbance change was very close to 
linear.
Inhibition of DHFR by free MTX occurred in a dose related manner with up 
to about 80% inhibition being achieved at 0.2/zM. This degree of inhibition was 
gradual taking place over 2 to 3 log cycles which proved too shallow to model 
by the standard procedures for a sigmoidal dose/response relationship. Similar 
profiles were obtained by Peterson et al. [166] using bovine DHFR at pH 8  and 
Thillet and Picket with the mouse enzyme [235]. The response could infer neg­
ative cooperativity however this has not been suggested to occur with this well 
documented enzyme.
When the conjugate NLDP-MSH-MTX was used a similar dose/inhibition re­
sponse was observed, however this was shifted to the right corresponding to in­
creased inhibitor concentrations. The IC50 values corresponded to 8.98 ±1.32 and 
364.25 ±  121.15nM for MTX and NLDP-MSH-MTX respectively. The conjugate 
thus had a 41 fold lower affinity for the enzyme than the free drug. The paral­
lel profiles of the two inhibitors indicated that they both acted as competitive 
inhibitors with FH2 for the same site on the enzyme.
The decrease in affinity by the conjugate can easily be explained when the stere­
ochemistry of MTX inhibition of DHFR is examined. Early x-ray studies of the 
bacterial DHFR/MTX complex pointed towards two important features of in­
hibitor binding [236]. Firstly the possible inversion of the MTX pteridine ring 
relative to that of FH2 in the binding site of DHFR, and secondly the hydrogen
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bonding via the a-carboxyl group of the glutamate moiety of MTX. The pro­
posal of the former by Matthews et al. [236] was later confirmed, by Charlton et 
al. [237] using DHFR from Lactobacillus casei and Bolin et al. [231] with an iden­
tical enzyme source plus Escherichia coli. Similar findings were later observed 
with human DHFR and MTX in a crystalline structure [233, 234] and in solution 
[232].
During the aforementioned studies the importance of hydrogen-bonding via the 
a-carboxyl group was also noted in all DHFR sources whereas interaction through 
the 7 -carboxylate appeared weak and non-specific. This was supported with the 
study of DHFR inhibition by various analogues and conjugates of MTX involving 
its terminal glutamate residue. When Rosowsky et al. [238] prepared amide 
derivatives of MTX via the a  and 7  carboxyl groups together there was a dramatic 
increase in the IC 50 values for DHFR inhibition compared to free MTX. However 
a 7 -monohydroxamine acid analogue which had a free a-carboxylate retained 
similar activity to MTX. Other findings reported by Piper et al. [239] who used a 
and 7  substituted amides, peptides and esters of MTX led to similar conclusions. 
Inhibition of DHFR showed little variation when the a  carboxyl group remained 
intact, but when substituted with Gly, Asp or Glu there resulted in a 100,000 
fold incease in the values of Ki for DHFR inhibition in mouse L1210 cells.
When Fan et al. [240] synthesised a fluorescein-MTX conjugate they obtained 
similar reaction products as those obtained here with NLDP-MSH-MTX, i.e. a  
and 7  isomers, which on further investigation were found to have undergone 
racemization of the 1-glutamate moiety in MTX. When the isomers were resolved 
the a conjugate was found to be almost 60 times less effective in DHFR inhibition 
than the 7  isomer, which in turn was 5.5 times less effective than free MTX. 
This would imply that the NLDP-MSH-MTX conjugate, which is also thought to 
comprise of the a  and 7  isomers, would be expected to demonstrate weaker DHFR 
inhibition than MTX, in particular the a  form. If the two isomers were to be 
separated a difference in the IC50 values would almost undoubtably be observed, 
with the 7  form perhaps displaying a lower value than the one recorded with the
174
mixed isomer conjugate.
Other conjugates of MTX have been reported with varying degrees of DHFR 
inhibition, they all observed a similar inhibitory profile for the free drug i.e. 
inhibition over approximately 2 to 3 log cycles. Antibody conjugates of MTX 
synthesised by different methods (ECDI reaction or the active ester method) 
displayed similar activities compared to MTX [241]. Conjugates prepared by 
either method were about 2.5 and 3.8 fold weaker inhibitors of DHFR activity 
(at 40% inhibition) with incorporation levels of 5 and 12 moles of MTX per mole 
of antibody respectively. Kulkarni et al. [80] prepared a MTX conjugate with an 
antibody and its F(ab) 2  fragment. Both had identical inhibitory action against 
DHFR and had an IC50 value two fold greater than free MTX.
Various polymer-linked MTX derivatives displayed more diversity in DHFR in­
hibition [242] when bound to poly-l-lysine or carboxycellulose, IC50 values were 1 
and 2 log cycles greater than free MTX respectively. A co-polymer of divinylether- 
maleic anhydride had very similar activity to MTX. This latter observation was 
unexpected as the polymer was bound to the pteridine ring of MTX which is 
essential for binding. In this case hydrolysis of the conjugate and the release of 
MTX was suggested. Although not tested in the enzyme assay, stability of the 
NLDP-MSH-MTX was thought to be high.
Although inhibitory activity of the complete conjugate is almost desirable in 
some respects, certain non-specific uptake processes e.g. via the MTX membrane 
transport protein, will allow entry to non-targeted cells avoiding the lysosomal 
pathway hence the conjugate remains intact inside the cell cytoplasm. In this 
case a low inhibitory action would be advantageous with the cytotoxic ability only 
being released upon lysosomal contact. It is envisaged that the majority of the 
cellular uptake of NLDP-MSH-MTX will occur via receptor-mediated endocytosis 
terminating in exposure to the lysosomes (although a portion may be recycled 
to the cell exterior if still attached to the MSH receptor which may undergo this 
process). In this situation DHFR inhibition is expected to be the result of the
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lysosomal degradation products of the conjugate, which have been emulated in 
this present study with the use of rat liver lysosomes.
The results of two separate lysosomal incubations of the conjugate revealed sim­
ilar results with greatest inhibitory activity after 16 hours incubation. This may 
indicate the reaction has not yet reached optimal conditions and further periods 
of incubation are worth investigating. The inhibition by the 2 hour incubation 
in reaction B appeared rather strong and is possibly explained by inadequate 
mixing before sample removal or variability in the reaction, which at that stage 
was probably in its initial phase.
All time points displayed increased inhibitory action than the undegraded conju­
gate implying the formation or release of more toxic component(s). The activity of 
the mixtures after the longest incubation periods, 18.65±2.54% and 28.15±0.58% 
were similar, and in the former case greater, than the activity of the free drug at 
the equivalent concentration. This would suggest the possible release of free MTX 
from the conjugate or alternatively MTX derivatives with an increased affinity for 
the enzyme. Separation and individual testing of the degradation products would 
give a clearer indication of the mechanisms of the inhibitory action observed.
A similar investigation was performed with trypsin by Shen and Ryser [74] using 
a poly-l-lysine conjugate which had an IC5 0  value 400 fold greater than free MTX. 
After the conjugate was incubated with trypsin the IC50 value decreased to 20 
fold greater. Cell lysates incubated with the conjugate revealed a peak of low 
molecular weight material which eluted just before MTX after HPLC separation. 
This was believed to be a digestive product of the conjugate, presumably MTX- 
lysine or MTX-oligolysine. A corresponding experiment with NLDP-MSH-MTX 
may reveal similar findings.
The release of cytotoxic agents from macromolecules has been investigated over 
the last fifteen years, with various reports of efforts to increase the efficiency of 
drug release. Early studies discovered the necessity of employing spacer linkages
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between the carrier and the drug in question, in order to allow access to the 
lysosomal enzymes. Trouet et al. [228] conjugated daunorubicin to succinylated 
serum albumin directly or with up to four amino acid residues as spacer linkages. 
The direct linkage proved resistant to lysosomal attack whilst a single amino 
acid spacer resulted in very slow release. A slight improvement was attained 
with a di-peptide spacer when 8 % of the daunorubicin was released. However 
when the tri- and tetra-peptide spacers were used, 60 and 75% of the drug was 
cleaved respectively. Duncan et al. [243] investigated the degradation of peptide 
side chains of poly-N-(2-hydroxypropyl)-methacrylamide derivatives to release a 
terminal 4-nitroaniline residue. Spacers varied from 2-4 amino acids in length but 
out of 22 tested only 4 were digestable. This demonstrated that release was not 
purely based on physical distance from the linear backbone of the macromolecule 
but was also dependent on the structure of the linkage. This was later confirmed 
with further studies with the same polymer backbone [244, 104].
In order to rationalise this approach for linkage design the basis behind the degra­
dation had to be elucidated. Studies of the proteases involved [245, 246] revealed 
that the enzymes posessed a large active site performing two main functions; 
binding of the substrate, and catalysis of the reaction. The active site has been 
conveniently divided into subsites which interact with one amino acid residue of 
the substrate. Each site is aligned such that the -CO-NH- group to be hydrolysed 
always occupies the same position. Therefore the efficiency of cleavage will be 
dependent on the amino acids that occupy each enzyme subsite. This explains 
why 3/4 residues are required for spacer linkage but also why their identity is 
very important.
The precise requirements of all the lysosomal enzymes have yet to be elucidated, 
however, an example of conjugate design using the existing knowledge has been 
demonstrated [247]. It was discovered that the cleavage of the peptide spacers 
employed in the system was due to proteases, mainly cathepsins B, L and H. 
Cathepsin L was known to be a thiol dependent enzyme requiring hydrophobic 
residues in two of its subsites [248]. When phenylalanine or valine were introduced
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at certain positions in the spacer linkage, an increase in the amount of cleavage 
occurred.
Although the NLDP-MSH-MTX conjugate would be unlikely to require a spacer 
linkage as such (due to the relatively small size of the peptide and the linkage 
of MTX to the N-terminus), rearrangement of the last 3-4 terminal amino acid 
residues before the MTX component, or even the addition of further residues, may 
yield a conjugate with an increased efficiency of lysosomal MTX release. However 
this may alter the binding properties of the peptide to the MSH receptor even 
though the residues thought to be involved are at the C-terminus (see chapter 
6 ). It should also be noted that as well as the structure of the amino acids being 
important for interaction with the subsites on the enzymes, the terminal moiety 




Site-specific drug delivery requires the direction of the therapeutic agent in ques­
tion, to a specified site of action. An immense task when the physiological bar­
riers involved are considered, but through the use of macromolecular carriers 
and/or targeting groups, success has been achieved to a limited extent. These 
targeting moieties or homing devices are generally employed to maximise the in­
teraction of the drug-conjugate with the target cells and through this, minimise 
non-specific binding to other cells. However this would imply the sole expres­
sion of the targeted binding site on the selected cells which is rarely the case. 
In cancer chemotherapy the increased expression of the receptor/antigen site in 
tumour cells over the healthy cell population, is usually encountered. Therefore 
the plasma membrane interaction of a conjugate must be carefully assessed in 
vitro in order to partially predict its chances of successful site-specific delivery in 
vivo.
The conjugate employed in this study, although not available until the later 
stages of the work, consisted of two components, both capable of binding to 
cell membranes. The antifolate MTX enters cells through the reduced folate 
carrier, present on almost all human cells due to the dependence on extracellular 
reduced folate sources. The drug not suprisingly exhibits a very low specificty
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against tumor cells due to an increased folate requirement. However the peptide 
analogue of MSH, NLDP-MSH, interacts with high affinity to specific membrane 
receptors and will thus have a more defined mode of cellular binding.
Before studying the fate of NLDP-MSH-MTX with the selected B16 murine 
melanoma cell line, the individual components of the conjugate were examined 
with respect to membrane binding and subsequent fate. Particulary in view of 
the proposed mode of cellular uptake for MTX in the conjugate form, which was 
expected to be different to the uptake of free drug. Would this new route of drug 
delivery be as efficient as the former, and if not would therapeutic intracellular 
levels be achieved ?
MTX binding and subsequent uptake in tumour cells is predominantly through 
the reduced-folate carrier, often described as a ‘high affinity, low capacity’ system, 
with respect to MTX and reduced folates [120]. However this nomenclature is 
misleading as the affinities usually encountered for MTX and reduced folates 
are in the micro-Molar range. Indeed when 3 H-MTX binding at 4°C with B16 
cells was assayed, a value for Kd in the order of 0.21/xM was recorded, which 
in fact is a relatively low affinity for a ligand/receptor complex. Although the 
presence of a second membrane folate binding protein has been reported [124], 
which does display an affinity for folic acid in the nM range, it has a low affinity 
for MTX which appears to undergo intracellular uptake predominantly through 
the reduced-folate carrier [126].
Uptake of MTX initially proved difficult to measure until a reliable acid-wash 
buffer was established. Although the amount of cell associated 3 H- activity was 
essentially identical after 24 hours at 4°C and 37°C, the majority of the latter 
was acid-resistant or internalised within the cells (presumably retained associated 
with MTX). The validity of in vitro cell culture models in comparision to the 
in vivo state has to be questioned since the cells axe grown in an abundance 
of extracellular folate far above serum levels in the body; thereby perpetually 
possessing high intracellular levels of folate. The inability of B16 cells to grow in
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low folate media without the use of a gradual decline in the extracellular folate 
concentration, did not permit binding or uptake experiments upon cells under 
these conditions.
Although the MTX moiety of the conjugate may have the potential for a wide 
degree of specific binding via the reduced-folate carrier (c.270,000 binding sites 
per B16 cell as an estimate), it has a low binding affinity. Indeed it was this low 
affinity that was responsible for the problems encountered in the work involving 
the radio-labelled ligand. Notably the danger of a degree of dissociation during 
the washing procedure, and the relatively high levels of non-specific binding en­
countered. Binding of the NLDP-MSH-MTX conjugate to the MTX transport 
proteins was weak and would be minimal in comparision to its binding to the 
MSH receptor.
Although 125I-NLDP-MSH did display specific binding of a higher affinity, Ka
0.37-0.87nM, there was a much lower number of binding sites (4000-5000 per 
B16 cell). Since uptake of the conjugate is unlikely via the reduced-folate carrier, 
internalisation after NLDP-MSH binding would be essential for action. Although 
MSH elicits its biological action through binding to the MSH membrane receptor, 
it is unresolved whether or not this process also involves internalisation of the 
ligand/receptor complex. Experiments at 37°C revealed the appearance of acid- 
resistant 125I activity with B16 cells, but it was impossible to ascertain if this 
was still associated with the peptide, without analysis of the cell contents via 
chromatographic techniques. Further experiments revealed the likelihood of this 
internalisation process occurring after binding to the receptor. When permitted 
to bind at 4°C, the amount of the surface-bound tracer decreased upon transfer 
to a 37°C enviroment, with about 40% appearing internalised. However these 
experiments were not performed at a saturating concentration of the ligand. This 
resulted in difficulties in the detection of acid-resistant 125I activity above non­
specific levels. Further experiments should be carried out at higher receptor 
occupancy with a larger population of cells, to reduce non-specific effects.
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Of course at 37°C many cellular processes are occurring, including pinocytosis. 
The question arises as to whether the appearance of acid-resistant activity can 
be attributed to the constitutive process of membrane internalisation reflected 
by pinocytosis ? The rate of fluid-phase endocytosis, or more strictly the lyso­
somal accumulation of extracellular fluid, for B16 cells at 37°C was established 
as 0.038/d/hr/106cells. If one makes the assumption that endocytic vesicles are
0.2/zm in diameter, and the average diameter of a B16 cell is 15/xm (considering 
the cell for theoretical purposes as a smooth spherical body), then 150 vesicles 
are formed per minute per cell. This represents a cell-surface membrane inter­
nalisation rate of 2.7% per minute, i.e. the entire cell membrane will be inter­
nalised after 37 minutes. So can the appearance of 40% of the original bound 
125I-NLDP-MSH activity within the cells after 10 minutes be attributed to con­
stitutive membrane turnover ? From these predictions, and assuming an even 
receptor distribution on the cell surface, 27% of the surface-bound peptide will 
be internalised after 10 minutes. This theoretical value is not too disimilar to 
that recorded experimentally.
A similar calculation can be considered when examining the data from the con­
tinual exposure of B16 cells at 37°C in the presence of O.lnM 125I-NLDP-MSH. 
After 60 minutes the acid-resistant fraction had increased to 0.3fmoles/106 cells 
which is equivalent to 180 molecules per cell. The determined amount delivered 
by pinocytosis to the lysosomes after 1 hour would be 2.28 molecules per cell. 
This does not include molecules present in the endosomal compartment, which 
was estimated to have a volume of approximately 109nl/cell. This translates 
to 6.6 molecules per cell. Therefore fluid-phase uptake could account for about 
9 molecules of 125I-NLDP-MSH per cell in 1 hour at 37°C. This is obviously 
exceeded by the value of 180 molecules/cell as expected due to the membrane 
interaction of the peptide. However can constitutive membrane internalisation 
account for the observed amount of internalisation ? An extracellular concen­
tration of O.lnM 125I-NLDP-MSH was approximately one tenth of the receptor 
saturating concetration, the latter determined as c.4500 sites/cell, i.e. approx­
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imately 450 binding sites would be occuppied by the tracer. It was calculated 
earlier that the entire cell surface area of the cell membrane would be internalised 
after 37 minutes, however a value of only 180 molecules per cell was attained, 
less than half the expected amount. There are a number of possible reasons for 
this observation:
1. Binding to 450 sites was not achieved, or a lower amount of receptor ex­
pression than previously recorded.
2. Cells exhibited a decreased rate of membrane internalisation.
3. The assumption of the cell as a spherical body has resulted in an unaccept- 
ably low value for the cell surface area.
4. After 60 minutes some radio-label has been internalised and subsequently 
exited the cell.
It should also be noted that the surface-bound activity achieved a maximum at 
30 minutes before declining, i.e. there was a decrease in the number of mem­
brane binding sites. A plausible hypothesis to these observations and theoretical 
calculations would be a constant recycling of the receptor due to membrane in­
ternalisation and subsequent reappearance at the cell surface (e.g. as is the case 
for LDL and transferrin receptors [250]). After the binding of 125I-NLDP-MSH, 
the fate of the receptor could be a return to the cell surface in a state unable 
to bind further ligand, or the receptor could be processed intracellulary. Either 
fate will result in a decrease in the number of available binding sites on the cell 
surface, which would account for the decrease in bound labelled peptide. Cycling 
from plasma membrane to early endosome and back is likely to be rapid with 
some delivery to the lysosome which accounts for the observed intracellular 125I 
activity.
The fate of the ligand is very difficult to predict from the current data as we only 
have a measure of the 125I activity. Once internalised the ligand may dissociate
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from the receptor in the endosomes and be transferred further along the vesic­
ular pathway to the lysosomes. Alternatively it may return to the cell exterior 
either in solution or bound to the receptor with subsequent dissociation. If the 
ligand/receptor complex was recycled intact back to the cell surface, dissociation 
would be expected to occur slowly due to the high affinity of the peptide. Dis­
sociation would be too slow to explain the decrease in specifically bound ligand 
observed.
The low activity inside the cell (180 molecules/cell) could be an underestimate as 
ligand may have been returned to the extracellular medium, or the iodine label 
may also be returned either passively or actively after separation from the peptide 
(possibly after exposure to lysosomal enzymes). The latter is certainly possible, 
fluid-phase markers appear in the lysosomal compartment from 10 minutes after 
exposure to a cellular enviroment [179].
To summarise; the measure of acid-resistant activity at 37°C was probably an 
underestimate of total internalised peptide due to the subsequent loss of iodine- 
label back to the extracellular medium, either as 125I-NLDP-MSH or a derivative 
of the peptide. It can be postulated that the internalisation of the ligand/receptor 
complex is unecessary for the biological action of NLDP-MSH, and is only a mode 
of desensitisation or termination of the stimulus. Thus the receptor is constantly 
being recycled until ligand is bound which then alters the fate of the receptor, 
probably being processed further along the vesicular endocytic pathway.
Some membrane receptors are known to recycle, e.g. LDL and transferrin are 
thought to be internalised 4 and 10 times an hour respectively, whilst others, 
e.g. EGF, remain for longer periods at the cell membrane surface [250]. Sat­
urating levels of ligand binding result in the majority of EGF receptors being 
internalised with a half-time of 2.5 minutes [251]. The existence of relatively long 
term membrane proteins suggests that not all the regions of the cell membrane 
are recycled. Thus the MSH receptor may also escape recycling. The presence 
of the receptor at the cell surface could be further investigated by two methods.
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The first would involve initial exposure of B16 cells to a saturating concentration 
of unlabelled peptide at 4°C. Unbound ligand would be subsequently removed, 
the cells re-incubated at 37°C, and challenged after various time periods to assay 
the number of membrane binding sites. Due to the high binding affinity of the 
peptide, ligand dissociation would be minimal, thus the radio-ligand will bind 
only to new or unoccupied receptors arriving at the cell surface.
Secondly, exposing the cell to a salt of a weak base, such as ammonium chloride, 
and then challenging the cells with radio-ligand after various time periods, will 
indicate if the receptors are involved with membrane turnover. Weak bases can 
alter vesicle pH and fusion events leading to the entrappment within the cell 
of surface receptors, e.g. the presence of monensin prevented the recycling of 
LDL receptors [252]. A loss of membrane binding sites in the absence of ligand 
indicated the internalisation of empty receptors can occur.
The receptor recycling proposed for the NLDP-MSH binding site presents many 
questions with respect to site-specific drug delivery:
1. Are there sufficient cell surface binding sites to account for an increased 
accumualtion of a conjugate within tumour cells ?
2. Once internalised is the peptide recycled to the cell exterior or processed 
within the cell ?
3. What is the time period before full receptor expression is reinstated at the 
cell surface after exposure to the ligand ?
4. Will NLDP-MSH-MTX follow an identical pathway to the parent peptide, 
and if so will sufficient drug levels be attained within the cell for a thera­
peutic effect ?
It is important to assess the subsequent fate of the ligand/receptor complex after 
internalisation. This is probably optimally achieved with covalent labelling of
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the receptor in conjunction with subcellular fractionation and electronmicroscope 
studies. Also the use of ionophores (e.g. monensin) or weak bases which are able 
to increase the intraluminal pH of endosomes and lysosomes, have profound effects 
on the fate of ligand/receptor complexes.
From the results presented here it can be predicted that interaction between 
the NLDP-MSH-MTX conjugate and the B16 cell plasma membrane was pre­
dominantly via binding to the high affinity MSH receptor. The MTX moiety was 
expected to display little specific binding which was duly demonstrated. The con­
jugate, with at least a ten-fold lower binding affinity than free MTX, displayed 
no specific displacement of the latter at 4°C. However in a similar binding inhi­
bition experiment with 125I-NLDP-MSH the conjugate exhibited only a ten-fold 
lower affinity for the MSH receptor. This confirmed the conjugate was binding 
predominantly via the NLDP-MSH component, but would it be internalised ?
When InM of the successfully iodinated conjugate was incubated at 37°C with 
B16 cells, a similar profile of surface binding was demonstrated, although in­
ternalised 125I activity was masked by non-specific binding. This indicated the 
conjugate may be following the same route as the labelled peptide. When the 
conjugate was initially permitted to bind at 4°C before further incubation at 37°C 
(after washing), similar results to 125I-NLDP-MSH were again obtained. The de­
gree of internalisation was difficult to assess with certainty due to the levels of 
non-specific binding. Subsequent assay experiments must employ an increased 
cell number to well size ratio, or a similar cell suspension technique to that used 
for the measurement of fluid-associated 125I-PVP uptake.
As the conjugate retained a relatively high affinity for the binding sites on B16 
cells, uptake was assummed to occur by an identical mechanism to the parent 
peptide. However would adsorptive endocytosis with maximum receptor occu­
pation be sufficient to achieve therapeutic levels of drug within the cell ? This 
is very much dependant on the toxicity of the drug in question, MTX, which is 
estimated to require c.l million molecules to cause cell death, is unlikely to attain
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such levels in this system. Conversely, toxins such as ricin A-chain, which require 
only one or two molecules to be internalised, will achieve sufficient amounts. Tox­
ins are likely though to prove too potent for clinical use, with only small levels 
required for non-specific cell death, whereas MTX is at the opposite end of the 
scale. The clinical situation requires increased drug levels in tumour cells over 
the normal healthy cells in the body. For malignant melanoma, which is the 
focus of this study, this necessitates a sufficient level of receptor expression on 
the tumour cells with low levels of uptake by non-specific processess in other cell 
types. Non-malignant melanocytes which will also express MSH receptors are 
likely to accumulate some of the conjugate, however this will probably result in 
non-fatal de-pigmentation.
From binding studies on human melanoma cell lines, the number of binding sites 
is generally lower than murine melanomas, e.g. from undetectable to c.2000 
sites/cell [113]. If the rate of internalisation is slow (albeit by receptor-mediated 
or adsorptive endocytosis) then improvements to the drug conjugate have to be 
made, e.g. a more potent cytotoxic component and/or analogue, or an increased 
drug incorporation ratio (although this is likely to decrease the binding affinity 
of the peptide). The rate of receptor recycling and subsequent re-expression at 
the cell surface also need to be assessed.
The amount of non-specific cellular uptake by non-melanotic cells must be estab­
lished. The assay system in this study, although not employed with a non-target 
cell line, would prove unsuitable to measure the predicted uptake, due to relative 
high background levels of 125I activity. A similar experimental system to the as­
say of fluid-phase uptake would be required. The likely route for this non-specific 
internalisation would be either pinocytosis or adsorptive endocytosis, the latter 
due to any membrane binding of the conjugate, e.g. through the MTX moiety or 
the hydrophobic nature of the peptide.
As the work in chapter 3 demonstrated, the rate and profile of fluid-phase uptake 
is very dependent on the tissue type and origin. Human SVK-14 keratinocytes
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appeared to accumulate little or no extracellular fluid in the lysosomes and would 
therefore be expected to display minimal toxicity due to the conjugate. Even 
the pinocytic rate of B16 cells would account for little toxicity, if 106 cells were 
incubated at 37°C in 1ml of a InM solution of a non-polar compound, only 
23 molecules would be internalised per cell per hour. Although this is a poor 
reflection of an in vivo enviroment, the number of molecules internalised per cell 
is very low. Thus fluid-phase endocytosis would account for a very small amount 
of the toxic effects of a macromolecular-drug conjugate. However the rate of 
adsorptive endocytosis can be a hundred to a thousand fold greater [44], again 
depending on the degree of membrane binding and the rate of cell membrane 
turnover.
It should be noted that due to the structural similarity between MSH and related 
peptides, e.g. ACTH, a drug conjugate may cross react with other membrane 
binding sites of these peptides, leading to a degree of non-selectivity. Conversely 
these other peptides, in addition to the natural MSH produced by the host, may 
block some of the available binding sites on the tumour cells. This is one of 
the disadvantages of hormone-targeted conjugates, although circulating hormone 
levels are generally of a very low concentration e.g. 10_12-10-loM, and their 
plasma levels are not usually sustained for long periods.
The internalisation of a drug-conjugate does not necessarily result in toxic effects 
on the cell. Generally the drug(s) must first be released from the macromolecu- 
lar carrier in an active form. The cellular uptake of most conjugates will occur 
through endocytosis [253], resulting in a disposition towards the lysosomal com­
partment of the cell. The degradative processes then experienced being respon­
sible for some release of active drug. Therefore once inside the lysosomes there 
are two factors determining the appearance of active drug in the cell cytosol, the 
efficiency of lysosomal degradation, and the diffusion of these products across the 
lysosomal membrane. The former of these was investigated in this present study, 
the activity of the active drug and drug-derivatives assayed for their inhibitory 
action on DHFR.
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The intact conjugate displayed a forty fold lower affinity for DHFR compared 
to the free drug. The levels of intact conjugate expected in the cell cytosol are 
minimal, and in conjunction with a lower affinity, little DHFR inhibition would 
be envisaged. However when the conjugate was incubated with a rat lysoso­
mal extract, an increase in DHFR inhibition was demonstrated (which increased 
with the length of incubation in the presence of the extract). Optimal reaction 
conditions had not yet been achieved by 16 hours when the inhibitory action 
of the degradation products was equivalent to that of free MTX at an identi­
cal concentration. This suggested the release of free MTX, or MTX derivatives 
with a similar affinity for DHFR. Further work would involve the identification 
of these degradation products, and the lysosomal incubation of non-conjugated 
NLDP-MSH and MTX.
Although the formation of active degradation products was demonstrated, their 
ability or efficiency to cross the lysosomal membrane remains unknown. The time 
period of lysosomal incubation was a good representation of the in vivo situation 
where lysosomes are generally regarded as the terminal vesicular department. 
Most molecules are resident indefinitely or enzymatically degraded and lost to 
the cell cytosol.
It must be remembered that the NLDP-MSH-MTX consisted of four compounds 
of equal concentrations, as yet unseperated. Of course a homogenous yield is 
essential for further work, particulary in the assessment of lysosomal degradation 
and cytotoxic studies. One of the four compounds may display more efficient 
MTX release or active MTX-derivatives. An identical situation applies to other 
cellular processes, e.g. membrane binding.
To briefly summarise, some of the properties established in this work, for the 
interaction of the NLDP-MSH-MTX conjugate and NLDP-MSH with B16 cells; 
are listed below.
1. The MSH analogue NLDP-MSH has a high affinity (<1.0nM) for specific
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membrane sites on the cell surface of B16 cells.
2. There are c.4500 binding sites/cell.
3. The peptide was internalised at 37°C through the binding site.
4. From the measurement of fluid-associated 125I-PVP uptake, theoretical cal­
culations predicted the internalisation of 125I-NLDP-MSH could conceivably 
occur through adsorptive endocytosis.
5. NLDP-MSH-MTX was successfully iodinated for experimental use.
6. NLDP-MSH-MTX was internalised via an identical route to the free pep­
tide.
7. NLDP-MSH-MTX demonstrated little or no specific membrane binding 
through the MTX moiety.
8. NLDP-MSH-MTX had a forty fold lower affinity for DHFR than MTX, and 
inhibited the enzyme through an identical mechanism to the free drug.
9. The lysosomal degradation products of NLDP-MSH-MTX had an equiva­
lent inhibitory activity on DHFR as free MTX.
In addition to providing information for macromolecular-drug targeting via the 
MSH receptor, this study has proposed a pathway for the natural interaction 
and fate of the native hormone and receptor membrane stability. Further work 
in this direction would necessitate the employment of more suitable probes and 
an improved definition of the intracellular location of the ligand and receptor. 
The process of ligand/receptor uncoupling remains a relatively unknown function 
with only a change in the pH enviroment as a plausible mechanism. It would 
be interesting to study in detail the stability of bound NLDP-MSH at about 
pH 6.0, a value experienced in the endosomes where uncoupling is thought to 
occur. However from the present work the complex would be expected to be 
quite stable, as an acid-wash of pH 2.5 was required to remove all extracellular
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bound peptide. Therefore it is likely that uncoupling of receptors and ligand is 
quite slow.
NLDP-MSH-MTX certainly has potential as an experimental model system, it 
is internalised within the cell and active products are formed from lysosomal 
enzyme degradation. In practice MTX should presumably be replaced by a more 
potent toxic agent, but the MTX conjugate would prove a useful tool for in vivo 
studies. Even if a conjugate was successful in vitro, it may still prove ineffective 
due to the one characteristic fundamental to site-specific cancer chemotherapy;- 
an identical biodistribution to the metastases of the tumour which must involve 
extravasation from the vasculature. The fatality of this disease is primarily due to 
the widespread growth of secondary tumours which makes malignant melanoma 
a very siutable in vivo model system, with its high metatastatic potential.
Hormones may prove useful tools for drug targeting, due to their high affinity for 
specific membrane receptors. There are few reports of drug conjugates utilising 
the MSH system. A daunomycin-/?-MSH conjuagte has been synthesised and 
demonstrated to posess a more toxic effect than free drug in melanoma cells 
[13, 254]. However in vivo it displayed a distinct lack of success, possibly due 
to a rapid clearance, or endogenous ligands competing for a finite number of cell 
surface receptors.
Undoubtedly the study of drug-targeting via MSH (or other hormones) involves 
many different aspects with apparently insurmountable problems, e.g. the es­
tablishment of a suitable model for the study of transcytosis in the endothelial 
vasculature, or a successful biodistribution of the conjugate in vivo. However I 
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Appendix A




Fluid Uptake (jil/106 cells)
A B C D
1 0 0 . 1 0 2 0.132 0.069 0.151
15 0.108 0.135 0.073 0.150
30 0.123 0.154 0.078 0.167
45 0.130 0.163 0.099 0.165
60 0.141 0.183 0.103 0.179
75 0.148 0.180 0 . 1 1 2 0.184
90 0.154 0.197 0.125 0.180
105 0.188 0 . 2 0 1 0.128 0.170
Table A.l: Fluid-associated uptake of 125I-PVP by B16 cells in suspension at 





(/d /1 0 6 cells)
A B C
1 0 0.055 0.124 0.103
15 0.061 0.136 0.108
30 0.073 0.099 0.128
45 0.077 0.107 0.143
60 0.082 0 . 1 1 2 0.142
75 0.079 0.127 0.148
90 0.092 0.128 0.151
105 0.093 0.160 0.153
150 0.086 0.138 0.155
Table A.2: Fluid-associated uptake of 12 5I-PVP by HMB-2 cells in suspension at 




(/d /1 0 6 cells)
A B









Table A.3: Fluid-associated uptake of 125I-PVP by SVK-14 cells in suspension at 
37°C for two individual experiments (A and B).
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1 . 0 0
2 . 0 0
4.00
50.41 ±  3.46 
68.55 ±  4.82 
87.69 ±  5.03 
81.75 ± 6 . 8 8  
58.26 ±  4.97
9.18 ±  1.02 
15.50 ±  2.01 
27.41 ±  2.54 
24.53 ±  1.89 
20.21 ±  1.98
41.23 ±3.61
53.05 ±  5.22 
60.28 ±  5.64 
57.22 ±  7.14
38.05 ±  5.35
Table B.l: Binding of 25nM 3 H-MTX with B16 cells at 4°C with time in a Hepes 
based buffer, pH 7.4 (n= 6 ).
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1 . 0 3.59 ±  0.32 2.03 ±0.16 1.56 ±0.36
2 . 0 5.41 ±  0.32 2.69 ±  0.14 2.72 ±  0.35
4.0 16.20 ±  0.74 3.35 ±  0.21 12.85 ±  0.77
8 . 0 20.48 ±  0.72 5.91 ±  0.33 14.57 ±  0.79
1 2 . 0 24.48 ±  0.99 7.05 ±  0.42 21.43 ±1.08
15.0 37.78 ±1.49 8.78 ±1.17 29.00 ±  1.90
2 0 . 0 54.69 ±  2.86 11.52 ±0.52 43.17 ±  2.91
25.0 59.86 ±  2.79 12.14 ±  0.27 47.72 ±  2.80
30.0 71.42 ±  1.21 16.84 ±  0.45 54.58 ±  1.29
50.0 124.25 ±  5.35 32.09 ±  2.00 92.16 ±  5.71
60.0 157.19 ±5.59 46.63 ±  10.13 110.56 ±11.57
70.0 177.95 ±  5.45 66.45 ±  10.34 111.50 ±11.69
150.0 295.23 ±  9.30 91.94 ±4.07 203.29 ±  10.15
Table B.2: I. Adsorption isotherm of increasing concentrations of 3 H-MTX incu­











1 . 0 6.15 ±0.26 3.02 ±  0.18 3.13 ±0.32
2 . 0 10.56 ±  0.57 4.22 ±  0.35 6.34 ±  0.67
4.0 16.07 ±  1.17 5.55 ±  0.46 10.52 ±  1.26
8 . 0 26.17 ±1.31 6.58 ±  0.27 19.59 ±1.36
1 2 . 0 42.35 ±  1.34 9.20 ±  0.47 33.15 ±  1.42
15.0 58.73 ±  3.40 11.86 ±0.43 46.87 ±  3.43
2 0 . 0 62.73 ±1.19 18.01 ±  1.44 44.72 ±  1.87
25.0 70.08 ±1.69 19.20 ±  1.29 50.88 ±2.13
30.0 75.11 ±  1.97 20.17 ±2.25 54.94 ±  2.99
50.0 129.33 ±  3.87 45.17 ±  3.28 84.16 ±5.07
60.0 117.19 ±3.37 45.19 ±  2.33 72.00 ±  4.10
70.0 197.97 ±  8.81 52.32 ±  2.59 145.65 ±9.18
Table B.3: II. Adsorption isotherm of increasing concentrations of 3 H-MTX in­











1 . 0 5.59 ±  0.66 3.31 ±  0.34 2.28 ±  0.74
2 . 0 13.93 ±1.44 5.95 ±  1.00 7.98 ±  1.75
4.0 14.60 ±  0.44 5.17 ±0.19 9.43 ±  0.48
8 . 0 29.60 ±  1.61 8.62 ±  0.84 20.98 ±  1.82
1 2 . 0 34.79 ±1.31 11.04 ±1.04 23.75 ±1.67
15.0 37.10 ±  0.92 9.29 ±  0.49 27.81 ±  1.04
2 0 . 0 44.78 ±1.99 9.95 ±  0.22 34.83 ±  2.00
25.0 48.64 ±1.45 12.5 ±1.15 36.14 ±  1.85
30.0 55.53 ±  2.00 10.76 ±  0.94 42.77 ±  2.21
50.0 113.48 ±3.76 34.66 ±8.10 78.82 ±  8.93
60.0 143.18 ±  14.50 14.50 ±  1.85 118.32 ±14.62
70.0 158.44 ±  9.73 27.71 ±  3.79 130.73 ±  10.44
Table B.4: III. Adsorption isotherm of increasing concentrations of 3 H-MTX 
incubated with B16 cells at 4°C for 30 minutes (pH 7.4), n= 6 .
3 H-MTX
(nM)







150 176.30 ±  9.36 56.83 ±  3.00 119.47 ±9.83
250 299.99 ±10.19 113.02 ±6.05 186.97 ±11.85
400 394.34 ±  22.80 174.06 ±  14.94 220.28 ±  27.26
600 581.27 ±23.95 269.77 ±  10.95 311.50 ±26.33
Table B.5: I. Adsorption isotherm of high concentrations of 3 H-MTX incubated 
with B16 cells at 4°C for 30 minutes (pH 7.4), n= 6 .
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1 0 0 233.25 ±  14.21 72.74 ±  12.79 160.51 ±  19.12
2 0 0 275.36 ±  10.41 94.82 ±  7.38 180.54 ±  12.76
400 530.12 ±23.88 226.95 ±  53.44 303.17 ±  58.53
1 0 0 0 1018.04 ±  24.05 640.59 ±  144.62 377.45 ±  144.61
Table B.6 : II. Adsorption isotherm of high concentrations of 3 H-MTX incubated 
with B16 cells at 4°C for 30 minutes (pH 7.4), n= 6 .
TIME Cell-Associated 3 H-MTX fmoles/1 0 6cells
(minutes) Total Non-Specific Specific
Binding Binding Binding
15 57.56 ±  4.62 10.56 ±  0.59 47.00 ±  4.66
30 60.87 ±  1.53 12.00 ±  3.00 47.13 ±3.37
45 84.18 ±11.53 12.92 ±  3.16 71.26 ±  11.96
105 68.53 ±  13.30 11.58 ±1.39 56.95 ±  13.37
145 46.19 ±3.87 15.01 ±  5.34 31.18 ±6.60











15 115.72 ±8.71 40.18 ±11.72 75.54 ±  14.60
30 150.63 ±  5.01 22.71 ±  4.01 127.92 ±  6.42
45 184.38 ±  12.49 58.90 ±  23.60 125.48 ±  26.70
105 157.54 ±  18.21 23.72 ±  3.55 133.82 ±  18.55
Table B.8 : Incubation of lOOnM 3 H-MTX with B16 cells at 37°C with time, n = 6 .
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TIME Cell-Associated 3 H-MTX fmoles/106cells
(hours) Total Non-Specific Acid-Washed
Binding Binding Cells
4°C
1 75.13 ±8.16 13.03 ±  2.61 19.67 ±  1.98
2 88.28 ±  9.92 30.19 ±  5.50 25.63 ±  3.41
37°C
1 96.11 ±6.74 65.04 ±  6.41 17.07 ±1.78
2 57.50 ±  9.42 45.81 ±  8.96 16.28 ±  1.40
Table B.9: Incubation of lOOnM 3 H-MTX with B16 cells at 4°C and 37°C for 1 






2.5 541.4 ±  21.0
8 . 0 570.8 ±  22.8
25.0 587.5 ±  43.4 465.5 ±45.9
80.0 548.2 ±  21.4
250.0 315.5 ±  68.9
Table B.10: I. 3H activity after incubation of 25nM 3 H-MTX with B16 cells 
at 4°C for 30 minutes in the presence of increasing concentrations of the two 
conjugate forms of NLDP-MSH-MTX, G0133/1 and G0133/3 (n= 6 ). The total 
and non-specific binding (n=12) in the absence of the conjugate were 625.1 ±20.8 





2.5 411.3 ±25.2 416.9 ±  34.6
8 . 0 338.4 ±  20.6 356.9 ±  40.0
25.0 272.6 ±  8.4 261.4 ±  13.3
80.0 313.9 ±  19.8 292.0 ±  13.8
250.0 327.7 ±  34.4 367.9 ±  39.4
Table B .ll: II. 3H activity after incubation of 25nM 3 H-MTX with B16 cells 
at 4°G for 30 minutes in the presence of increasing concentrations of. the two 
conjugate forms of NLDP-MSH-MTX, G0133/1 and G0133/3 (n= 6 ). The total 
and non-specific binding (n=12) in the absence of the conjugate were 491.1 ±  17.9 






2.5 354.9 ±  40.0 323.1 ±  10.7
8 . 0 303.2 ±  49.4 370.0 ±45.1
25.0 240.1 ±  11.3 318.4 ±  20.1
80.0 390.5 ±  13.3 283.7 ±  10.5
250.0 226.3 ±  31.8 260.8 ±  20.7
Table B.12: III. 3H activity after incubation of 25nM 3 H-MTX with B16 cells 
at 4°C for 30 minutes in the presence of increasing concentrations of the two 
conjugate forms of NLDP-MSH-MTX, (n= 6 ). The total and non-specific bind­






2.5 69.89 ±  26.70 59.82 ±  26.95
8 . 0 60.78 ±  25.55 58.68 ±  27.94
25.0 50.33 ±  35.26 48.88 ±  20.50
80.0 69.08 ±  28.35 40.88 ±  16.93
250.0 41.66 ±40.31 44.65 ±  31.29
Table B.13: Inhibition of 25nM 3 H-MTX binding with B16 cells at 4°C for 30 min­
utes in the presence of increasing concentrations of the two conjugate forms of 
NLDP-MSH-MTX, G0133/1 and G0133/3 (n>12). Values are expressed as a % 
of the control binding (specific binding of 3 H-MTX in the absence of conjugate) 
from single wells in individual experiments.
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Appendix C
Experimental D ata for 
Chapter 5
TIME 12 5I-NLDP-MSH Bound (fmoles/1 0 6 cells).
(hours) Total Non-Specific Specific
Binding Binding Binding
2 1.43 ±0.03 0.35 ±  0.04 1.08 ±0.05
4 1.81 ±0.09 0.47 ±  0.04 1.34 ±0.10
8 2.51 ±  0.07 0.92 ±  0.05 1.59 ±0.09
2 2 2.74 ±0.12 1.12 ±0.04 1.62 ±0.13
Table C.l: Binding of 0.1 nM 125I-NLDP-MSH with B16 cells at 4°C with time 











4 7.30 ±0.31 2.00 ±  0.19 5.30 ±  0.36
8 9.39 ±0.11 3.25 ±0.15 6.14 ±0.19
2 2 10.63 ±  0.44 3.66 ±  0.24 6.97 ±  0.50
Table C.2 : Binding of 0.4nM 1 2 5I-NLDP-MSH with B16 cells at 4°C with time 
in a Hepes based buffer containing 0.2% BSA, pH 7.4, n= 6
TIME 1 2 5I-NLDP-MSH Bound (fmoles/106 cells).
(hours) Total Non-Specific Specific
Binding Binding Binding
2 0.54 ±  0.05 0.15 ±0.01 0.40 ±  0.05
4 0.84 ±  0.03 0.16 ±  0 . 0 2 0.68 ±  0.04
8 1.14 ±0.06 0 . 2 0  ±  0 . 0 1 0.94 ±  0.06
2 2 1.81 ± 0 . 2 0 0.30 ±  0.01 1.51 ±0.02
Table C.3: Binding of O.lnM 12 5I-NLDP-MSH with B16 cells at 4°C with time 











0 . 0 1 0 0.291 ±  0.042 0.014 ±  0.003 0.195 ±  0.042
0 . 0 2 0 0.182 ±0.096 0.015 ±  0.003 0.167 ±  0.096
0.050 0.720 ±  0.127 0.039 ±  0.004 0.682 ±  0.127
0.075 0.755 ±  0.337 0.076 ±  0.018 0.680 ±  0.338
0 . 1 0 0 1.369 ±0.353 0.063 ±  0.010 1.306 ±0.353
0.150 1.491 ±0.247 0.127 ±0.002 1.364 ±  0.248
0 . 2 0 0 2.232 ±  0.673 0.249 ±  0.035 1.983 ±0.674
0.300 4.300 ±  1.382 0.284 ±0.104 4.016 ±  1.386
0.600 4.486 ±  1.008 0.618 ±  0.071 3.868 ±  1.010
0.800 5.781 ±  1.887 0.693 ±0.162 5.089 ±  1.894
1.000 4.222 ±  0.319 1.299 ±0.231 2.933 ±  0.394
Table C.4: I. Adsorption binding isotherm of increasing concentrations of 125I- 











0 . 0 1 0.056 ±  0.009 0.019 ±  0.005 0.037 ±  0.010
0 . 0 2 0.136 ±0.017 0.023 ±  0.004 0.113 ±0.018
0.05 0.270 ±  0.044 0.040 ±  0.014 0.229 ±  0.046
0.07 1.005 ±0.053 0.110 ±0.036 0.896 ±  0.064
0 . 1 0 1.528 ±0.102 0.186 ±  0.026 1.342 ±  0.105
0.15 1.316 ±0.109 0.220 ±  0.025 1.097 ±0.111
0 . 2 0 2.795 ±0.168 0.340 ±0.123 2.455 ±  0.208
0.30 3.259 ±  0.418 0.395 ±  0.094 2.864 ±  0.429
0.60 4.893 ±  0.850 0.958 ±  0.143 3.936 ±  0.862
0.80 6.400 ±  0.526 2.486 ±  0.779 3.910 ±  0.939
1 . 0 0 7.535 ±  0.517 2.977 ±  0.518 4.559 ±  0.732
Table C.5: II. Adsorption binding isotherm of increasing concentrations of 1 25I- 
NLDP-MSH incubated with B16 cells at 4°C for 8  hours at pH 7.4, n= 6 .
Time Cell Associated 1 2 5I-NLDP-MSH (fmoles/106 cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
1 0 0.579 ±0.016 0.107 ±0.013 0.081 ±  0.072 0.498 ±  0.074
2 0 0.805 ±  0.034 0.139 ±0.006 0.076 ±  0.018 0.729 ±  0.038
30 0.947 ±0.137 0.220 ±  0.025 0.139 ±  0.026 0.807 ±  0.139
40 0.866 ±  0.098 0.277 ±  0.030 0.141 ±0.023 0.725 ±  0.101
60 0.724 ±0.162 0.310 ±0.126 0.024 ±  0.003 0.700 ±0.162
1 2 0 0.230 ±  0.093 0.166 ±0.039 0.024 ±  0.006 0.206 ±  0.094
Table C.6 : 125I activity after incubation of O.lnM 1 25I-NLDP-MSH with B16 cells 
at 37°C with time, n=4.
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Time Cell Associated 12 5I-NLDP-MSH (fmoles/1 0 6 cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
0 6.812 ±  0.484 1.059 ±0.243 1.582 ±0.285 5.230 ±  0.562
5 6.461 ±  0.353 1.345 ±0.173 0.945 ±  0.138 5.516 ±  0.379
1 0 4.534 ±  0.507 1.317 ±0.108 0.583 ±  0.432 3.952 ±  0.667
2-0 4.440 ±  0.658 1.545 ±0.174 1.200 ±  0.384 3.240 ±  0.762
40 1.303 ±0.523 0.632 ±  0.203 0.402 ±  0.166 0.901 ±  0.548
80 1.456 ±0.181 0.622 ±0.146 0.338 ±  0.089 1.118 ± 0 . 2 0 2
Table C.7: I. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4 (n=4). Cells were previously exposed to 0.5nM 12 5I-NLDP-MSH 
for 1 hour at 4°C before being washed and re-incubated at 37°C.
Time
(minutes)









0 5.811 ±0.572 0.927 ±  0.268 1.413 ±  0.241 4.398 ±  0.620
5 4.333 ±  0.278 1.105 ±0.323 0.556 ±  0.281 3.778 ±  0.395
1 0 4.427 ±  0.555 1.648 ±0.480 0.696 ±0.193 3.730 ±  0.587
2 0 3.327 ±  0.281 0.966 ±0.176 0.609 ±0.185 2.628 ±  0.336
40 2.206 ±  0.490 0.796 ±0.111 0.265 ±  0.060 1.941 ±0.494
80 1.114 ±0.145 0.539 ±  0.047 0.333 ±  0.083 0.781 ±0.168
Table C.8 : II. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4 (n=4). Cells were previously exposed to 0.5nM 1 2 5I-NLDP-MSH 
for 1 hour at 4°C before being washed and re-incubated at 37°C. Also an acid- 
wash of cells exposed to the radio-ligand in the presence of excess unlabelled 
NLDP-MSH, 0.861 ±  0.179.
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Time Cell Associated 1 2 5I-NLDP-MSH (fmoles/106 cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
0 7.584 ±  1.087 1.935 ±  0.234 2 . 1 2 2  ±0.066 5.462 ±  1.089
5 5.661 ±  0.350 0.979 ±0.117 0.446 ±  0.148 5.215 ±  0.380
1 0 5.145 ±0.319 1.237 ±0.237 0.973 ±  0.336 4.172 ±  0.463
2 0 4.528 ±  0.441 1.155 ±0.232- 0.860 ±  0.214 3.668 ±  0.490
40 1.864 ±0.324 0.790 ±  0.071 0.279 ±0.111 1.585 ±0.343
80 2.101 ±0.462 0.989 ±0.143 0.768 ±  0.133 1.333 ±  0.480
Table C.9: III. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer supplemented with 0.5nM NLDP-MSH, pH 7.4 (n=4). Cells were previ­
ously exposed to 0.5nM 1 2 5I-NLDP-MSH for 1 hour at 4°C before being washed 
and re-incubated at 37°C.
Time
(minutes)









0 6.300 ±  0.242 1.118 ±0.091 1.698 ±0.603 4.602 ±  0.650
5 5.493 ±  0.387 1.138 ±0.132 2.238 ±  1.504 3.255 ±  1.553
1 0 3.031 ±0.158 0.754 ±0.130 0.316 ±  0.025 2.714 ±0.160
2 0 4.398 ±0.711 1.332 ±0.677 0.410 ±0.153 3.988 ±  0.728
40 1.230 ±0.291 0.401 ±  0.072 0.258 ±  0.126 0.970 ±  0.318
80 1.743 ±0.358 1.046 ±0.402 0.880 ±  0.213 0.864 ±  0.417
Table C.1 0 : IV. Incubation of B16 cells at 37°C with time in normal Hepes 
binding buffer supplemented with 0.5nM NLDP-MSH, pH 7.4 (n=4). Cells were 
previously exposed to 0.5nM 1 2 5I-NLDP-MSH for 1 hour at 4°C before being 
washed and re-incubated at 37°C.
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Bound 12 5I-NLDP-MSH (fmoles/1 0 6 cells)
Experiment A Experiment B
0.50 3.23 ±  0.33
1 . 0 0 3.98 ±  0.23 3.86 ±0.36
2 . 0 0 3.29 ±  0.22 3.19 ±0.20
5.00 3.63 ±  0.24 3.04 ±  0.08
1 0 . 0 3.06 ±0.15 2.59 ±  0.08
15.0 2.89 ±  0.09
2 0 . 0 2.25 ±0.15 2.77 ±  0.25
30.0 2.23 ±0.19
50.0 1.78 ±0.08 1.89 ±0.15
1 0 0 . 0 1.71 ±0.28 1.48 ±0.05
2 0 0 . 0 1.27 ±0.04 1.31 ±0.11
5000 0 . 8 6  ±  0 . 0 1 0.73 ±  0.05
Table D.l: Binding competition assay (representing two individual experiments, 
A and B) of 0.25nM 12 5I-NLDP-MSH incubated with increasing concentrations of 
NLDP-MSH-MTX at 4°C for 8  hours, n= 6 . Experiment A total (3.21 db0.16) and 
non-specific (1.17 ±  0.04) binding. Experimnt B (3.80 ±  0.27) and non-specific 
(1.04 ±  0.07) binding.
Time Cell Associated 1 2 5I-NLDP-MSH (fmoles/1 0 6 cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
1 0 6.119 ±1.276 2.249 ±  0.328 1.742 ±0.422 3.870 ±  1.317
2 0 10.205 ±  1.563 2.773 ±  0.198 2.538 ±  0.473 7.432 ±1.575
30 12.027 ±  1.719 3.213 ±  0.700 3.523 ±  0.762 8.814 ±  1.856
40 10.677 ±0.719 2.267 ±  0.140 3.799 ±  0.462 8.411 ±0.732
60 6.754 ±  1.538 3.621 ±  0.475 2.820 ±  0.371 3.133 ±  1.610
1 2 0 1.410 ±0.384 1.194 ±0.321 0.992 ±  0.536 0.215 ±  0.500
Table D.2: Cell associated 125I activity after incubation of l.OnM 12 5I-NLDP- 
MSH-MTX with B16 cells at 37°C with time, n=4.
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Time Cell Associated 1 2 5I-NLDP-MSH (fmoles/1 0 6cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
0 6.181 ±0.053 1.162 ±0.030 2.618 ±  0.232 3.563 ±  0.238
1 0 4.834 ±  0.199 1.304 ±0.212 1.002 ±  0.163 3.833 ±  0.258
2 0 3.697 ±  0.063 1.125 ±0.248 0.493 ±  0.093 3.205 ±0.113
30 3.161 ±0.220 1.147 ±0.256 0.464 ±  0.071 2.697 ±  0.232
Table D.3: I. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4 (n=4). Cells were previously exposed to l.OnM 12 5I-NLDP-MSH- 
MTX for 2 hour at 4°C before being washed and re-incubated at 37°C.
Time
(minutes)









0 16.308 ±  1.615 4.035 ±  0.501 6.047 ±  0.703 10.260 ±  1.761
5 8.089 ±  0.689 2.075 ±  0.339 2.120 ±  0.293 5.969 ±  0.749
1 0 8.030 ±  0.944 2.359 ±0.117 2.110 ±0.213 5.920 ±  0.968
2 0 6.894 ±  1.088 2.696 ±  0.344 1.324 ±  0.164 5.569 ±  1.100
30 5.424 ±  0.309 1.881 ±0.559 1.032 ±  0.143 4.393 ±  0.340
60 2.048 ±  0.465 2.017 ±0.573 1.343 ±  0.058 0.705 ±  0.468
Table D.4: II. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4 (n=4). Cells were previously exposed to l.OnM 12 5I-NLDP-MSH- 
MTX for 2  hour at 4°C before being washed and re-incubated at 37°C.
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Time Cell Associated 125I-NLDP-MSH (fmoles/106cells).
(minutes) Total Acid-Washed Non-Specific Specific
Binding Cells Binding Binding
0 10.479 ±  1.210 2.029 ±  0.607 2.835 ±  0.349 7.644 ±  1.259
5 7.251 ±1.051 1.228 ±0.220 0.707 ±0.141 6.543 ±  1.060
10 3.811 ±0.746 1.317 ±%%[A PrinterError:Ai mtAofApaper^
20 5.913 ±0.368 1.526 ±0.182 1.059 ±0.269 4.854 ±  0.456
30 4.784 ±  0.261 1.458 ±0.116 0.521 ±  0.217 4.263 ±  0.339
]%%AA%%[i
Table D.5: III. Incubation of B16 cells at 37°C with time in normal Hepes binding 
buffer, pH 7.4 (n=4). Cells were previously exposed to l.OnM 125I-NLDP-MSH- 
MTX for 2 hour at 4°C before being washed and re-incubated at 37°C.
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% of Maximum Activity
MTX NLDP-MSH-MTX
0.1 101.00 ±  11.15
0,1 90.05 ±  9.38
1.0 85.17 ±  6.94
2.0 68.86 ±  3.57
5.0 60.91 ±  16.98
10.0 46.15 ±  11.61 92.29 ±21.32
20.0 30.25 ±  2.91
50.0 27.07 ±  0.91 79.63 ±  1.84
100 53.54 ±  7.81
200 16.10 ±  5.36
500 45.24 ±  3.60
1000 43.11 ±4.07
5000 24.62 ±4.49
Table E.l: Inhibition of 1)11 FH at 37UC by MTX and NLDP-MSH-MTX, ex­
pressed as a percentage of maximum activity (120/zM FII2 represents 100% in 
the absence of inhibitor)
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